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Hepatocellular carcinoma (HCC) is one of the most common cancers of South East 
Asia and evidence suggests that persistent Hepatitis B virus (HBV) infection is the 
most important risk factor of the HCC development. It is one of the major cancers 
amongst Southern Chinese population. HBV-infections commonly occur at an early 
age and become persistent in populations in which this virus is highly endemic, such 
as those in Eastern Asia and Sub-Saharan Africa. In Hong Kong, about one tenth of 
residents are chronic hepatitis B carriers. A quarter of these carriers will suffer from 
HCC or cirrhosis and die of these consequences. 
Oncogenesis of HCC caused by the HBV is considered to be a complex process and 
likely involves multiple steps. One of the apparent consequences of oncogenesis of 
HCC is a deregulated expression of specific host genes. However, the precise 
mechanism of carcinogenesis by HBV is not well understood. In order to investigate 
the gene expression profile and find out some deregulated genes expressed in 
HBV-infected HCC of local Chinese, our laboratory made good use of random 
sequencing of two human liver cDNA libraries to identify and tag genes expressed in 
liver cancer. Fresh samples of HBV-induced liver cancer were obtained from a local 
female patient. Of 11,606 cDNA clones in HCC library and 4,788 cDNA clones in 
HBV-infected normal counterpart library analyzed by sequence similarity searches 
against the GenBank/EMBL database, 19% and 16% of these transcripts matched to 
other ESTs currently deposited in the GenBank/EMBL databases, although not to 
any other known sequences. Clones matching to known genes were categorized 
according to their putative structural and cellular functions. 
vii 
Abstract 
Detailed comparison of individual gene expression was studied by the in silico 
statistical analysis. Fifty four genes were identified as strong candidates (P<0.0002) 
for differentially expression in HCC (17 genes were found up-regulated and 37 genes 
were found down-regulated). The information of this gene catalogue may provide 
insight into the expression profile of liver cancer, as well as generating a set of ESTs 
for future use as diagnostic markers. 
In addition, characterization of a novel clone called KIAA0022, which was found to 
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1.1 General Introduction 
This thesis is mainly divided into four parts. The first chapter will be the general 
introduction and background information of Hepatitis B virus and human 
hepatocellular carcinoma - the current situation in global and Hong Kong. Then, the 
pathogenesis of HBV induced HCC will be elucidated. Afterward, the tumor markers 
for HCC screening and diagnosis will be reviewed and the uses of Expressed 
Sequences Tag (EST) sequencing in studying differentially expressed genes will be 
described. Furthermore, the background information of novel clone KIAA0022 and 
C-type lectin will also be presented in the final section of this chapter. 
The second chapter will talk about the materials and methods employed in this 
project including large-scale expressed sequences tag sequencing, identification of 
the candidate genes differentially expressed in HCC by statistical analyzes. Besides, 
protocol used in the characterization of a novel clone KIAA0022 including Northern 
blot analysis, subcellular localization investigation and yeast two-hybrid library 
screening assay will be described. 
The third chapter will present the results of expressed sequences tag sequencing in 
HCC and its normal counterpart cDNA library. The highly significant potential 
differentially expressed genes in HCC identified by statistical analyses will be listed 
out. The results of the characterization of novel clone KIAA022 such as 
investigation of its expression level in different human tissues, the subcellular 
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localization and its potential protein interacting partners will be described in this 
chapter. 
The last chapter will focus on the implication of the ESTs sequencing results. 
Besides, the results in the characterization of KIAA0022 will also be discussed at the 
end of this chapter. 
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1.2 Hepatitis B Virus and Hepatocellular Carcinoma 
Hepatitis B Virus (HBV) is one of the most common human pathogens in the world. 
It has a diameter of 42 nm. It is mainly present in the body fluid of patients such as 
blood, semen and vaginal secretion. It is also found in saliva, milk, urine and tear in 
trace quantity but the virus is usually not infectious. The transmission routes for 
HBV infection are mainly through perinatal transmission and horizontal transmission 
included sexual contact, bloodborne and other intimate contact. More than 2 billion 
people have been exposed to the HBV in the globe and about 50 million new cases 
are being diagnosed annually. Chronic hepatitis B patients defined as those who 
carry hepatitis B surface antigen (HbsAg) for more than 6 months. It is estimated 
that 350 million of people are chronic carriers of HBV currently. Three quarters of 
them live in Asia and the Western Pacific. The prevalence of the chronic HBV 
infection is high (prevalence>8%) in Southeast Asia and sub-Saharan Africa 
(Maddrey, 2000; Merican et al., 2000). 
Hepatocellular carcinoma (HCC) is the most common malignant tumor in the world, 
with an incidence of 1,000,000 new cases a year. The geographic variation of HCC 
indicates its association with chronic HBV. There is a close correspondence between 
areas where HCC is common and areas where HBV infection has been 
hyperendemic (Figure 1) (Arbuthnot & Kew，2001; Dominguez-Malagon & 
Gaytan-Graham, 2001). Several environmental factors, such as aflatoxins, 
alcoholism, as well as genetic backgrounds have been implicated in the development 
and progression of HCC (Chen et al, 1991). Besides, cigarette smoking, low 
vegetable intake, inorganic arsenic ingestion, radioactive thorium dioxide exposure, 
iron overload, use of oral contraceptives, anabolic steroids, low serum retinal level 
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and high serum testosterone levels are also associated with an increased HCC risk 
(Chen et al., 1997). However, chronic hepatitis B virus (HBV) and hepatitis C virus 
(HCV) infections are considered to be the best-documented factors associated with 
the progression of chronic hepatitis to cirrhosis and eventually HCC (Chen & Chen, 
1999; Chen & Sung，1978). Approximately 80% of HCC worldwide is etiologically 
associated with HBV (Chen et al., 2000; Yu et al., 2000). 
In Hong Kong, one tenth of the population is chronic HBV carriers. A quarter of 
chronic carriers will suffer from cirrhosis or HCC and die of these consequences. 
The incidence of HCC is predominant in male with a male to female of ratio 4:1. 
HCC is considered to be the second and the fourth most frequent cause of cancer 
death in males and females respectively. According to local statistics, there are over 
1，500 new cases of HCC being diagnosed annually and more than 1,000 people die 




Figure 1. Global maps showing the close similarity between the geographical 
distributions of chronic hepatitis B virus infection and human hepatocellular 
carcinoma, (adapted from Arbuthnot P and Kew M, 2001) 
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1.3 Pathogenesis of HBV related HCC 
We have known that chronic hepatitis B virus infection is the major risk factor for 
the development of hepatocellular carcinoma. Individuals who are chronic carriers 
have a greater than 100-fold increase in relative risk of developing the tumor. There 
are several carcinogenic mechanisms that are considered to underlie HBV-associated 
HCC. However, the precise mechanism of carcinogenesis by HBV still remains to be 
elucidated. Hepatocarcinogensis is considered to be a complex process that 
associated with the accumulation of a series of genetic and epigenetic changes and it 
also depend on some external factors such as hepatitis B or C infection and chronic 
alcohol intake. These factors can cause the development of a pre-neoplastic lesion 
and then progression to early cancer and finally, culminate with advanced HCC (Nita 
etal., 2002). 
The relation between HBV and HCC has been demonstrated in different animal 
models included Peking ducks, ground squirrels and woodchucks. The homology of 
the virus infection is not only in genomic structures and tissue tropism but also in the 
ability to cause chronic infection and liver cancer (Schafer & Sorrell, 1999). 
Integration of viral DNA into the host genome 
Integration of HBV DNA into the genome of hepatocytes has been detected in a high 
proportion of HBV-related HCC (Brechot et al., 1980; Imazeki et al, 1986; Shafritz 
& Kew, 1981). The event of integration does not have any effect on mutagenesis but 
it can directly induce chromosomal rearrangements such as mutations, deletions, 
translocations, inversions of the host chromosomes and this may lead to the 
disruption of host cellular protein encoding sequences and alternation of normally 
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tightly controlled growth regulatory genes, i.e. overexpression and amplification of 
proto-oncogene and inactivation of tumor suppressor genes (Dejean et al, 1986; 
Hada et al., 1986; Rogler et al, 1985; Transy et al., 1992; Yaginuma et al., 1987). 
However, there are no common pattern of viral integration and no characteristic 
chromosomal abnormality have been identified. Integration of viral DNA can take 
place at multiple sites on various chromosomes. High level of integrants in 
chromosomes 11 have been illustrated in previous reports (Nagaya et al., 1987; 
Rogler et al., 1985; Tokino & Matsubara, 1991) but the implications of this 
observation are unknown. Only few examples showed HBV integration at cellular 
sequences that are potentially oncogenic. In one study, the HBV-cyclin A fusion was 
shown to have oncogenic properties which are lacking in either the viral sequence or 
amino-terminally deleted cyclin A proteins alone (Berasain et al., 1998; Wang et al., 
1992). In another study, hepatocarcinogenic effect of HBV integration at retinoic 
acid receptor (RAR) beta gene has also been described (Dejean et al., 1986). 
Actually, the integration of HBV DNA is not restricted to tumor cells; clonally 
expanded cells containing integrated HBV-DNA molecules can also be identified in 
non-tumoral patients. Although some characters of HBV integration in HCC have 
been emerged, identification of the molecular basis of the link between HBV DNA 
integration and hepatocarcinogenesis have been complicated. Therefore, the 
relationship between integration of viral DNA and hepatocarcinogenesis still remains 
to be investigated. 
Effect on the viral transactivating protein HBx 
The transcriptional transactivation ability of the X protein was considered to be a 
potential oncogenic mechanism induced by HBV. However, the relevance of the 
HBx transactivation function to the viral life cycle and oncogenesis is unclear, but it 
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is generally believed to be crucial (Brechot et al., 2000). It has been shown that HBx 
activates a wide variety of cellular genes include the oncogenes c-myc (Balsano et 
al, 1991)，c-fos (Avantaggiati et al, 1993) and c-jun (Twu et al., 1993) in certain 
cell lines. Besides, HBx also transactivates cytokine-encoding genes such as tumor 
necrosis factor a (Lara-Pezzi et al., 1998) and transforming growth factor (3 (Yoo et 
al., 1996). The activation of gene expression may thus be important for viral 
infection and also for the disruption of cellular genes that normally regulate 
hepatocyte proliferation. The mechanisms through which HBx stimulates gene 
transcription are only partially understood. HBx does not contain any structural 
motifs that are capable of binding DNA directly, suggesting that it stimulates 
transcription, probably by interacting with cellular proteins and/or components of 
signal transduction pathways. The transactivation function of HBx has been shown 
to involve direct interaction with transcription factors such as, RPB5 of RNA 
polymerases (Cheong et al., 1995). Mobility shift assays also showed that HBx binds 
to CREB and to ATF-2 transcription factors (Maguire et al., 1991). Previous reports 
also showed HBx increases the DNA binding and activation properties of the 
transcription factors NF-/cB and API (Benn & Schneider, 1994; Su & Schneider, 
1996). Besides, HBx can also activate cell signaling cascades involving 
mitogen-activated protein kinase (MAPK) (Benn et al., 1996; Kekule et al., 1993) 
and Janus family tyrosine kinase (JAK)/signal transducer and activators of 
transcription (STAT) pathways (Lee & Yun, 1998). The transactivation of cellular 
genes controlling cell growth by HBx suggested that HBx might participate in the 
transformation of hepatocytes by HBV. 
Inactivation of tumor suppressor gene p53 by the viral X protein 
A direct interaction between HBx and p53 still remains controversial (Feitelson et al., 
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1993; Truant et al, 1995). The p53 gene has characteristics of tumor suppressor in 
its wild-type form and can function as a dominant oncogene when mutated. In 
transgenic mice expressing HBx from integrated HBV DNA, it was shown that 
tumor development correlates with binding of p53 by HBx (Ueda et al., 1995). It 
was proposed that decreased nuclear concentration p53, caused by HBx 
sequestration of p53 in the cytoplasm, inhibits hepatocyte apoptosis. However, 
cytoplasmic sequestration of p53 has not been consistently associated with inhibition 
of apoptosis caused by HBx (Wang et al., 1995). Several studies have demonstrated 
effects of HBx on the transactivation properties of p53. HBx was reported to inhibit 
sequence specific DNA binding and transcriptional activation by p53 (Wang et al., 
1994). Important and potentially carcinogenic consequences of the inhibition of p53 




1.4 Current screening test for HCC and tumor marker 
Because of the poor prognosis for the patient with HCC, chances of intervention and 
survival rate were low. Symptoms often develop always until the tumor has 
metastasized and is more than 10 cm in diameter that is beyond surgical treatment. 
The median survival in these conditions is 2 to 4 months, and the chance of 2 year 
survival is virtually nil. As a result, effective screening methods for early detection 
of HCC are needed. Alpha-fetoprotein (AFP) and/or ultrasonography (USG) 
screening have been implemented in many countries and shown that it is effective 
for detecting small HCC and decreases mortality in high risk populations (Collier & 
Sherman, 1998; Tang, 2000). However, the specificity of alpha-fetoprotein remains 
controversial and it's levels are often not elevated until the tumor is beyond surgical 
treatment (Di Bisceglie et al., 1998; Wu & Sell, 1990). 
For the diagnosis of HCC, serum markers for HCC need to be used in combination 
with imaging modalities, such as magnetic resonance imaging, computed 
tomography and echography (Di Bisceglie et al., 1998; Fujiyama et al., 2002). 
Actually, blood examinations are practically more convenient than the imaging 
modalities for screening. To date, lots of serum markers for HCC have been 
published. These genes include serum ferritin (Zhou et al., 1988), serum C-reactive 
protein (Lee et al., 1989)，serum type IV collagen (Hong et al., 1995), serum acidic 
isoferritin (Zou et al., 1997), Des-gamma-carboxy Prothrombin (DCP) (Grazi et al., 
1995; Hamamura et aL, 2000), serum transforming growth factor-beta 1 (Song et al., 
2002; Yang et al., 1997)，intercellular adhesion molecule 1 (Mei et al, 1999), soluble 
interleukin-2 receptor (Izzo et al., 1999) and alpha-fetoprotein (Matsumura et al., 
1999). AFP-L3 is considered to be a new generation of tumor marker for HCC and it 
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has been reported that it was produced by the malignant liver cells in the early stage 
of HCC (Li et al., 2001). Expression of metallothionein was found to be increased 
significantly in a study of pre-neoplastic liver lesion which was induced by chemical 
carcinogen (Sawaki et al., 1999). Besides, telomerase activity was found to be more 
intense in de-differentiated tumors of HCC and its activation was believed to be 
associated with the malignant potential of the tumor (Kanamaru et al, 1999). 
Simultaneous determinations of serum AFP and plasma nitrite/nitrate concentrations 
gave significant improvement in detection of HCC in chronic liver disease patient 
compared with that of serum AFP alone (Moriyama et al., 2000). Membrane cofactor 
protein (MCP, CD46) was also reported to be highly expressed in HCC; furthermore, 
its expression was found throughout the different stages of development of HCC 
(Kinugasa et al, 1999). Some particular p53 mutations are found to be characteristic 
ofaflatoxin-induced HCC (Wong et al., 2001b) but the incidence ofp53 mutation of 
HCC in Hong Kong is approximately 23% only (Ng et al., 2001). Currently, the 
combination of AFP and DCP has gained wide popularity (Fujiyama et al, 2002). 
Ideally，a tumor marker should be 100% sensitive and 100% specific for a particular 
type of cancer. To be useful in prognosis it should also assess the malignant potential, 
the stage of the disease, the extent of spread of tumor cells and the survival time of 
the patient with HCC, so that treatment can be monitored effectively. However, at 
present such tumor markers for HCC do not exist although lots of serum markers 
have been found as described above. This problem is compounded by the fact that 
HCC have very heterogeneous chromosomal abnormalities (Lai & Wong，2001; 
Wong e/a/., 2001a). 
Effective treatment for the HCC patients is important since it can prolong the 
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survival rate and improve the prognosis of them. At present, surgery is a better 
choice for HCC patients including either partial hepatectomy or total hepatectomy 
with orthotopic liver transplantation (OLT). However, the use of OLT is limited by 
the difficulty of obtaining donor liver. Therefore, partial hepatectomy is still the most 
important way to obtain long-term survivals. In recent years, some therapies such as 
transcatheter arterial chemoembolization (TACE), and various kinds of liver tumor 
ablation therapies have been developed. These are therapies that are promising in 
further improving the prognosis of HCC patients who have no opportunity to receive 
surgical treatment or postoperative recurrence (Qin & Tang，2002). 
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1.5 Expressed Sequences Tag Sequencing 
Expressed sequence tags (ESTs) are gene sequences, typically 300-400 nucleotides 
in length, obtained from 3'- or 5'-end complementary-DNA (cDNA) clones from 
different tissues sources. In the past decade, gene-discovery efforts have turned to 
large-scale sequencing of expressed sequence tags (ESTs) to accelerate the 
identification of new genes (Fannon, 1996). The application of ESTs are basically in 
the discovery of new human genes, mapping of the human genome, and 
identification of coding regions in genomic sequences (Adams et al, 1991; Khan et 
a/.，1992; Wilcox et al., 1991). To date, the cDNA libraries of many different human 
tissues have been sequenced, these include heart, brain, liver, lung, pancreas, prostate, 
spleen, testis, thymus, ovary, retina, etc (Hwang et al, 2000) and more than three 
million ESTs derived from cDNA libraries from various human tissues and 
developmental stages are accessible in the public database dbEST. Other notable 
achievements are the microbial complete genomic DNA sequences oi Mycoplasma 
genitalium (Fraser et al, 1995), Methanocuccus jannaschii (Bult et al, 1996) and 
Saccharomyces cereviseae (Dujon, 1996). 
The ESTs come from different cDNA libraries, each of which was prepared from one 
particular cell type, organ, or tumor. Therefore, the occurrence of ESTs in different 
libraries provides information about the organ, cell type, or tumor specificity of 
expressed genes. Normally, a gene is represented by many ESTs, therefore, the more 
a gene is expressed in the tissue, the more ESTs for that gene will be found in the 
library. As a result, the number of ESTs that represent the same gene may reflect the 
expression level of the gene in the tissue from which the library is derived (Miernyk, 
2001). All these data made up a huge resource for learning about the human genome, 
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and they provided valuable information for differential gene expression in different 
tissues. High-throughput sequencing of randomly selected clones from cDNA 
libraries to generate expressed sequence tags (ESTs) has proven to be a powerful 
means in discovering novel genes and of examining their expression in a wide 
variety of tissues (Hwang et al, 2000). Bioinformatics methods partially automate 
the characterization of EST sequences and provide tools for analyzing large 
databases of ESTs (Fannon, 1996). Therefore, a database of EST sequences derived 
from a comprehensive set of human tissues and cell lines defines a population of 
gene-expression events suitable for statistical analysis. 
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1.6 Aim of the present study 
To reveal the genes expressed in HCC of a typical local Chinese patient who was 
infected by HBV, steps were taken to establish a database resource for the search of 
genes differentially expressed in HCC. Extensive sequencing of cDNA clones 
derived from cDNA libraries of both human liver cancer and its normal counterpart 
tissue was performed. The expression profiles of HCC and its normal counterpart 
with a systematic categorization of genes and expression levels of individual genes 
were compared with statistical analyses. 
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1.7 Characterization of KIAA0022 
More than seventeen thousands unique novel sequences were found in the 
large-scale liver EST sequencing project. Three of the EST clones matched to 
KIAA0022 from the homology search using BLASTN algorithm, showed 
overexpression in HCC from the semi-quantitative PGR experiment (Figure 2). 
KIAA0022 is a hypothetical protein with unknown function and has a coding region 
of 513 base pair. The predicted protein sequence contains a C-type lectin (CTL) 
domain. Lectins are proteins that capable of recognizing carbohydrate residues and 
they may be found in cell surface, extracellular matrix, or soluble glycoproteins. 
Lectins have highly conserved carbohydrate binding regions and have been 
identified in a broad range of multicellular organisms ranging from nematodes to 
humans. Previous report showed that lectins may play roles in biological recognition 
events such as cell-cell interactions, intracellular glycoprotein routing and 
phagocytosis (Chay & Pienta, 2000; Drickamer & Taylor，1993) and also in cellular 
invasion and metastasis (Ochieng & Warfield，1995). Drickamer was the first to 
organize animal lectins into two categories, so-called C- and S-lectins in 1988. 
Afterward, the animal lectins were re-organized into five distinct categories 
including the C-type, the P-type, the I-type，pentraxins and galectins (S-type) in 1995 
(Drickamer, 1995). All lectins share the property of having conserved carbohydrate 
recognition domains (CRDs), but with different binding motifs and target ligands 
they clearly represent distinct families. 
Protein-carbohydrate interactions have important roles in the immune response 
including pathogen recognition and the cellular interactions that lead to pathogen 
neutralization. Many of these proteins components are members of C-type animal 
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lectin family. C-type lectins comprises a large family of multifunctional proteins 
found in serum, extracellular matrix, and membranes which require calcium ion for 
carbohydrate binding, in addition to having highly conserved CRD domain (Weis et 
al., 1998). This family of lectins includes the selectins (L, P, and E), as well as CD69, 
CD72, and the asialoglycoprotein receptors (ASGPR) (also known as hepatic lectins) 
(Chay & Pienta，2000). Selectins are cell adhesion molecules implicated in the 
interaction of leukocytes with platelets or vascular endothelium. CD69 and CD72 are 
proteins expressed on the surface of natural killer T-cells and B-cells respectively. 
The CTL-domain in these proteins is unclear whether they are likely to bind 
carbohydrates. The ASGPR's was found to be mediated the endocytosis of plasma 
glycoproteins. Recently, Lasserre and his co-workers found a gene called HIP/PAP 
gene encoding a C-type lectin, and was shown to have overexpression in primary 
liver cancer by differential screening of a human hepatocellular carcinoma cDNA 
library. It was found that this gene might participate in the expansion of liver cells 
during liver carcinogenesis (Lasserre et al., 1999). 
In order to have a better understanding of the KIAA0022, this novel clone was 
selected to be further characterised. The full-length cDNA of KIAA0022 was cloned 
and sequenced in this project. The expression level of KIAA0022 in various human 
adult tissues was investigated using Northern blot analysis. The subcellular 
localization was determined by tagging with green fluorescence protein (GFP). 




Figure 2. Semi-quantitative PCR experiment of KIAA0022. The expression of 
KIAA0022 mRNA in cancerous tissue and its adjacent non-tumor region tissue of 
two HCC patients were investigated. The cancerous tissue and its adjacent 
non-tumor region cDNA pools were normalized using ubiquinol-cytochrome c 
reductase core protein II gene. KIAA0022 mRNA showed up-regulated in cancerous 
tissue in both patients. The information of the patient is indicated in parentheses. 




Patient 15905 (male, 51 age, Anti-HCV (+ve)-by clinical history) 
^ ^ ^ ^ ^ ^ ^ E 
Tumor H 
Band ^ B C D E 
Dilution of original 丨乂 i /2x l/lOX 1/20X ubiquinol-cytochrome c 
cDNA concentration reductase core protein II 
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Materials and Methods 
2.1 Construction of liver HCC and normal counterpart libraries 
The HCC tissue and its normal counterpart were kindly provided by Prof C T. Liew, 
Department of Anatomical and Cellular Pathology, Prince of Wales Hospital, Shatin, 
Hong Kong. The tissues were obtained from a 53 years old local female patient who 
suffered from HCC with HBV positive serum. The tumor size was about 13cm in 
diameter. The libraries construction was performed by STRATAGENE. Details of 
the cDNA libraries were summarized in Table 1. 
2.2 Plating out the human liver cDNA libraries 
A single colony of E. coli XL 1-Blue MRF' was inoculated into 50ml of LB broth 
supplemented with 0.2%(w/v) maltose and lOmM MgS04 and allowed to grow 
overnight with shaking at 30�C. The cells were spun down in a sterile conical tube 
for 10 minutes at 2000 rpm. They were diluted to ODeoo = 0.5 with lOmM MgS04. 
Afterward, 100 to 150 plaque-forming units (pfu) of human liver cDNA library were 
mixed with 200|LII of diluted host cells. The mixture was incubated at 37°C for 15 
min. Then 3ml ofNZY medium (0.5% NaCl, 0.2% MgS04-7H20, 0.5% yeast extract, 
1% casein hydrolysate) at 50°C containing melted 0.4% agarose were added. After 
gentle vortexing，the whole content was poured immediately onto a labeled 
prewarmed (42°C) NZY plate. The plate was swirled and stood for 10 min at room 
temperature. The plate was inverted and incubated at 37°C for overnight. Plaques 
were picked by Pasteur pipettes and resuspended in 50|j,l of SM buffer (lOOmM 
NaCl, 9mM MgS04, 50mM Tris-HCl, 0.01% gelatin). The phage stocks were stored 
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Table 1. Details of the human HCC and normal counterpart liver cDNA libraries. The 
libraries were constructed by STRATAGENE. 
HCC cDNA library Normal counterpart 
cDNA library  
Source Tumor region from a Adjacent non-tumor 
53 years old female region from a 53 years 
with HCC old female with HCC 
Vector Uni-ZAP XR Uni-ZAP XR 
Primer Oligo(dT) Oligo(dT) 
Insert size range 1.0-2.6kb 0.5-3.0kb 
Average insert 1.6kb 1.5kb 
size 
Primary plaques 6.6x10^ 1.5x10'^  
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at 4 T . 
2.3 PCR amplification of cloned human liver cancer and the normal 
counterpart cDNA libraries 
An aliquot (1.5|j,l) of phage suspension was subjected to PCR in the presence of 
50mM KCl, l.SmM MgCl】，and lOmM Tris-HCl, 200|aM of each dNTP, 2.5 units 
Tag DNA polymerase, and 5pmol of each 入 - Z A P forward primer (5，-CCA AGC 
TCG AAA TTA ACC CTC AC-3') and M13 universal primer (5'-CGA CGT TGT 
AAA ACG ACG GCC AGT-3，) in a final volume of 50|il. The PCR reaction was 
carried out under 5 min initial denaturation at 95°C, followed by 35 cycles of 
amplification (95°C, 36 sec; 55°C, 36 sec; 72T, 90 sec) and 10 min final extension 
at 72®C. The PCR product was examined on a 1.0% agarose/EtBr gel run in IX TBE 
buffer. 
2.4 Cycle sequencing of cloned human liver cancer and the normal 
counterpart cDNA libraries 
2.4.1 Dye-primer cycle sequencing (Pharmacia) 
2.4.1.1 Using Pharmacia LKBA.L.F. DNA sequencer 
Two microliter of unpurified PCR product was used as the template for cycle 
sequencing. It was combined with 30mM Tris-HCl (pH9.5), 7.5mM MgCl2, 2\il 
Thermo Sequenase DNA polymerase (Pharmacia), and Spmol of CY5 conjugated T3 
primer (CY5-5'-GCT CGA AAT TAA CCC TCA CTA AAG-3') in a final volume of 
17.5|il. The sequencing reaction mix was subjected to a 5 min initial denaturation at 
95'C, followed by 35 cycles of amplification (95°C, 30 sec; 50�C, 30 sec; 72'C, 2 
min) and 10 min final extension at 72°C. 
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2.4,1.2 Using Li-Cor 4200 Automated DNA sequencer 
Two microliter of unpurified PCR product was used as the template for cycle 
sequencing. It was combined with 30mM Tris-HCl (pH9.5), 7.5mM MgCli, 2|j.l 
Thermo Sequenase DNA polymerase (Pharmacia), and 1.5|imol of IRD700 or 
IRD800 conjugated T3 primer (IRD700 or IRD800-5'-GCT CGA AAT TAA CCC 
TCA CTA AAG-3') in a final volume of 17.5|il. The sequencing reaction mix was 
subjected to a 5 min initial denaturation at 95°C, followed by 40 cycles of 
amplification (95°C, 30 sec; 50°C, 30 sec; 72°C, 2 min) and 10 min final extension at 
72°C. The reactions were stopped by addition of A\\X "Li-Cor stop bufFer"(Cat. No. 
830-04997). The sequencing products were stored at 4°C before resolving on a 5.5% 
acrylamide gel using Li-Cor 4200 DNA sequencer. 
2.4.2 Dye-terminator cycle sequencing (Pharmacia) 
DNA sequencing was performed by using Cycling Sequencing Kit DYEnamic ET 
Dye Terminator for MegaBACE. It is based on traditional dideoxynucleotide chain 
termination chemistry. Four dideoxy terminators-ddQ ddA, ddT and ddC-is labeled 
with fluorescein and one of different acceptor dyes. They are rhodamine 110， 
rhodamine-6-Q tetramethyl rhodamine and rhodamine X. Energy transfer 
technology was utilized for signal detection in automated DNA sequencing. 
The sequencing reaction was carried out in a 96-well plate (Robbins, Cat. No. 
1055-00-0). Two microliter of unpurified PCR product from section 2.3 was used 
directly as the DNA template for cycle sequencing. It was subjected to sequencing 
reaction in the presence of 8|xl of DYEnamic ET reagent premix, lOpmol of T3 
primer (5'-GCT CGA AAT TAA CCC TCA CTA AAG-3 ’）in a final volume of 20|il. 
Sequencing reaction mix was cycled for 30 cycles at 95®C, 10 sec; 50�C，15 sec; 
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60®C, 60 sec. The sequencing products were purified by post reaction clean up using 
ethanol precipitation. In each reaction tube, 2\x\ of 7.5M ammonium acetate and 2.5 
volumes (5 5 pi) of 100% ethanol were added so that the final concentration of 
ethanol was 70%. Then it was subjected to centrifugation at 4,000 rpm for 30 min at 
14°C. Afterward, the supernatant was drawn off by performing a brief inverted spin 
(1 min at 500 rpm). The DNA pellet was washed by lOOjal of 70% ethanol. Then, it 
was subjected to centrifugation at 4,000 rpm for 15 min at 14�C and the supernatant 
was drawn off by performing a brief inverted spin (1 min at 500 rpm). Then the DNA 
pellet was allowed to air dry and was resuspended in 10|il of loading buffer (70% 
formamide and ImM EDTA). The samples were stored at 4°C before gel 
electrophoresis analysis on MegaBACE 1000 DNA sequencer. 
2.5 Sequences analysis 
In this project, sequence similarity search and comparisons against the nonredundant 
GenBank/EMBL/DDBJ nucleotide and protein databases were done by the BLAST 
algorithm at the National Center for Biotechnology Information (NCBI). The genetic 
profile was then constructed by categorizing the information of the EST matched to 
known genes. Results returned from the BLAST program were examined carefully to 
determine the identity of each clone. The information of the match with the highest 
score and matching percentage were stored in a database for further data analysis. An 
EST was classified as known gene if Expected value (E-value) was less than or equal 
to 10-20. Categorization of ESTs with known gene matches were carried out 
according to their putative structural and cellular functions as described in Liew et 
al., 1994， with minor modifications, with assistance of Unigene 
(http://www.ncbi.nlm.mh.gov/UmGene/index.htm), Entrez, PubMed and Locuslink. 
(at the NCBI (http://www. ncbi • nlm. nih. gov/Entrez/. 
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and 
http://www.ncbi.nlm.nih. gov/LocusLink/, respectively), GeneCards 
(http://bioinformatics.weizmann.ac.il/cards) and Gene Ontology 
rhttp://www. geneonotology. org) databases. 
To identify genes differentially expressed in hepatocellular carcinoma, ESTs were 
generated from the HCC and normal counterpart cDNA libraries. Known genes 
respresented by EST matches in two library samples were identified. Relative 
frequencies of known ESTs for each gene were compared in two libraries (HCC and 
normal counterpart). Poisson probability (P) was used to test the significance of 
differential expression of individual gene (Appendix 4). Genes that existed in the 
libraries were sorted by Poisson probability into two categories: A, strong candidates 
for differentially expressed genes: P<0.00002. B, weak candidates for differentially 
expressed genes: 0.00002<P<0.0002. 
2.6 Cloning of full-length cDNA of KIAA0022 
Cloning of KIAA0022 full-length was performed by TOPO TA cloning Kit 
(Invitrogen). 
2.6.1 Amplification of KIAA0022 gene using PGR 
The primer set to amplify KIAA0022 mRNA was designed according to a cDNA 
with the GenBank accession number NM—014880. DNA template (a normal liver 
cDNA pool) in the presence of 40mM Tricine-KOH, 15mM KOAc, 3.5mM 
Mg(DAc)2，3.75|Lig/ml BSA, 200|iM of each dNTP, 0.5^1 50X Advantage cDNA 
Polymerase Mix and 0.5|aM of both forward (5'-GCT CCG GGC CGC GCT GCC 
CGC G-3') and reverse (5'-CTG CTT AAC CCA TAA AAC TTT A-3') primers 
were prepared in final volume of 50|j,l. The PCR reaction mix was subjected to a 2 
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min initial denaturation at 95°C, followed by 30 cycles of amplification (95°C, 36 
sec; 45 sec; 68''C, 60 sec) and 10 min final extension at 
2.6.2 Purification of the PGR product 
Purification of the PCR product was performed by GENECLEAN III Kit (Bio 101 
Inc., Cat. no. 1001-600). Fifty microliter of PCR product was electrophoresed on a 
1% TAE (0.04M Tris acetate, ImM EDTA) agarose gel. The desired band was cut 
and was dissolved in 3 volumes of 4.5M sodium iodide (provided by the Kit). It was 
then incubated at 55°C for 5 min with mixing gently and occasionally until the 
agarose gel was dissolved. Ten microliter of EZ GLASSMILK (provided by the Kit) 
was added for the binding of DNA. It was incubated at room temperature and was 
mixed occasionally for 20 min. Afterward, the mixture was centrifuged at 14,000 xg 
for 1 min. The supernatant was discarded and the pellet was washed 2 times with 
200|al of ice-cold NEW WASH (provided by the Kit). Before the elution of the 
bound DNA, the pellet was dried on a 55�C incubator for 5 min. Then, \5\x\ of sterile 
double-distilled water was added to resuspend the pellet. After centrifugation, the 
supernatant was saved and quantitated by gel electrophoresis on a 1% TBE agarose 
gel with ethidium bromide. 
2.6.3 Ligation 
Four microliter of fresh PCR product (purified in section 2.6.2), l|al salt solution and 
l|Lil of TOPO® vector (pcDNA4/HisMax®-T0P0®) were added into a 0.5ml 
microcentrifuge tube. The reaction mix was mixed gently and was incubated for 30 
min at room temperature (22-23�C). 
2.6.4 One Shot® TOPIO Chemical Transformation 
Two microliter of the TOPO® cloning reaction mix from the above was added into a 
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vial of One Shot® TOP 10 Chemically Competent E.coli and mixed gently. Afterward, 
the tube was incubated on ice for 20 min and the mixture was heat-shocked at 42°C 
for 30 sec without shaking. Then it was immediately chilled on ice for 2 min and 
250|j,l of room temperature SOC medium was added. The tube was then incubated at 
37 for 1 hour with shaking at 200 rpm. Fifty microliter transformed cells were 
spread onto LB agar plates containing the appropriate antibiotics and was incubated 
overnight at 37 
2.6.5 Small-scale preparation of the plasmid DNA 
A transformant was inoculated from the agar plate into 1ml of Luria Broth (LB) 
medium containing the appropriate antibiotics. The culture was incubated at 37°C 
overnight with shaking at 250 rpm. Preparation plasmid DNA was performed using 
Concert Rapid Plasmid Purification Systems (GIBCOBRL). The DNA was eluted 
with 75|j1 pre-warmed sterile distilled water. The plasmid DNA was quantitated by 
electrophoresis on a 1% TBE agarose gel with ethidium bromide. The plasmid DNA 
was stored at -20°C. 
2.6.6 Large-scale preparation of the plasmid DNA 
Large-scale preparation of plasmid DNA was performed using HiSpeed Plasmid 
Midi Kit (QIAGEN). After the transformation of the recombinant plasmid into the 
appropriate E.coli strain, a single bacterial colony with the recombinant plasmid of 
interest was picked and inoculated in 100ml LB medium with appropriate antibiotics, 
for example, ampicillin (lOOfxg/ml). The culture was incubated at 37 for 12-16 
hours with shaking at 270 rpm. The bacterial cells were centrifuged at 6000 xg for 15 
min at 4°C, and the pellet was resuspended in 6ml of Buffer PI (50mM Tris-Cl, pH 
8.0; lOmM EDTA; 100}ag/ml RNase A). Then 6ml of Buffer P2 (200mM NaOH, 1% 
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SDS (w/v)) was added. The content was mixed gently, but thoroughly, by inverting 
the centrifuge bottle five times and incubated at room temperature for 5 min. After 
the incubation, 6ml chilled Buffer P3 (3M potassium acetate, pH 5.5) was added to 
the mixture. The contents were mixed gently, but thoroughly, by inverting the 
centrifuge bottle five times, immediately after addition of Buffer P3. Then the lysate 
was poured into the barrel of the QIAfilter Cartridge and was incubated at room 
temperature for 10 min. 
During the incubation time, HiSpeed Midi was equilibrated by applying 4 ml Buffer 
QBT (750mM NaCl; 50mM MOPS, pH 7.0; 15% isopropanol (v/v); 0.15% triton 
X-100 (v/v)) and the column was allowed to empty by gravity flow. The cell lysate 
was filtered into the previously equilibrated HiSpeed Midi and the cleared lysate was 
allowed to enter the resin by gravity flow. Afterward, the HiSpeed Midi was washed 
with 20ml of Buffer QC (IM NaCl; 50mM MOPS, pH 7.0; 15% isopropanol (v/v)). 
The plasmid DNA was precipitated with 3.5ml (0.7 volume) room-temperature 
isopropanol and was incubated at room temperature for 5 min. 
A 20ml syringe (the plunger was removed) was attached to the QIAprecipitator Midi 
Module outlet nozzle. The eluate/isopropanol mixture was transferred into the 20ml 
syringe and the plunger was inserted. The eluate/isopropanol mixture was filtered 
through 20ml the QIAprecipitator using constant pressure. The QIAprecipitator was 
removed from the 20ml syringe and the plunger was pulled out. The QIAprecipitator 
was attached to the 20ml syringe again, the plunger was inserted and the membrane 
was dried by pressing air through the QIAprecipitator. The outlet nozzle of the 
QIAprecipitator was dried with absorbent paper to prevent isopropanol carryover. 
Afterward, the plunger was removed from a new 5ml syringe and the 
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QIAprecipitator was attached onto the outlet nozzle. One milliliter of pre-warmed 
sterile distilled water was added to the 5ml syringe. The plunger was inserted and the 
DNA plasmid was eluted into the collection tube using constant pressure. The 
concentration of the plasmid DNA was determined by the spectrophotometric 
method at OD260 
2.6.7 DNA sequencing of the full-length cDNA of KIAA0022 
The DNA sequencing of the full-length cDNA of KIAA0022 was performed as 
described in section 2.4.1.2. Strategy primer walking was used. Six microliter of 
plasmid DNA (prepared in section 2.6.6) was added into the sequencing reaction mix. 
Six pairs of primers that conjugated with Infar-red 700 (IRD700) were used: 
1. IRD700-5，-TAA TAC GAC TCA CTA TAG GG-3， 
(T7 promoter) 
2. IRD700-5'-GCT GGATAT CTG CAG AAT TC-3' 
(Nucleotide 1234-1215 ofTOPO vector) 
3. IRD700-5'-TTT AGT TGACAC CTG TGC TT-3， 
(Nucleotide 367-386 of my sequence) 
4. IRD700-5'-ACA CAC ACC ATT TTA TCA CA-3 ’ 
(Nucleotide 1233-1250 of my sequence) 
6. IRD700-5'-CCACAT GAATCG AAAACACT-3' 
(Nucleotide 2102-2121 of my sequence) 
7. IRD700-5'-GCAGCT CTT CCAAAATAG CT-3' 
(Nucleotide 2791-2810 of my sequence) 
In order to get the higher revolution results, the sequencing products were resolved 
on a 3.75% instead of a 5.5% acrylamide gel using Li-Cor 4200 DNA Sequencer. 
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2.7 Northern Hybridization 
The multiple human tissues distribution of KIAA0022 mRNA were studied by 
Northern blot analysis. 
2.7.1 The Human multiple tissue Northern Blot 
Human multiple tissue Northern (MTN) blot (Cat. No. PT1200-1) was purchased 
from Clontech. It contains approximately l^g of poly A+ RNA per lane from twelve 
different human tissues. The integrity of the poly A+ RNA was examined by 
denaturing gel electrophoresis and probe with a radioactively labeled human P-actin 
cDNA probe (unpublished data, quality control sheet supplied from Clontech, Palo 
AHO, CA，USA). 
2.7.2 Synthesis of the radiolabeled DNA probe 
The radiolabeled probe was synthesized using Ready-To-Go DNA Labeling Beads 
[-dCTP] (Amersham). PCR product of KIAA0022 was used as the template. It was 
adjusted to 45|il by sterile H2O after the gel purification, denatured at 100 for 5 
min and then chilled on ice for 2 min. The labeling bead that consisted of buffer, 
dATP, dGTP, dTTP, FPLCpure™ Klenow Fragment (7-12 units) and random 
oligodeoxyribonucleotides, primarily 9-mers was reconstituted with SOfiCi of [a-^^P] 
dCTP (3000Ci/mmol, Amersham Pharmacia Biotech, cat no. PB10205), and then 
with the denatured cDNA. The reaction mixture was incubated at 37°C for 30 min. 
The reaction mixture prepared above was passed through a size exclusion 
chromatography column, CHROMA™ SPIN + STE 100 (Clontech) for removing of 
unincorporated [a-^^P] dCTP from the labeled reaction mixture. First, the column 
was centrifuged at 700 xg for 5 min to drain off the equilibration buffer from the 
column and re-establish the matrix bed. Then, the labeled probe was collected as a 
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flow-through by a further centrifugation at 700 xg for 5 min. 
2.7.3 Hybridization of the Northern blot 
The human multiple tissue Northern (MTN) blot was pre-hybridized at 55�C for 1 
hour with ExpressHyb^^ Hybridization Solution alone, then hybridized at SS'^ C for 2 
hours in ExpressHyb^^ Hybridization Solution with the radioactively labeled 
denatured probe which produced in section 2.7.2. Both pre-hybridization and 
hybridization were performed in a hybridization bottle incubated in a rotatory 
hybridization oven. After the hybridization, the blots were washed several times until 
a final stringency of 30�C in O.IX SSC, 0.1% SDS was achieved. The blots were 
then exposed to autoradiography film Biomax MS (Eastman Kodak) at -80°C with 
intensifying screens for 1 day. The band intensities were quantified by densitometer. 
2.8 Subcellular localization of KIAA0022 by tagging with green 
fluorescence protein (GFP) 
KIAA0022 cDNA was cloned into a eukaryotic GFP expression vector pEGFP-Cl, 
which encodes a red-shifted variant of wild-type GFP that has been optimized for 
brighter fluorescence and higher expression in mammalian cells (Clontech). 
2.8.1 Amplification and purification of the KIAA0022 gene product 
Amplification and purification of the KIAA0022 gene product were performed as the 
procedures described previously. PCR of KIAA0022 clone was obtained by using a 
pair of primers flanking the coding regions (CDS) of KIAA0022 (Forward: 5'-TAG 
GGC GAA l i e TAT GAT AAG CAT ACA TAA TGA AGA A-3 ' ; Reverse: 5，-TAG 
GGC CTC GAC TTA GTC AAA TTG AAC AGG ATA TTC AT-3，). Both primers 
have end clamps that facilitated cleavage by restriction enzymes. An £coRI site and 
Sail site, shown as the underlines bases, were present in the forward and reverse 
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primers respectively. After the enzymatic digestion, the PCR product was cloned into 
the pEGFP-Cl vector and the transformants were plated onto LBK agar plate 
(30|ag/ml kanamycin). Large-scale preparation of the pEGFP-C 1 -KIAA0022 
plasmid was performed as procedures described in section 2.6.6. 
2.8.2 Restriction enzymes digestion 
The total volume of restriction digestion of the purified PCR was 20|j.l included 2X 
One-Phor-All PLUS buffer (Pharmacia), l|_il of the EcoRI and Sail restriction 
enzymes (Fermentas), and 10|al of purified PCR product as prepared in section 2.8.1. 
The digestion took placed at 37°C for 3 hours. Restriction enzyme digestions of the 
eukaryotic GFP expression vector pEGFP-Cl were performed in parallel. The 
restriction enzymes digested PCR product and pEGFP-Cl expression vector were 
then purified by GENECLEAN III Kit (Bio 101 Inc., Cat. no. 1001-600) as 
described in section 2.6.2. 
2.8.3 DNA ligation 
The digested and purified KIAA0022 cDNA was ligated into eukaryotic GFP 
expression vector, pEGFP-Cl using T4 DNA ligase (1 Unit/|al, GibcoBRL). Ten 
microliter of digested and purified KIAA0022 cDNA with 4jal 5X ligation buffer 
(GibcoBRL) and 1|LI1 of T4 DNA ligase were used. The ligation reaction mixtures 
were then incubated at 16°C overnight. Control reactions were performed in parallel. 
2.8.4 Preparation of the Escherichia coli competent cells for transformation 
A single colony bacterial strain DH5a was inoculated in 10ml LB medium. The 
culture was incubated in 37°C overnight with shaking at 250 rpm. Two hundred and 
fifty microliter overnight inoculum was inoculated in 25ml LB medium and was 
incubated at 3TC for 3 hours with shaking until log phase was reached (i.e. 
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0.4<OD6OO<0.6). The culture was collected into a centrifuge bottle. The cells were 
spun down by centrifuging at 2,500 rpm for 10 min at 4°C. The supernatant was 
discarded and one-third volume (8.3ml) of the original culture volume of RFl buffer 
(lOOmM RbCl, 50mM MnCl2-4H20, 30mM potassium acetate, lOmM CaCl2-2H20, 
15% w/v glycerol, pH 5.8) was added to resuspend the cell pellet. The cells were 
chilled on ice for 30 min. Afterward, the cells were spun down by centrifuging at 
2,500 rpm for 10 min at 4�C. The supernatant was discarded and 1/12.5 volume (2ml) 
of the original culture volume of RF2 buffer (lOmM MOPS, lOmM RbCl, TSmM 
CaCl2.2H20，15% w/v glycerol, pH 6.8) was added to resuspend the cell pellet. The 
cells were chilled on ice for 15 min and aliquoted into 200|al fractions in 1.5ml tubes. 
The cells were frozen immediately in liquid nitrogen and stored at -80°C for later 
use. 
2.8.5 Transformation of the plasmid DNA into competent Escherichia coli cells 
The frozen competent cells were incubated on ice for 20 min. Then the ligation 
product was added and was mixed gently. Afterward, the mixture was incubated on 
ice for 30 min and then heat shocked at 42°C for 1.5 min. Next, it was immediately 
chilled on ice for 2 min and 800|j,l LB medium was added. The tube was then 
incubated at 37°C for 1 hour and 15 min with shaking at 250 rpm. The transformed 
cells were spread onto LB agar plates containing the appropriate antibiotics. 
2.8.6 Small-scale preparation of the plasmid DNA 
As described in section 2.6.5 
2.8.7 Large-scale preparation of the plasmid DNA 
As described in section 2.6.6 
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2.8.8 DNA sequencing of the cloned plasmid DNA 
The inserts were checked by restriction enzyme digestion after the transformation 
that was described previously. To ensure the proper open reading frame was obtained, 
DNA sequencing was carried out as procedures described previously. Eight 
microliter template (plasmid DNA from small scale preparation of plasmid) was 
added into the reaction mixture. 
2.8.9 Transfection 
In this experiment, HepG2 cells (from ATCC) were used. HepG2 cells were 
transfected with plasmid construct (prepared in section 2.8.7) using Lipofectamine 
Plus Reagent (Life Technologies, Inc.). Approximate 1x10^ HepG2 cells were 
inoculated on cover slips in a six-well plates, until the cells were 60-70% confluent. 
l|ig of DNA and 4[i\ of the Plus Reagent were added to 125|il RPMI-1640 medium 
lacking serum and antibiotics and incubated for 15 min at room temperature. 4\i\ of 
lipofectamine reagent were added to 125|il medium without serum and antibiotics to 
another new tube and incubated for 15 min at room temperature. After incubation, 
these two solutions were mixed and incubated for another 15 min at room 
temperature. The cells were washed with PBS twice. 1ml of serum free medium was 
added to the cells. The DNA-lipofectamine plus mixture was added to the cells and 
incubated for 3 hours at 37�C. After that, the cells were rinsed with PBS and fresh 
medium supplemented with 10% FBS and antibiotics was added followed by 
incubation for another 24 hours before microscopic examination. 
2.8.10 Fluorescence microscopy examination 
For epi-fluorescence microscopy (Zeiss Axioskop fluorescence microscopy), cells 
expressing GFP fusion protein were viewed with a GFP filter set (Omega Optical, 
Inc.). Images were captured by cooled CCD camera (Photometeric, Inc) (exposure 1 
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to 4sec) and were artificially colored using IpLab spectrum software. 
2.9 Yeast two-hybrid screening assay 
2.9.1 Cloning of the KIAA0022 gene into the yeast two-hybrid DNA-BD vector, 
pGBKT? 
PCR product of the KIAA0022 clone was obtained by using a pair of primers 
flanking the coding regions (CDS) of KIAA0022 (Forward: 5’-TAG GGC CCA 
TGG TAT GAT AAG CAT ACA TAA TGA AGA A-3'; Reverse: 5'-TAG GGC GTC 
GAC TTA GTC AAA TTG AAC AGG ATA TTC AT-3'). Both primers have end 
clamps that facilitated cleavage by restriction enzymes. An Nco\ site and Sail site, 
shown as the underlines bases, were present in the forward and reverse primers 
respectively. After the enzymatic digestion, the PCR product was cloned into the 
pGBKTT vector and the transformants were plated onto LB agar plate with 30|ig/ml 
kanamycin. Large-scale preparation of the pGBKT7-KIAA0022 plasmid was 
performed as procedures described previously. 
2.9.2 Small-scale transformation of pGBKT7-KIAA0022 plasmid 
2.9.2.1 Preparation of yeast competent cells 
Saccharomyces cerevisiae strains PJ69-2A was used in this experiment. Several 
colonies of PJ69-2A[bait] with 2-3mm in diameter were inoculated into 50ml YPDA 
medium. The culture was incubated at 30°C for 16-18 hour with shaking at 250 rpm 
to stationary phase (OD6oo>1.5). The overnight culture was transferred into 300ml 
YPDA medium, with ODeoo equal to 0.2. The culture was incubated at 30�C for 3 
hour with shaking at 250 rpm. When the ODeoo of the culture arrived 0.5, the cells 
were placed in the 250ml centrifuge bottle and were centrifliged at 1,000 xg for 5 
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min at room temperature (20-21°C). The supernatant was discarded and 25ml of 
sterile water was added to resuspend cell pellets. The cells were centrifuged at 1,000 
xg for 5 min at room temperature again. The supernatant was discarded and 1.5ml of 
sterile IX TE/LiAc was added to resuspend cell pellets. 
2.9,2.2 Transformation of the pGBKT7-KIAA0022 plasmid into the yeast strain 
PJ69-2A 
0.1 i^ g of pGBKT7-KIAA0022 plasmid and 0.1 mg Herring testes carrier DNA 
(denatured at 100�C for 20 min and then chilled on ice) were added into a 1.5ml tube 
with 0.1ml yeast competent cells (prepared in section 2.9.2.1). 0.6ml PEG/LiAc 
solution was added and was mixed by vortexing. The mixture was incubated at 30°C 
for 30 min with shaking (200 rpm). Afterward, 70|j.l DMSO was added and the 
mixture was mixed by gently inversion. The mixture was heat shocked for 15 min in 
a 42°C water bath and was chilled on ice for 2 min. Transformed cells were spun 
down at 14,000 rpm and the supernatant was removed. The cells were resuspended 
in 0.5ml IX TE. Transformed cells were selected by plating on SD/-Trp agar plated 
and incubated at 30�C. 
2.9.3 Screening a pretransformed library by yeast mating 
Self-activation of the pGBKT7-KIAA0022 plasmid should be tested before this 
experiment. One large, fresh colony of PJ69-2A[bait] was inoculated into 50ml of 
SDZ-Trp medium (Synthetic dropout (SD) medium supplemented with amino acids 
omitting tryptophan). The culture was incubated at 30�C overnight (16-24 hours) 
with shaking at 270 rpm to ODeoo > 0.8. The cells were spun down by centrifuging 
the entire 50ml culture at 1,000 xg for 5 min. The cell pellet was resuspended in the 
residual liquid ( �5 m l ) by vortexing. Afterward, the entire PJ69-2A[bait] culture and 
the 1ml normal liver pretransformed library culture (Clontech) was combined in a 2 
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liter sterile flask. Forty five-miniliter of YPDA/kan (50|j,g/ml) was added and swirled 
gently. The total volume of the mixture was brought up to 50ml with YPDA/kan. The 
mating mixture was incubated at 30�C overnight (24 hours) with gently swirling (50 
rpm). After the incubation, the mating mixture was transferred to a sterile 100ml 
centrifuge bottle and was spun down by centrifuging at 1,000 xg for 10 min. 
Meanwhile, the mating flask was rinsed two times with YPDA/kan (50ml each rinse). 
The rinses were combined and were used to resuspend the first pellet. The cells were 
spun down again at 1,000 xg for 10 min. The cell pellet was resuspended in 10ml of 
YPDA/kan. The mating mixtures were spread onto the SD/-Ade/-His/-Leu/-Trp 
(QDO) plates. The plates were incubated at 30°C until colonies appeared. 
2.9.4 P-Galactosidase analysis - colony lift filter assay 
In order to get better result, fresh colonies (i.e., grown at 30°C for 2-4 days and the 
colony with 1-3mm in diameter) should be used. A sterile VWR grade 410 filter 
paper was presoaked by 1ml of Z-buffer/X-gal solution [2ml Z-buffer (16.1 g/L 
Na2HP04-7H20; 5.5 g/L NaHzPCVHsO; 0.75 g/L KCl; 0.246 g/L MgSCVTHsO， 
adjust to pH 7.0 and autoclave); 16.7|j,l X-gal(50mg/ml); 5.4|al mercaptoethanol], A 
sterile dry filter was placed over the surface of the plate of colonies to be assayed by 
using forceps. When the filter paper has been evenly wetted, it was lifted off the agar 
plate with forceps and was transferred to a pool of liquid nitrogen for 10 sec. 
Afterward, the filter paper was moved from the liquid nitrogen and was allowed to 
thaw at room temperature (This freeze/thaw treatment was used to permeabilizes the 
cells). Then, the filter was placed, with the colony side up, on the presoaked filter 
paper. The filter paper was incubated at 30�C and the appearance of blue colonies 
was observed periodically. Those positive colonies turned blue in colour within 30 
min to 8 hours. 
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2.9.5 Analysis of yeast plasmid inserts using PCR and DNA sequencing 
2.9.5.1 PCR 
The cDNA inserts from all plasmids encoding candidate interacting proteins was 
amplified by PCR. A toothpick amount of fresh yeast colonies were subjected to 
PCR in the presence of 50mM KCl, l.SmM MgCb, and lOmM Tris-HCl, 200nM of 
each dNTP, 2.5 units Taq DNA polymerase, and 5pmol of each AMPl primer 
(5'-TAC CAC TAC AAT GGA TGA TG-3') and AMP2 primer (5'-CAC AGT TGA 
AGT GAA CTT GC-3') in a final volume of 50^1. The PCR reaction mix was 
subjected to a 5 min denaturation at 95°C, followed by 40 cycles of amplification 
(95"C, 36 sec; 55°C, 36 sec; 72°C，4 min) and 10 min final extension at ITC. The 
PCR product was analyzed on a 1.0% agarose/EtBr gel run in IX TBE buffer. 
2.9.5.2 DNA sequencing 
Six microliter of unpurified PCR product from above was used as the template for 
cycle sequencing. It was combined with 30mM Tris-HCl (pH9.5), 7.5mM MgCh, 
21^ 1 Thermo Sequenase DNA polymerase (Pharmacia), and 1.5|imol of IRD700 
conjugated 2-Hybrid primer (IRD700-5'-CTA CAA GGA TGA TGT ATATAAC-3') 
in a final volume of 17.5|il. The sequencing reaction mix was subjected to a 5 min 
denaturation at 95°C, followed by 40 cycles of amplification (95°C, 30 sec; 50°C, 30 
sec; 72�C, 2 min) and 10 min final extension at 72°C. The reactions were stopped by 
the addition of 4|li1 "Li-Cor stop buffer" (Cat. No. 830-04997). The sequencing 
products were stored at 4 � C before being resolved on a 5.5% acrylamide gel using 





3.1 Results of ESTs sequencing in normal counterpart and HCC 
libraries 
3.1.1 The sequencing results of the normal counterpart cDNA clones 
Four thousand seven hundred and eighty eight cDNA clones and a total of 3,495,489 
bases were sequenced from the normal counterpart cDNA library. The average 
success rate was about 67.5%. The average length of the sequences was 730 bases. 
The sequences were sent to NCBI for homology searches using the BLASTN 
program. The information of each cDNA clones was stored in a database including 
the clone number, length of the cDNA sequence, accession number, putative 
identities, the Expect value (E-value) and the percentage of homology. The results of 
the homology searches were summarized in Table 2. 
Of 4,788 cDNA clones sequenced, 4,014 sequences, or approximate 84% of the 
partial sequences, exhibited significant identities with known genes in the 
GenBank/EMBL databases using the BLAST algorithm at the National Center for 
Biotechnology Information, among which 19% (an acceptable scores for the quality 
of the construction of cDNA library) represented mitochondrial transcripts out of a 
total of 4,788 sequenced cDNA clones. Another 16% of these transcripts matched to 
other ESTs currently deposited in the GenBank/EMBL databases, although not to 
any other known sequences. 
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Table 2. Summary of EST data from human normal counterpart cDNA library 
Number of Clones Percentage (%) 
Human matches 3120 65.16 
Non-human matches 8 0.17 
Mitochondrial genes 886 18.50 




Table 3. Accuracy assessment using 50 clones which match with the mitochondrial 
genome in the normal counterpart library. 
Range of sequences Number of base pairs Accuracy (%) 
(bases) aligned 
1-100 5000 99.2 
101-200 5000 99.2 
201-300 4977 99.3 
>300 12840 97.8 
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3.1.2 Sequencing results of the human liver cancer cDNA clones 
Eleven thousand six hundred and six human liver cancer cDNA clones and a total 
5,290,791 bases were sequenced from the cDNA library. The average success rate 
was about 54.5%. The average length of the sequences was 456 bases. The DNA 
sequences were sent to NCBI for homology searches using the BLASTN program. 
The information of each cDNA clone was stored in a database including the clone 
number, length of the cDNA sequence, accession number, putative identities, the 
Expect value (E-value) and the percentage of homology. The results of the homology 
searches were summarized in Table 4. 
Of the 11,606 cDNA clones sequenced, 9,428 sequences, or approximate 81% of the 
partial sequences, exhibited significant identities (E-value less than or equal to e-20) 
to known genes in the GenBank/EMBL databases using the BLAST algorithm at the 
National Center for Biotechnology Information, among which 11% (an acceptable 
scores for the quality of the construction of cDNA library) represented mitochondrial 
transcripts. Another 19% of these transcripts matched to other ESTs currently 
deposited in the GenBank/EMBL databases, although not to any other known 
sequences. 
3.1.3 The accuracy of the automated sequencing technique 
In order to assess the accuracy of the automated sequencing technique, ESTs 
matching to the human mitochondrial consensus sequence in both normal 
counterpart library and HCC library were analyzed. Fifty clones were randomly 
selected from those 886 and 1,216 clones that matched with the mitochondrial 
genome for analysis respectively. The number of mismatches, insertions and 
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deletions were counted and summarized in Table 3 and Table 5. Of 27,817 and 
22,038 base pairs aligned in normal counterpart and HCC libraries, the average 
accuracy over the first 300 base pairs of sequence was 99.2% and 98.8% respectively. 
The average accuracy for portions of sequence complied beyond 300 base pairs was 
slightly lower (97.8% and 97.3% respectively). This level of ambiguity did not 
significantly affect the identification of known and previously unknown transcripts 
by database searches. 
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Table 4. Summary of EST data from human adult HCC cDNA library 
Number of clones Percentage (%) 
Human matches 8181 70.5 
Non-human matches 31 0.3 
Mitochondrial genes 1216 10.5 




Table 5. Accuracy assessment using 50 clones which match with the mitochondrial 
genome in the HCC library. 
Range of sequences Number of base pairs Accuracy (%) 
(bases) aligned 
1-100 5000 99.4 
101-200 4853 99.0 
201-300 3822 97.9 
>300 8363 97.3 
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3.1.4 Catalogue of normal counterpart ESTs 
Of 4,788 partial cDNA sequences, there were 3,120 human matches and 8 
non-human matches. A total of 885 specific known genes (excluding mitochondrial 
genes and repetitive elements) were found. All these 3,128 ESTs were classified 
according to their putative cellular localization and function into 11 groups. They are 
contractile elements, cytoskeleton and related proteins, extracellular matrix protein, 
proteins that participate in energy metabolism, hormones and proteins involved in 
hormonal regulation, proteins involved in signal transduction and cell cycle 
regulation, proteins of transcription and translation machinery, membrane associated 
proteins, secretory proteins, proteins involved on other metabolism and 
miscellaneous proteins (Table 6 and 7) as described by Liew et al., 1994. The 
proportion of gene expression represented in each category was estimated by 
calculating the proportion of ESTs with known gene matches in each category, 
allowing for comparisons of gene expression patterns. 
The most frequently expressed genes were coding for secretory proteins which 
contribute 44.3% of total ESTs. It is followed by genes involved in transcription and 
translation (17.6%), other metabolism (14.4%), signal transduction and cell cycle 
regulation (4.6%), energy metabolism (4.4%), membrane associated (3.6%), 
cytoskeletal related (1.2%), hormone and hormonal control (1.1%), extracellular 
matrix (0.8%) and contractile element (0.2%). The remaining 7.8% were contributed 
by genes lacking adequate information for classification. The most frequently 
occurring transcript in normal counterpart tissue cDNA library was albumin, which 
was represented by 252 ESTs (5.3%) followed by apolipoprotein A-I, which was 
recorded 120 times (2.5%). 
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Table 6. Gene expression profile of the normal counterpart tissue 
Category Frequency Percentage 
Contractile element 7 0.2% 
Cytoskeleton related 37 1.2% 
Energy metabolism 139 4.4% 
Extracellular matrix 24 0.8% 
Hormone and hormonal 33 1.1% 
control 
Membrane associated 111 3 .6% 
Miscellaneous 244 7.8% 
Other metabolism 451 14.4% 
Secretory protein 1387 44.3% 
Signal transduction/cell cycle regulation 144 4.6% 
Transcription and translation ^ 17.6% 
3 m 1 0 0 % ^ 
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3.1.5 Catalogue of liver cancer ESTs 
Of 11,606 partial cDNA sequences, there were 8,181 human matches and 31 
non-human matches. A total of 1,615 specific known genes (excluding mitochondrial 
genes and repetitive elements) were found. All these 8,181 ESTs were classified 
according to their putative cellular localization and function into 11 groups and the 
proportion of ESTs with known gene matches in each category was calculated as 
described previously. 
It was found that the gene expression in human liver cancer tissue was quite different 
from that of normal counterpart one. The most frequent expressed category was 
genes involved in transcription and translation (30.4%) in HCC instead of secretory 
protein (17.6%) in normal. It is followed by genes involved in other metabolism 
(22.6%), energy metabolism (7.2%), signal transduction and cell cycle regulation 
(6.99%), membrane associated (3.2%), cytoskeletal related (1.6%), extracellular 
matrix (1.1%), hormone and hormonal control (0.7%) and contractile element (0.4%). 
The remaining 8.6% were contributed by the genes lacking enough information for 
classification. The most frequently occurring gene in liver cancer cDNA library was 
ferritin L chain, which was represented by 817 ESTs (7.0%), followed by 
apolipoprotein A-II, which was recorded 548 times (4.7%). 
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Table 7. Gene expression profile of the HCC tissue 
Category Frequency Percentage 
Contractile element 30 0.4% 
Cytoskeleton related 129 1.6% 
Energy metabolism 592 7.2% 
Extracellular matrix 94 1.1% 
Hormone and hormonal control 57 0.7% 
Membrane associated 263 3.2% 
Miscellaneous 708 8.6% 
Other metabolism 1859 22.6% 
Secretory protein 1414 17.2% 
Signal transduction/cell cycle regulation 574 7.0% 




Table 8. Human liver ESTs that were matched to known genes in the GenBank and 
EMBL databases. Presented are genes that the HCC and normal counterpart tissue 
matched, together with unigene cluster ID for these genes and the number of clones 
from which the ESTs were derived in two different cDNA libraries (Normal ExpFrq: 
the expresseion frequency in normal counterpart library; Tumor ExpFrq: the 
expression frequency in HCC library). In cases where multiple clones representing a 
single gene exist, only a single, representative clone is given. In the case where ESTs 
matched to non-human sequences, the organism of that matching sequence was 
indicated in parentheses simultaneously. 
Unigene Normal Tumor 
Putative Identity cluster ID ExpFrq ExpFrq 
Contractile elements (n=ll) 
myosin I [Bos taurus] NIL 0 1 
MLC-B Myosin regulatory light chain Hs. 180224 0 7 
gelsolin (amyloidosis, Finnish type) Hs.290070 0 1 
MYOIB Myosin IB Hs.l21576 1 1 
myosinic Hs.82251 0 1 
myosin VIIA (Usher syndrome IB (autosomal recessive, Hs.95361 1 0 
• severe)) 
myosin, heavy polypeptide 9, non-muscle Hs. 146550 0 2 
myosin, light polypeptide 1, alkali; skeletal, fast Hs.90318 1 0 
myosin，light polypeptide 6，alkali, smooth muscle and Hs.77385 3 15 
non-muscle 
myosin, light polypeptide kinase Hs.211582 0 1 
myosin, light polypeptide, regulatory, Hs.233936 1 1 
non-sarcomeric (20kD) 
Cytoskeletal related proteins (n=63) 
actin related protein 2/3 complex, subunit 1A Hs. 11538 0 4 
actin related protein 2/3 complex, subunit 2 Hs.83583 0 3 
actin related protein 2/3 complex, subunit 3 Hs.6895 0 1 
actin related protein 2/3 complex, subunit 5 Hs. 82425 0 1 
actin, beta Hs.288061 5 7 
actin, gamma 1 Hs. 14376 1 8 
actinin, alpha 1 Hs. 119000 0 1 
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actinin, alpha 4 Hs. 182485 1 2 
alpha actinin 4 [Mus musculus] Mm. 143830 1 0 
ARPl (actin-related protein 1, yeast) homolog A Hs. 153 961 0 1 
capping protein (actin filament) Hs. 184270 0 1 
muscle Z-line, alpha 1 
capping protein (actin filament) Hs.75546 1 0 
muscle Z-line, alpha 2 
capping protein (actin filament) Hs.76368 2 0 
muscle Z-line, beta 
clathrin, light polypeptide (Lea) Hs. 104143 1 1 
coatomer protein complex, subunit alpha Hs.75887 0 6 
coatomer protein complex, subunit beta Hs.3059 0 1 
coatomer protein complex, subunit beta 2 Hs.75724 1 1 
coatomer protein complex, subunit epsilon Hs. 10326 0 2 
cofilin 1 (non-muscle) Hs. 180370 1 1 
collagen, type IV, alpha 3 (Goodpasture antigen) Hs.21276 0 1 
binding protein 
collagen, type V, alpha 1 Hs. 146428 0 2 
collagen, type XVIII, alpha 1 Hs.78409 2 1 
collagenase and stromelysin genes, complete cds，and NIL 0 1 
metalloelastase gene, partial cds 
cytoskeleton-associated protein 1 Hs.31053 0 1 
destrin (actin depolymerizing factor) (ADF) Hs.82306 0 1 
dynactin 2 (p50) Hs.84153 1 0 
dynactin 3 (p22) Hs.l5961 0 1 
dynactin 4 (p62) Hs. 180952 0 1 
dynamin2 Hs. 167013 0 1 
dynein, cytoplasmic, light polypeptide Hs.5120 1 7 
dystrobrevin, beta Hs. 13451 0 2 
exostoses (multiple) 2 Hs.75334 0 1 
filamin B, beta (actin-binding protein-278) Hs.81008 0 1 
gamma-tubulin complex protein 2 Hs. 13386 1 0 
keratin 10 Hs.99936 0 1 
keratin 18 Hs.65114 2 5 
keratin 8 Hs.242463 1 2 
kinesin family member IC Hs. 139648 1 0 
kinesin family member 5B Hs. 149436 0 1 
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kinesin-like 4 Hs. 119324 1 3 
kinesin-like 5 Hs.270845 0 1 
kinesin-like 6 Hs.69360 0 . 1 
myelin protein zero Hs.93883 0 2 
neurotrophic tyrosine kinase, receptor, type 1 Hs.85844 0 3 
profilin 1 (PFNl) Hs.75721 2 0 
profilin 2 Hs.91747 0 1 
restin (Reed-Steinberg cell-expressed intermediate Hs.31638 0 2 
filament-associated protein) 
serine (or cysteine) proteinase inhibitor，clade H (heat Hs.9930 0 1 
shock protein 47)，member 2 
spectrin, alpha, non-erythrocytic 1 (alpha-fodrin) Hs.77196 0 1 
spectrin, beta, non-erythrocytic 1 Hs. 107164 0 1 
synaptopodin Hs.5307 1 0 
tissue inhibitor of metalloproteinase 1 (erythroid Hs.5831 1 2 
potentiating activity, collagenase inhibitor) 
transgelin Hs.75777 1 1 
transgelin 2 Hs.75725 3 13 
tubulin, alpha 1 (testis specific) Hs.75318 0 2 
tubulin, alpha, brain-specific Hs.272897 0 1 
tubulin, alpha, ubiquitous Hs.278242 0 6 
tubulin, beta polypeptide Hs. 179661 1 5 
tubulin, beta, 2 Hs.251653 0 2 
tubulin-specific chaperone a Hs.24930 1 1 
tubulin-specific chaperone c Hs.75064 1 0 
vimentin Hs. 297753 1 2 
vinexin beta (SH3-containing adaptor molecule-1) Hs.33787 1 0 
Energy metabolism (n=152) 
3-hydroxybutyrate dehydrogenase Hs.76893 2 0 
acetyl-Coenzyme A acetyltransferase 1 Hs.37 1 1 
acetyl-Coenzyme A acyltransferase 2 Hs.32500 1 3 
acyl-Coenzyme A dehydrogenase family, member 8 Hs. 14791 0 1 
acyl-Coenzyme A dehydrogenase, Hs. 127610 2 0 
C-2 to C-3 short chain 




acyl-Coenzyme A dehydrogenase, very long chain Hs.82208 2 3 
ATP synthase, H+ transporting, mitochondrial FO Hs.81634 0 2 
complex, subunit b，isoform 1 . 
ATP synthase, H+ transporting, mitochondrial FO Hs.429 4 3 
complex, subunit c (subunit 9) isoform 3 
ATP synthase, H+ transporting, mitochondrial FO Hs.80986 0 3 
complex，subunit c (subunit 9) isoform 1 
ATP synthase, H+ transporting, mitochondrial FO Hs.89399 0 3 
complex, subunit c (subunit 9)，isoform 2 
ATP synthase, H+ transporting, mitochondrial FO Hs.85539 1 3 
complex, subunit e 
ATP synthase, H+ transporting, mitochondrial FO Hs. 155751 1 11 
complex, subunit f, isoform 2 (ATP5J2) 
ATP synthase, H+ transporting, mitochondrial FO Hs.73851 0 5 
complex, subunit F6 
ATP synthase, H+ transporting, mitochondrial F1 Hs. 155101 3 1 
complex, alpha subunit, isoform 1，cardiac muscle 
ATP synthase, H+ transporting, mitochondrial F1 Hs.25 0 4 
complex, beta polypeptide 
ATP synthase, H+ transporting, mitochondrial F1 Hs.89761 0 1 
complex, delta subunit 
ATP synthase, H+ transporting, mitochondrial F1 Hs. 177530 1 27 
complex, epsilon subunit 
ATP synthase, H+ transporting, mitochondrial F1 Hs. 155433 2 5 
complex, gamma polypeptide 1 
ATP synthase, H+ transporting, mitochondrial F1 Hs.76572 1 8 
complex, O subunit 
ATP synthase, H+ transporting, mitochondrial FIFO, Hs.64593 0 11 
subunit d 
ATP synthase, H+ transporting, mitochondrial FIFO, Hs. 107476 0 10 
subunit g 
ATPase inhibitor precursor Hs.241336 1 2 
ATPase, Ca++ transporting, cardiac muscle, Hs.l526 0 1 
slow twitch 2 
ATPase, Ca++ transporting, plasma membrane 1 Hs.78546 0 1 




ATPase, H+ transporting, lysosomal (vacuolar proton Hs.7476 1 3 
pump) 21kD 
ATPase, H+ transporting, lysosomal (vacuolar proton Hs.24322 1 . 3 
pump) 9kD 
ATPase, H+ transporting, lysosomal Hs.281866 1 0 
(vacuolar proton pump), alpha polypeptide, 
70kD, isoform 1 
ATPase, H+ transporting, lysosomal Hs. 106876 0 1 
(vacuolar proton pump), member D 
ATPase, H+ transporting, lysosomal (vacuolar proton Hs.90336 0 1 
pump), member J 
ATPase, Na+/K+ transporting, alpha 1 polypeptide Hs.76549 0 1 
ATPase, Na+/K+ transporting, beta 1 polypeptide Hs.78629 1 2 
ATPase, vacuolar, 14 kD Hs.78089 2 1 
ATP-binding cassette, sub-family B (MDR/TAP), Hs.21330 0 1 
member 1 
ATP-binding cassette, sub-family B (MDR/TAP), Hs. 107911 0 1 
member 6 
ATP-binding cassette, sub-family C (CFTR/MRP), Hs. 193852 0 1 
member 2 
ATP-binding cassette, sub-family D (ALD), Hs.76781 0 2 
member 3 
ATP-binding cassette, sub-family E (OABP), Hs. 12013 0 1 
member 1 
ATP-binding cassette, sub-family F (GCN20), Hs.9573 1 2 
member 1 
ATP-binding cassette, sub-family F (GCN20), Hs. 153612 0 2 
member 2 
ATP-binding cassette, sub-family G (WHITE), Hs.302030 0 1 
member 8 (sterolin 2) 
COX 11 (yeast) homolog, cytochrome c oxidase Hs.241515 0 1 
assembly protein 
COX 17 (yeast) homolog, cytochrome c oxidase Hs. 16297 1 2 
assembly protein 
cytochrome b-245, alpha polypeptide Hs.68877 2 0 
cytochrome b-5 Hs.83834 3 18 
cytochrome c Hs. 169248 0 4 
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cytochrome c oxidase subunit IV Hs. 113205 3 7 
cytochrome c oxidase subunit Va Hs. 181028 1 0 
cytochrome c oxidase subunit Va pseudogene 1 Hs.278595 0 . 2 
cytochrome c oxidase subunit Vb Hs.l342 2 2 
cytochrome c oxidase subunit Via polypeptide 1 Hs. 180714 2 19 
cytochrome c oxidase subunit VIb Hs. 174031 2 26 
cytochrome c oxidase subunit Vic Hs.74649 2 11 
cytochrome c oxidase subunit Vila Hs.70312 2 10 
polypeptide 2 (liver) 
cytochrome c oxidase subunit Vila Hs.30888 1 2 
polypeptide 2 like 
cytochrome c oxidase subunit Vllb Hs.75752 2 9 
cytochrome c oxidase subunit VIIc Hs.3462 1 11 
cytochrome c oxidase subunit VIII Hs.81097 2 11 
cytochrome c-1 Hs. 289271 1 8 
dihydrofolate reductase Hs. 83765 1 1 
H-L(3)MBT Lethal (3) malignant brain tumor l(3)mbt Hs.300863 0 1 
protein (Drosophila) homolog 
electron-transfer-flavoprotein, alpha polypeptide Hs.169919 0 2 
(glutaric aciduria II) 
electron-transfer-flavoprotein, beta polypeptide Hs.74047 2 27 
enolase 1, (alpha) Hs.254105 1 15 
enoyl Coenzyme A hydratase 1, peroxisomal Hs.196176 1 3 
enoyl Coenzyme A hydratase, short chain, 1 Hs.76394 3 4 
enoyl-Coenzyme A, hydratase/3-hydroxyacyl Coenzyme Hs.l531 1 0 
A dehydrogenase 
galactokinase 1 Hs.92357 1 0 
galactokinase 2 Hs. 129228 0 1 
glucan (1,4-alpha-), branching enzyme 1 (glycogen Hs.l691 0 2 
branching enzyme, Andersen disease, glycogen 
storage disease type IV) 
glucokinase (hexokinase 4) regulatory protein Hs. 89771 1 1 
glucose phosphate isomerase Hs. 180532 1 10 
glucose-6-phosphatase, transport protein 1 Hs.26655 1 0 
glucose-6-phosphate dehydrogenase Hs.80206 0 1 
glyceraldehyde-3 -phosphate dehydrogenase Hs. 169476 8 14 




hydroxyacyl-Coenzyme A Hs.75860 1 1 
dehydrogenase/3-ketoacyl-Coenzyme A . 
thiolase/enoyl-Coenzyme A hydratase (trifiinctional 
protein), alpha subuni 
hydroxyacyl-Coenzyme A Hs. 146812 2 1 
dehydrogenase/3 -ketoacyl-Coenzyme A 
thiolase/enoyl-Coenzyme A hydratase (trifiinctional 
protein), beta subunit 
isocitrate dehydrogenase 1 (NADP+), soluble Hs.ll223 0 2 
isocitrate dehydrogenase 3 (NAD+) alpha Hs. 250616 0 1 
isocitrate dehydrogenase 3 (NAD+) gamma Hs.75253 0 1 
lactate dehydrogenase A Hs.2795 1 9 
lactate dehydrogenase B Hs.234489 0 2 
low molecular mass ubiquinone-binding protein Hs.3709 3 19 
malate dehydrogenase 1，NAD (soluble) Hs.75375 0 2 
malate dehydrogenase 2, NAD (mitochondrial) Hs. 111076 1 2 
malonyl-CoA decarboxylase Hs. 150748 0 1 
methylmalonyl Coenzyme A mutase Hs. 155212 2 0 
NADH dehydrogenase (ubiquinone) 1 alpha Hs.74823 3 9 
subcomplex, 1 (7.5kD, MWFE) 
NADH dehydrogenase (ubiquinone) 1 alpha Hs. 163867 1 5 
subcomplex, 2 (8kD, B8) 
NADH dehydrogenase (ubiquinone) 1 alpha Hs. 198269 0 2 
subcomplex, 3 (9kD, B9) 
NADH dehydrogenase (ubiquinone) 1 alpha Ms. 50098 0 9 
subcomplex, 4 (9kD, MLRQ) 
NADH dehydrogenase (ubiquinone) 1 alpha Hs.274416 0 6 
subcomplex, 6 (14kD, B14) 
NADH dehydrogenase (ubiquinone) 1 alpha Hs. 19561 1 1 
subcomplex, 7 (14.5kD, B14.5a) (NDUFA7) 
NADH dehydrogenase (ubiquinone) 1 alpha Hs.31547 0 1 
subcomplex, 8 (19kD, PGIV) 
NADH dehydrogenase (ubiquinone) 1 beta Hs. 183435 1 4 
subcomplex, 1 (7kD, MNLL) 
NADH dehydrogenase (ubiquinone) 1 beta Hs. 198274 0 1 
subcomplex, 10 (22kD, PDSW) 
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NADH dehydrogenase (ubiquinone) 1 beta Hs. 198272 2 5 
subcomplex，2 (8kD, AGGG) 
NADH dehydrogenase (ubiquinone) 1 beta Hs. 109760 1 . 1 
subcomplex, 3 (12kD, B12) 
NADH dehydrogenase (ubiquinone) 1 beta Hs.227750 1 8 
subcomplex, 4 (15kD, B15) 
NADH dehydrogenase (ubiquinone) 1 beta Hs. 109646 1 2 
subcomplex, 6 (17kD, B17) 
NADH dehydrogenase (ubiquinone) 1 beta Hs.661 2 2 
subcomplex, 7 (18kD, B18) 
NADH dehydrogenase (ubiquinone) 1 beta Hs. 198273 0 1 
subcomplex, 8 (19kD, ASHI) 
NADH dehydrogenase (ubiquinone) 1 beta Hs. 15977 2 14 
subcomplex, 9 (22kD, B22) 
NADH dehydrogenase (ubiquinone) 1，alpha/beta Hs.5556 0 1 
subcomplex, 1 (8kD, SDAP) (NDUFABl) 
NADH dehydrogenase (ubiquinone) 1，subcomplex Hs.84549 0 2 
unknown, 1 (6kD, KFYI) 
NADH dehydrogenase (ubiquinone) 1, subcomplex Hs.l93313 2 10 
unknown, 2 (14.5kD, B14.5b) 
NADH dehydrogenase (ubiquinone) Fe-S protein 2 Hs.173611 0 2 
NADH dehydrogenase (ubiquinone) Fe-S protein 3 Hs.5273 0 2 
NADH dehydrogenase (ubiquinone) Fe-S protein 4 Hs. 10758 0 2 
NADH dehydrogenase (ubiquinone) Fe-S protein 5 Hs.80595 0 5 
NADH dehydrogenase (ubiquinone) Fe-S protein 6 Hs.49767 0 1 
NADH dehydrogenase (ubiquinone) Fe-S protein 7 Hs.211914 3 0 
NADH dehydrogenase (ubiquinone) Fe-S protein 8 Hs. 90443 1 2 
NADH dehydrogenase (ubiquinone) flavoprotein 1 Hs.7744 2 0 
NADH dehydrogenase (ubiquinone) flavoprotein 2 Hs.51299 1 0 
NADH dehydrogenase (ubiquinone) flavoprotein 3 Hs.59745 0 2 
NADH:ubiquinone oxidoreductase MLRQ subunit Hs. 110024 0 1 
homolog 
neighbor of C0X4 Hs. 173162 0 1 
nicotinamide nucleotide transhydrogenase Hs. 18136 0 1 
ornithine carbamoyltransferase Hs. 117050 2 1 
P450 (cytochrome) oxidoreductase Hs. 167246 0 2 
phosphoenolpyruvate carboxykinase 1 Hs.l872 1 0 
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phosphoenolpymvate carboxykinase 2 Hs.75812 4 1 
phosphofmctokinase, liver Hs. 155455 0 1 
phosphofructokinase, muscle Hs.75160 0 . 1 
phosphofmctokinase, platelet Hs.99910 0 1 
phosphogluconate dehydrogenase Hs.75888 0 2 
phosphoglycerate dehydrogenase Hs.3343 1 3 
phosphoglycerate kinase 1 (PGKl) Hs.78771 0 9 
phosphoiylase, glycogen; liver Hs.771 0 1 
pyruvate carboxylase Hs.89890 1 0 
pyruvate kinase, muscle Hs. 198281 0 2 
ATP synthase lipid-binding protein P3 precursor Rn.2180 0 11 
[Rattus norvegicus ] 
sterol O-acyltransferase 1 Hs. 14553 0 1 
succinate dehydrogenase complex, subunit A, Hs.469 0 1 
flavoprotein (Fp) 
succinate dehydrogenase complex, subunit B, Hs.64 0 1 
iron sulfur (Ip) 
succinate dehydrogenase complex, subunit C， Hs.3577 0 4 
integral membrane protein, 15kD 
succinate dehydrogenase complex, subunit D, Hs. 168289 2 1 
integral membrane protein 
succinate-CoA ligase, GDP-forming, alpha subunit Hs.7043 0 4 
succinate-CoA ligase, GDP-forming, beta subunit Hs.247309 0 1 
transaldolase 1 Hs.77290 1 3 
triosephosphate isomerase 1 (TPIl) Hs.83848 6 5 
Tu translation elongation factor, mitochondrial Hs. 12084 2 0 
ubiquinol-cytochrome c reductase (6.4kD) subunit Hs.8372 3 12 
ubiquinol-cytochrome c reductase binding protein Hs. 131255 0 5 
ubiquinol-cytochrome c reductase complex (7.2 kD) Hs.284292 0 3 
ubiquinol-cytochrome c reductase core protein I Hs. 119251 0 1 
ubiquinol-cytochrome c reductase core protein II Hs. 173554 0 2 
ubiquinol-cytochrome c reductase hinge protein Hs.73818 0 8 
ubiquinol-cytochrome c reductase, Rieske iron-sulfur Hs.3712 1 1 
polypeptide 1 
Extracellular matrix (n=14) 
fibronectin 1 Hs.287820 6 29 
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laminA/C Hs.77886 0 3 
lamin B receptor Hs. 152931 0 1 
laminin receptor 1 (67kD, ribosomal protein SA) Hs. 181357 8 . 30 
laminin, beta 1 Hs.82124 0 1 
laminin, gamma 1 (formerly LAMB2) Hs.214982 0 1 
lectin, galactoside-binding，soluble, 1 (galectin 1) Hs.227751 1 6 
lectin，galactoside-binding, soluble, 2 (galectin 2) Hs. 113987 1 0 
lectin, galactoside-binding, soluble, 3 (galectin 3) Hs.621 0 1 
lectin, galactoside-binding, soluble, 3 binding protein Hs.79339 1 0 
(galectin 6 binding protein) 
lectin, galactoside-binding，soluble, 4 (galectin 4) Hs.5302 3 8 
nidogen (enactin) Hs.62041 0 1 
syndecan 2 (heparan sulfate proteoglycan 1，cell Hs.l501 0 3 
surface-associated, fibroglycan) 
tissue inhibitor of metalloproteinase 3 Hs.245188 0 4 
(Sorsby fundus dystrophy, pseudoinflammatory) 
Hormone and hormonal control (n=23) 
androgen induced protein Hs. 107528 0 1 
decidual protein induced by progesterone Hs.93675 0 1 
erythropoietin Hs.2303 1 0 
esterase D/formylglutathione hydrolase Hs.82193 1 1 
estrogen-related receptor alpha (ESRRA) Hs. 110849 0 1 
hepatoma-derived growth factor Hs.89525 1 5 
(high-mobility group protein 1-like) 
insulin-like growth factor 2 (somatomedin A) Hs.251664 2 0 
insulin-like growth factor binding protein 1 Hs. 102122 1 2 
insulin-like growth factor binding protein 2 (36kD) Hs. 162 5 0 
insulin-like growth factor binding protein 3 Hs.77326 3 1 
insulin-like growth factor binding protein 7 Hs. 119206 1 0 
insulin-like growth factor-binding protein 4 Hs.l516 3 0 
interferon stimulated gene (20kD) Hs. 183487 0 1 
interleukin 13 receptor, alpha 1 Hs.285115 0 2 
interleukin 18 (interferon-gamma-inducing factor) Hs.83077 1 0 
kininogen Hs.77741 10 11 
nardilysin (N-arginine dibasic convertase) Hs.4099 0 3 
ninjurin 1 Hs. 11342 0 1 
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oxidative 3 alpha hydroxysteroid dehydrogenase; Hs. 11958 1 3 
retinol dehydrogenase; 3-hydroxysteroid epimerase 
procollagen-proline, 2-oxoglutarate 4-dioxygenase Hs.75655 1 • 20 
(proline ‘-hydroxylase)�beta polypeptide (protein 
disulfide isomerase; thyroid hormone binding protein 
p55) 
Sigma receptor (SR31747 binding protein 1) Hs.24447 0 1 
stanniocalcin 1 Hs.25590 0 1 
trinucleotide repeat containing 3 Hs.21858 0 1 
Membrane associated proteins (n=154) 
accessory proteins BAP31/BAP29 (DXS1357E) Hs.291904 0 4 
adipose differentiation-related protein Hs.3416 1 17 
amyloid beta (A4) precursor protein Hs. 177486 1 0 
(protease nexin-II, Alzheimer disease) 
amyloid beta (A4) precursor-like protein 2 Hs.279518 1 4 
arsA (bacterial) arsenite transporter, ATP-binding, Hs. 165439 1 1 
homolog 1 
asialoglycoprotein receptor 1 Hs. 12056 6 3 
asialoglycoprotein receptor 2 Hs.l259 3 0 
basigin (OK blood group) Hs.74631 0 7 
benzodiazapine receptor (peripheral) Hs.202 1 2 
Betl (S. cerevisiae) homolog Hs.23103 1 0 
calnexin Hs. 155560 0 4 
calponin 3，acidic Hs. 194662 0 1 
CD 14 antigen Hs.75627 0 1 
CD 164 antigen, sialomucin Hs.43910 0 2 
CD24 antigen Hs.286124 0 4 
(small cell lung carcinoma cluster 4 antigen) 
CD27-binding (Siva) protein Hs. 112058 1 0 
CD36 antigen Hs.75613 0 1 
CDS6 antigen -like 1 Hs. 180616 1 1 
CD47 antigen Hs.82685 0 1 
CD59 antigen pl8-20 Hs. 119663 1 4 
CD63 antigen (melanoma 1 antigen) Hs.76294 6 9 
CD68 antigen Hs.246381 2 0 
CD74 antigen Hs. 84298 8 0 
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CD81 antigen (target of antiproliferative antibody 1) Hs.54457 2 1 
CD83 antigen Hs.79197 1 0 
CD97 antigen Hs.3107 0 3 
cell membrane glycoprotein, llOOOOM(r) Hs.90107 0 4 
centromere protein B (80kD) Hs. 85004 0 1 
claudin 1 Hs.7327 1 0 
claudin 14 Hs.266416 0 1 
claudin 4 Hs.5372 0 1 
cleft lip and palate associated transmembrane protein 1 Hs. 106671 0 1 
coat protein gamma-cop Hs. 102950 1 1 
colony stimulating factor 1 receptor, formerly Hs. 174142 0 1 
McDonough feline sarcoma viral (v-fms) oncogene 
homolog 
copine I Hs. 166887 0 3 
cyclin-dependent kinase inhibitor lA (p21, Cipl) Hs. 179665 0 1 
DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 19 Hs.289097 1 0 
(Dbp5，yeast, homolog) 
DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 5 Hs.76053 0 5 
(RNAhelicase, 68kD) 
DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 9 Hs.74578 1 0 
(RNA helicase A，nuclear DNA helicase II; 
leukophysin) 
dysferlin, limb girdle muscular dystrophy 2B Hs. 143897 0 1 
(autosomal recessive) 
ectonucleoside triphosphate diphosphohydrolase 5 Hs. 80975 0 1 
emopamil-binding protein (sterol isomerase) Hs.75105 1 1 
endoglin (Osler-Rendu-Weber syndrome 1) Hs.76753 1 0 
epithelial membrane protein 2 (EMP2) Hs.29191 0 1 
erythrocyte membrane protein band 4.9 (dematin) Hs.274122 1 0 
erythrocyte membrane protein band 7.2 (stomatin) Hs. 160483 1 2 
Fc fragment of IgE, high affinity I，receptor for; Hs.743 1 1 
gamma polypeptide 
Fc fragment of IgG, receptor, transporter, alpha Hs. 111903 2 2 
FK506 binding protein precursor Hs.24048 0 2 
FK506-binding protein 1A (12kD) Hs.752 0 2 
FK506-binding protein 2 (13kD) Hs.227729 1 2 
FK506-binding protein 8 (38kD) Hs. 173464 0 1 
6 0 
Results 
FXYD domain-containing ion transport regulator 3 Hs.301350 0 4 
GABA(A) receptor-associated protein Hs.7719 1 3 
glucagon receptor Hs.208 1 . 0 
glycoprotein (transmembrane) nmb Hs.82226 0 1 
glypican 1 Hs.2699 0 1 
glypican 3 Hs. 119651 0 3 
heat shock 70kD protein IB Hs.274402 0 1 
hepsin (transmembrane protease, serine 1) Hs.823 2 1 
integrin beta 1 Hs. 202661 1 1 
hyaluronic acid receptor Hs.278975 1 0 
insulin-like growth factor 2 receptor Hs.76473 1 0 
integral membrane protein 1 Hs.287850 0 2 
integral membrane protein 2B Hs.239625 4 1 
integrin beta 4 binding protein Hs.5215 0 5 
integrin, beta 2 (antigen CD 18 (p95), lymphocyte Hs.83968 0 1 
function-associated antigen 1; macrophage antigen 
l(mac-l) beta subunit) (ITGB2) 
integrin, beta 4 Hs.85266 1 0 
integrin, beta 5 Hs. 149846 1 0 
junctional adhesion molecule 1 Hs.286218 0 1 
leukocyte immunoglobulin-like receptor, Hs.77062 1 0 
subfamily B，member 5 
Ligatin Hs.274151 0 2 
low density lipoprotein-related protein-associated Hs.75140 1 1 
protein 1 
lymphocyte antigen 6 complex，locus E Hs.77667 1 4 
lymphocyte antigen 6 complex, locus H Hs. 159590 0 1 
lymphocyte cytosolic protein 1 (L-plastin) Hs.76506 0 1 
lymphocyte-specific protein 1 Hs.56729 0 1 
lymphotoxinbeta receptor Hs . l l l6 1 1 
lysosomal-associated protein transmembrane 4 alpha Hs. 111894 0 4 
macrophage scavenger receptor 1 Hs.49 0 1 
major histocompatibility complex, class I，A Hs. 181244 1 4 
major histocompatibility complex, class I, B Hs.77961 1 2 
major histocompatibility complex, class I，C Hs.277477 8 2 
major histocompatibility complex, class I，E Hs. 181392 1 0 
major histocompatibility complex, class I, F Hs. 110309 2 0 
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major histocompatibility complex, class II，DR alpha Hs.76807 2 0 
major histocompatibility complex, class II, DR beta 1 Hs. 180255 0 2 
major histocompatibility complex, class II，DR beta 5 Hs.308026 0 . 1 
major histocompatibility locus class III region NIL 0 1 
MHC class I polypeptide-related sequence A Hs.90598 0 1 
nesca protein Hs.226499 0 1 
Notch (Drosophila) homolog 2 Hs.8121 1 0 
nuclear receptor binding factor-2 Hs.27181 0 1 
p8 protein (candidate of metastasis 1) Hs.8603 0 3 
paired immunoglobulin-like receptor beta Hs.9408 0 1 
peroxisomal biogenesis factor 14 Hs. 19851 0 1 
peroxisomal farnesylated protein Hs. 168670 0 1 
peroxisome proliferative activated receptor, delta Hs. 106415 0 1 
phosphoinositide-3-kinase, regulatory subunit 4, pi50 Hs.83050 0 1 
poliovims receptor-related 2 Hs. 183986 1 1 
polymeric immunoglobulin receptor Hs.288579 1 0 
putative mitochondrial outer membrane protein import Hs.31334 0 5 
receptor 
reticulocalbin 1, EF-hand calcium binding domain Hs. 167791 0 1 
SB classll histocompatibility antigen alpha-chain Hs.914 2 1 
SEC 13 (S. cerevisiae)-like 1 Hs.227949 0 1 
secretory carrier membrane protein 3 Hs. 200600 0 2 
serologically defined colon cancer antigen 10 Hs.23557 0 1 
serologically defined colon cancer antigen 28 Hs.284134 1 1 
SHC transforming protein 1 Hs.81972 0 2 
small membrane protein 1 Hs. 107979 0 1 
SNARE associated protein snapin Hs.32018 0 2 
solute carrier family 1 Hs. 183556 0 1 
(neutral amino acid transporter), member 5 
solute carrier family 11 (proton-coupled divalent metal Hs.57435 0 1 
ion transporters), member 2 
solute carrier family 2 (facilitated glucose transporter), Hs. 167584 2 0 
member 2 
solute carrier family 2 (facilitated glucose transporter), Hs.244378 0 1 
member 6 




solute carrier family 21 (organic anion transporter), Hs.7884 2 0 
member 9 
solute carrier family 22 (organic anion transporter), Hs.251395 2 . 0 
member 7 
solute carrier family 22 (organic cation transporter), Hs. 50868 0 1 
member 1-like 
solute carrier family 25 (carnitine/acylcamitine t Hs. 13845 0 2 
ranslocase), member 20 
solute carrier family 25 (mitochondrial carrier; adenine Hs.79172 0 6 
nucleotide translocator), member 5 
solute carrier family 25 (mitochondrial carrier; adenine Hs. 164280 0 1 
nucleotide translocator), member 6 
solute carrier family 25 (mitochondrial carrier; ornithine Hs.78457 1 0 
transporter) member 15 
solute carrier family 25 (mitochondrial carrier; Hs.78713 0 4 
phosphate carrier), member 3 
solute carrier family 25, member 13 (citrin) Hs.9599 0 1 
solute carrier family 5 (sodium-dependent vitamin t Hs.321579 0 1 
ransporter), member 6 
solute carrier family 6 (neurotransmitter transporter, Hs. 187958 0 1 
creatine), member 8 (SLC6A8) 
solute carrier family 9 (sodium/hydrogen exchanger), Hs. 184276 0 1 
isoform 3 regulatory factor 1 
solute carrier family 9 (sodium/hydrogen exchanger), Hs. 101813 1 0 
isoform 3 regulatory factor 2 
stromal cell derived factor receptor 1 Hs.6354 1 0 
tetraspan 3 Hs. 100090 1 0 
transferrin receptor (p90, CD71) Hs.77356 0 5 
transferrin receptor 2 Hs.63758 1 1 
translocase of inner mitochondrial membrane 10 Hs.109571 0 4 
(yeast) homolog 
translocase of inner mitochondrial membrane 13 Hs.23410 1 1 
(yeast) homolog B 
translocase of inner mitochondrial membrane 23 Hs. 11866 1 0 
(yeast) homolog 
translocase of inner mitochondrial membrane 8 Hs.279915 2 4 
(yeast) homolog B 
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translocase of outer mitochondrial membrane 20 Hs.75187 2 0 
(yeast) homolog 
translocase of outer mitochondrial membrane 70 Hs.21198 0 1 
(yeast) homolog A 
translocating chain-associating membrane protein Hs.4147 1 2 
transmembrane 4 superfamily member 
(tetraspan NET-7) Hs.95583 0 1 
transmembrane 4 superfamily member 1 Hs.3337 0 1 
transmembrane 4 superfamily member 4 Hs. 11881 2 5 
transmembrane 4 superfamily member 5 Hs. 184194 0 5 
transmembrane 4 superfamily member 7 Hs.26518 1 0 
transmembrane 7 superfamily member 2 Hs.31130 1 0 
transmembrane protein (63kD), endoplasmic Hs.74368 0 1 
reticulum/Golgi intermediate compartment 
transmembrane protein 4 Hs.8752 1 3 
tumor rejection antigen (gp96) 1 Hs.82689 0 4 
vesicle-associated membrane protein 8 (endobrevin) Hs. 172684 0 3 
voltage-dependent anion channel 1 Hs. 149155 0 3 
voltage-dependent anion channel 2 Hs.78902 0 2 
voltage-dependent anion channel 3 Hs.7381 0 3 
zinc/iron regulated transporter-like Hs.7854 0 5 
Miscellaneous (n=488) 
16.7Kd protein Hs. 180859 1 5 
7-60 protein Hs.67896 0 1 
acidic 82 kDa protein (HSU15552) Hs.85769 0 1 
AD-015 protein Hs.32148 0 2 
AD024 protein Hs.21137 0 1 
adenylosuccinate lyase Hs.75527 0 1 
adipose specific 2 Hs.74120 0 15 
ADP-ribosyltransferase (NAD+; poly (ADP-ribose) Hs. 177766 0 1 
polymerase) 
ALEX3 protein (ALEX3) Hs. 172788 0 1 
ALL-1 gene exon 37 NIL 1 0 
ALL-1 gene exon 38 NIL 0 1 
alpha gene sequence NIL 0 1 




aminopeptidase puromycin sensitive Hs. 293007 0 1 
amino-terminal enhancer of split (AES) Hs.244 0 1 
amplified in osteosarcoma Hs.76228 1 2 
anaphase promoting complex subunit 11 Hs. 183180 0 4 
(yeast APCll homolog) 
ancient ubiquitous protein 1 Hs. 173736 0 1 
antizyme inhibitor Hs.223014 0 1 
Apobec-1 complementation factor; APOBEC-1 Hs.8349 1 0 
stimulating protein 
apoptosis antagonizing transcription factor Hs.l6178 0 1 
apoptosis related protein APR-3 Hs.9527 1 0 
apoptosis-associated speck-like protein containing a Hs.71869 1 1 
CARD 
apoptosis-related protein PNAS-1 Hs.52166 0 1 
archain 1 Hs.33642 1 0 
Arg/Abl-interacting protein ArgBP2 Hs. 278626 0 1 
arginine-rich, mutated in early stage tumors Hs.75412 0 1 
ataxin-1 ubiquitin-like interacting protein Hs.283739 0 1 
autonomously replicating sequence (ARS) NIL 6 4 
Bacteriophage lambda, complete genome NIL 0 4 
BAIl-associated protein 2 Hs.7936 1 0 
basic leucine zipper nuclear factor 1 (JEM-1) Hs. 158205 0 1 
BENE protein Hs. 185055 0 1 
bladder cancer associated protein Hs.5300 0 1 
bone marrow stromal cell antigen 1 Hs. 169998 0 1 
bone marrow stromal cell antigen 2 Hs.118110 3 0 
brain cDNA 7 [Mus musculus] Mm. 103583 0 1 
brain protein 13 Hs.75922 0 3 
Breakpoint cluster region protein, Hs.268763 0 1 
uterine leiomyoma, 1; barrier to autointegration factor 
bromodomain adjacent to zinc finger domain, lA Hs.8858 1 0 
bromodomain and PHD finger containing, 1 Hs.l004 0 1 
bromodomain-containing 2 Hs.75243 1 0 
budding uninhibited by benzimidazoles 3, yeast Hs.40323 0 1 
homolog 
BUP protein Hs.35660 0 1 
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calcium binding atopy-related autoantigen 1 Hs.61628 1 0 
calcyclin binding protein Hs.27258 0 1 
casein kinase 2, beta polypeptide Hs. 165843 0 1 
cation-chloride cotransporter-interacting protein Hs.ll9178 1 1 
caveolin 2 Hs. 139851 0 1 
CDP-diacylglycerol~inositol 3-phosphatidyltransferase Hs.227107 1 0 
cellular repressor of ElA-stimulated genes Hs.5710 0 3 
CGI-18 protein Hs. 121599 0 1 
CGI-69 protein Hs.237924 0 1 
CGI-81 protein Hs.279583 1 0 
cholinephosphotransferase 1 Hs. 171889 0 1 
clathrin, heavy polypeptide (He) Hs. 178710 0 2 
Cloning vector pGEM-9Zf(-) NIL 0 1 
ClpP homolog Hs.74362 0 2 
Coilin Hs.966 0 1 
cold inducible RNA-binding protein Hs. 119475 0 1 
complexin 2 NIL 0 1 
conserved gene amplified in osteosarcoma Hs. 180669 0 1 
core histone macroH2A2.2 Hs. 92023 0 1 
coronin, actin-binding protein, lA Hs. 109606 1 0 
CTCL tumor antigen se57-l Hs.30315 0 1 
cutaneous T-cell lymphoma-associated tumor antigen Hs. 136164 0 1 
e20-4 
CXC chemokine ligand 16 (CXCL16) Hs. 82407 0 1 
Cyclic AMP phosphoprotein, 19 kD Hs.7351 1 0 
cysteine and glycine-rich protein 2 Hs. 10526 0 1 
cysteine desulfurase Hs. 194692 0 3 
damage-specific DNA binding protein 1 (127kD) Hs. 108327 0 1 
DAZ associated protein 2 Hs.75416 0 1 
death-associated protein Hs.75189 0 1 
DEK oncogene (DNA binding) Hs. 110713 0 1 
Deleted in split-hand/split-foot 1 region Hs.85215 1 4 
delta sleep inducing peptide, immunoreactor Hs.75450 1 1 
dendritic cell protein Hs.69469 0 1 
deoxyhypusine synthase Hs.79064 0 1 
desmoplakin (DPI, DPII) Hs.74316 0 1 
DiGeorge syndrome critical region gene 6 Hs. 153910 0 1 
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dimethylarginine dimethylaminohydrolase 2 Hs.247362 1 0 
dipeptidyl peptidase 7 Hs. 14089 1 0 
divalent cation tolerant protein CUTA Hs. 107187 0 3 
IBTK Inhibitor of Bmton's tyrsoine kinase Hs.7387 0 1 
DNA segment, single copy probe LNS-CAI/LNS-CAII Hs. 178112 0 1 
DnaJ (Hsp40) homolog, subfamily B, member 4 Hs.41693 0 1 
DnaJ (Hsp40) homolog, subfamily B，member 9 Hs.6790 3 2 
DnaJ (Hsp40) homolog, subfamily C, member 8 Hs.74711 1 2 
Down syndrome critical region gene 2 Hs.5198 0 2 
DREV gene and IGSF6 gene for immunoglobulin NIL 0 1 
uperfamily 6 protein 
dUTP pyrophosphatase Hs.82113 0 2 
dyskeratosis congenita 1，dyskerin Hs.4747 0 2 
E-1 enzyme Hs. 18442 0 1 
ElB-55kDa-associated protein 5 Hs.l55218 0 1 
EBNA-2 co-activator (lOOkD) Hs.79093 0 1 
endoplasmic reticulum glycoprotein Hs.75864 1 5 
endothelial differentiation-related factor 1 Hs. 174050 1 7 
enhancer of invasion 10 Hs. 107003 1 0 
enhancer of polycomb 1 Hs. 129998 0 1 
estrogen-responsive B box protein (EBBP) Hs.241305 0 2 
ESTs, Highly similar to JE0160 sodium bicarbonate Hs.7917 0 1 
otransport protein 2 
Ewing sarcoma breakpoint region 1 (EWSRl) Hs.297666 0 2 
F-box only protein 22 Hs.289074 0 1 
FE65-LIKE 2 Hs. 173103 1 0 
fibrousheathin II Hs.314452 0 1 
Finkel-Biskis-Reilly murine sarcoma vims Hs. 177415 7 17 
FBR-MuSV) ubiquitously expressed (fox derived); 
ribosomal protein S30 
flap structure-specific endonuclease 1 Hs.4756 1 1 
flotillin 2 Hs. 184488 1 0 
fragile X mental retardation, autosomal homolog 1 Hs.82712 0 2 
FSHD region gene 1 Hs.203772 0 2 
fusion, derived from t(12;16) malignant liposarcoma Hs.99969 0 2 
G8 protein Hs. 109798 0 2 
gamma-glutamyl carboxylase Hs.77719 0 1 
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ganglioside expression factor 2 Hs.6518 0 1 
GCIP-interacting protein p29 Hs.20013 0 1 
genethonin 1 Hs. 109590 0 1 
genomic DNA of 8p21.3-p22 anti-oncogene of NIL 0 1 
hepatocellular colorectal and non-small cell lung 
cancer, segment 9/11 
glucose regulated protein, 58kD Hs.289101 0 1 
Golgi apparatus protein 1 Hs.78979 0 1 
golgi autoantigen, golgin subfamily a, 5 Hs.241572 0 1 
golgi phosphoprotein 1 Hs.6831 0 1 
goliath protein Hs. 102737 1 0 
GTP-binding protein Sara Hs.279582 1 0 
H-2K binding factor-2 Hs.278573 0 1 
HBSl (S. cerevisiae)-like Hs.221040 1 0 
heat shock 70kD protein lA Hs.8997 0 2 
heat shock 70kD protein 4 Hs.90093 0 1 
heat shock 70kD protein 8 Hs. 180414 0 8 
heat shock 90kD protein 1, alpha Hs.289088 1 4 
heat shock 90kD protein 1，beta Hs.74335 0 3 
heat shock factor binding protein 1 Hs.250899 0 3 
heat shock transcription factor 1 Hs.l499 0 1 
heme-regulated initiation factor 2-alpha kinase Hs.258730 1 2 
hemoglobin, beta Hs. 155376 1 0 
Hepatitis B virus isolate HBV/IK29902 NIL 0 1 
hepatitis B virus x-interacting protein (9.6kD) Hs. 80464 0 2 
hepatocellular carcinoma-associated antigen 112 Hs. 12126 1 1 
hepatocellular carcinoma-associated antigen 59 Hs.278429 1 0 
hepatocellular carcinoma-associated gene TD26 Hs.224121 2 0 
HERV-H LTR-associating 3 Hs. 142245 1 0 
heterogeneous nuclear ribonudeoprotein A/B Hs.81361 0 1 
HLA class III region containing N0TCH4 gene, partial NIL 1 0 
sequence, homeobox PBX2 (HPBX) gene, receptor 
for advancedglycosylation end products (RAGE) 
gene, complete cds, and6 unidentified cds 
HLA-B associated transcript-3 (D6S52E) NIL 2 0 
HMBA-inducible Hs. 15299 0 1 
holocytochrome c synthase (cytochrome c heme-lyase) Hs.211571 0 1 
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moderately similar to Homo sapiens gene for Hs.306649 1 0 
glycosylphosphatidylinositol anchor attachment 1 
chromosome 11 hypothetical protein (0RF5) Hs.42743 0 1 
PRO 1851 Hs. 189435 0 1 
similar to rhotekin, clone IMAGE:3958836 Hs.58215 0 1 
homocysteine-inducible, endoplasmic reticulum Hs. 146393 0 3 
stress-inducible, ubiquitin-like domain member 1 
homolog of mouse MAT-1 oncogene Hs.278268 0 1 
homolog of yeast SPBl Hs.23170 0 1 
host cell factor CI (VP16-accessory protein) (HCFCl) Hs.83634 0 1 
host cell factor homolog Hs.20597 0 1 
HSKM-B protein (HSKM-B) Hs.66170 1 0 
HSP22-like protein interacting protein Hs.302649 0 1 
HT014 Hs.31819 0 2 
JkAl mRNA induced upon T-cell activation, 3_ end NIL 1 0 
D9 splice variant B Hs.37616 1 4 
hepatitis B vims surface antigen (HBsAg) gene Hs. 113220 1 0 
(complete cds) insertion 
Huntingtin interacting protein K Hs.300954 0 2 
IL-17B receptor Hs.5470 1 0 
imidazoline receptor candidate Hs.26285 0 1 
Immediate early protein Hs.737 1 1 
Immediate early response 3 Hs.76095 0 1 
immoitalization-upregulated protein Hs. 145362 0 5 
immunoglobulin heavy constant gamma 3 (G3m Hs.300697 2 0 
marker) 
immunoglobulin kappa constant Hs. 156110 4 0 
immunoglobulin lambda locus Hs. 181125 2 0 
immunoglobulin superfamily containing leucine-rich Hs. 102171 2 0 
repeat 
indolethylamineN-methyltransferase Hs.204038 1 0 
insulin receptor tyrosine kinase substrate Hs.23449 0 1 
inter-alpha (globulin) inhibitor, HI polypeptide Hs.2777 6 4 
inter-alpha (globulin) inhibitor, H2 polypeptide Hs.75285 2 6 
interferon gamma receptor 1 Hs. 180866 0 1 
interferon induced transmembrane protein 1 (9-27) Hs. 146360 1 0 
interferon induced transmembrane protein 2 (1-8D) Hs.l74195 4 3 
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interferon induced transmembrane protein 3 ( 1 -8U) Hs. 182241 9 31 
islet cell autoantigen 1 (69kD) Hs. 167927 0 1 
isopentenyl-diphosphate delta isomerase Hs.76038 0 1 
JM4 protein Hs.29595 0 1 
jumping translocation breakpoint Hs.6396 0 3 
junction plakoglobin Hs.2340 1 0 
karyopherin (importin) beta 1 Hs. 180446 0 1 
Kelch motif containing protein Hs. 106290 0 1 
Kelch-like ECH-associated protein 1 Hs. 57729 0 2 
kidney- and liver-specific gene Hs. 14637 2 2 
L2DTL protein Hs. 126774 0 1 
LanC (bacterial lantibiotic synthetase component Hs. 13351 0 1 
C)-like 1 
LDL induced EC protein Hs.94392 0 1 
LENGl protein Hs. 172407 0 1 
lethal giant larvae (Drosophila) homolog 2 Hs.3123 0 1 
leucine-rich protein Hs. 182490 0 2 
leukocyte cell-derived chemotaxin 2 Hs. 167877 1 0 
ligase I，DNA，ATP-dependent Hs.l770 0 1 
ligase III, DNA, ATP-dependent Hs. 100299 0 1 
like mouse brain protein E46 Hs. 13493 0 1 
LIM and SH3 protein 1 Hs.75080 1 0 
lipopolysaccharide-binding protein Hs. 154078 0 1 
LIS 1-interacting protein NUDEL; Hs.3850 2 0 
endooligopeptidase A 
liver-expressed antimicrobial peptide Hs.8821 2 0 
loss of heterozygosity, 11, Hs. 152944 0 1 
chromosomal region 2，gene A 
L-pipecolic acid oxidase Hs.271167 0 1 
Lsm3 protein Hs. 111632 0 3 
lymphocyte antigen 117 Hs.88411 1 0 
Lysosomal-associated multispanning membrane Hs.79356 1 2 
protein-5 
MAD (mothers against decapentaplegic, Drosophila) Hs.79067 0 1 
homolog 1 




major vault protein Hs.80680 0 2 
mannose-P-dolichol utilization defect 1 Hs.6710 0 1 
matrin 3 Hs.78825 0 1 
matrix metalloproteinase 15 (membrane-inserted) Hs.80343 0 1 
McKusick-Kaufman syndrome Hs.46743 0 1 
membrane protein of cholinergic synaptic vesicles Hs. 157236 0 2 
mesenchymal stem cell protein DSCD75 Hs.25237 0 1 
mesoderm specific transcript (mouse) homolog Hs.79284 1 0 
metallothionein 1A (functional) Hs. 173451 1 0 
metallothionein IE (functional) Hs.74170 2 0 
metallothionein IG Hs.334409 2 0 
metallothionein IX Hs.278462 3 0 
metallothionein 2A Hs. 118786 18 4 
methyl CpG binding protein 2 (Rett syndrome) Hs.3239 0 1 
methyl-CpG binding domain protein 2 Hs.25674 1 0 
mevalonate kinase (mevalonic aciduria) Hs. 130607 0 1 
microtubule-associated proteins 1 A/IB light chain 3 Hs. 121849 0 1 
midkine (neurite growth-promoting factor 2) Hs.82045 0 1 
minichromosome maintenance deficient (S. cerevisiae) Hs. 168481 1 0 
3-associated protein 
mitochondrial carrier homolog 2 Hs.279609 0 3 
mitochondrial SDS-stable vimentin-bound DNA NIL 1 0 
fragment HEF42VIM8 
MLN51 protein Hs.83422 1 0 
modulator recognition factor I Hs.920 1 0 
moesin Hs. 170328 0 1 
MORF-related gene 15 Hs.6353 0 1 
MORF-related gene X (KIAA0026) NIL 1 3 
M-phase phosphoprotein 9 Hs.86178 0 1 
MSH55 gene, partial cds; and CLICl, DDAH，G6b, NIL 0 1 
G6c，G5b，G6d, G6e, G6f，BAT5，G5b，CSK2B, 
BAT4，G4, Apo M, BAT3，BAT2，AIF-1, 1C7, LST-1, 
LIB, TNF, and LTA genes, complete cds 
mucin and cadherin-like Hs. 165619 1 0 
murine leukemia viral (bmi-l) oncogene homolog Hs.431 0 2 
MURRl NIL 0 1 
Mus musculus DNA sequence NIL 0 1 
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LNV (Lnv) [Mus musculus] Mm.35600 0 1 
muscle specific gene Hs.283781 1 11 
MVP gene, promoter region NIL 0 1 
myogenic factor 3 Hs.284203 0 2 
myosin-binding protein C，cardiac (MYBPC3) NIL 0 1 
myotubularin related protein 6 Hs.79877 1 1 
myxovirus (influenza) resistance 1, homolog of murine Hs.76391 0 1 
(interferon-inducible protein p78) 
N-acylsphingosine amidohydrolase (acid ceramidase) Hs.75811 0 2 
NAG18 protein Hs.288736 0 2 
nebulette Hs.5025 0 1 
neoplasm-related CI40 NIL 0 1 
N-ethylmaleimide-sensitive factor attachment protein, Hs.75932 0 6 
alpha 
neural precursor cell expressed, developmentally Hs. 155595 0 3 
down-regulated 5 
neural precursor cell expressed, developmentally Hs.75512 0 3 
down-regulated 8 
neurobeachin Hs.3821 0 1 
neuronal cell adhesion molecule (NRCAM) Hs.7912 0 1 
neuronal pentraxin II Hs.3281 0 1 
neuronal She adaptor homolog Hs.30965 0 1 
Nicastrin Hs.4788 0 2 
NIMA (never in mitosis gene a)-related kinase 6 Hs.9625 0 2 
NIPSNAP, C. elegans, homolog 1 Hs. 173878 2 1 
nitrilase 1 Hs. 146406 0 1 
N-methylpurine-DNAglycosylase (MPG) Hs.79396 0 1 
non-POU-domain-containing, octamer-binding Hs. 172207 0 2 
NRAS-related gene Hs.69855 1 1 
NSl-associated protein 1 Hs. 155489 0 1 
N-terminal acetyltransferase complex ardl subunit Hs. 109253 0 1 
nuclear distribution gene C (A.nidulans) homolog Hs.263812 0 1 
nuclear DNA-binding protein (C ID) NIL 0 1 
nuclear LIM interactor-interacting factor Hs.283724 1 0 
nuclear prelamin A recognition factor Hs.256526 0 1 
nuclear protein Hs. 169984 0 1 
nucleobindin 1 Hs. 172609 1 2 
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nucleolar cysteine-rich protein Hs. 120766 1 0 
nucleolar protein 1 (120kD) Hs. 15243 0 1 
nucleolar protein NOP5/NOP58 Hs. 119908 0 1 
nucleolar protein p40; homolog of yeast Hs.74407 0 2 
EBNAl-binding protein 
nucleophosmin (nucleolar phosphoprotein B23, Hs.9614 0 2 
numatrin) 
nucleoside diphosphate kinase type 6 (inhibitor of Hs. 152717 0 1 
p5 3-induced apoptosis-alpha) 
nucleoside diphosphate linked moiety X-type motif 1 Hs.388 0 1 
nucleoside diphosphate linked moiety X-type motif 3 Hs.4815 0 1 
nucleoside diphosphate linked moiety X-type motif 5 Hs.301957 1 1 
over-expressed breast tumor protein Hs.306195 0 2 
oxygen regulated protein (150kD) Hs.277704 0 1 
oxysterol binding protein Hs.24734 0 1 
paired basic amino acid cleaving enzyme (ftirin, Hs.59242 0 1 
membrane associated receptor protein) 
papillomavirus regulatory factor PRF-1 Hs.27410 1 0 
Papio hamadryas ERV-9 like LTR insertion NIL 0 1 
aryl hydrocarbon receptor nuclear translocator Hs. 166172 0 1 
peptidase (mitochondrial processing) beta Hs. 184211 0 2 
pericentriolar material 1 Hs.75737 0 1 
period (Drosophila) homolog 1 Hs.68398 0 1 
peroxisome biogenesis factor 1 Hs.99847 0 1 
pescadillo (zebrafish) homolog 1，containing BRCT Hs. 13501 1 0 
domain 
PHD finger protein 2 Hs.323 835 0 1 
phenylalanine-tRNA synthetase-like Hs.23111 1 1 
phosphatidylcholine transfer protein Hs.285218 0 1 
phosphatidylserine synthase 1 Hs.77329 0 1 
phospholipase C，beta 3，neighbor pseudogene Hs. 100623 0 1 
phosphomannomutase 1 Hs.75835 1 0 
phosphoribosyl pyrophosphate synthetase-associated Hs. 13339 1 0 
protein 2 
Pirin Hs.279663 0 3 
pituitary tumor-transforming 1 Hs.252587 0 1 
pituitary tumor-transforming 1 interacting protein Hs. 111126 0 1 
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plastin 3 (T isoform) Hs.4114 0 2 
PLC beta 3 gene (exon 1) and SOM172 gene (exon 1) NIL 0 1 
pleckstrin homology-like domain, family A, member 3 Hs.268557 0 1 
pM5 protein Hs.227823 1 1 
polyA site DNA Hs.4934 1 0 
pre-alpha (globulin) inhibitor, H3 polypeptide Hs.76716 2 2 
pre-B-cell colony-enhancing factor Hs.239138 1 1 
prefoldin 1 Hs. 132881 0 1 
prefoldin 2 Hs.298229 0 6 
prefoldin 4 Hs.91161 0 9 
prefoldin 5 Hs.288856 5 6 
procollagen (type III) N-endopeptidase Hs. 183138 1 0 
proline synthetase co-transcribed (bacterial homolog) Hs.301959 1 0 
protein (peptidyl-prolyl cis/trans isomerase) Hs. 161362 0 1 
NIMA-interacting 1 
protein kinase domains containing protein similar to Hs. 26802 1 2 
phosphoprotein C8FW 
proteinase activated receptor-2 mRNA, 3'UTR Hs. 168102 0 1 
proteoglycan 4, (megakaryocyte stimulating factor, Hs.218791 1 1 
articular superficial zone protein) 
Pseudoautosomal GTP-binding protein-like Hs. 101033 0 1 
putative breast adenocarcinoma marker (32kD) Hs. 12107 0 3 
putative L-type neutral amino acid transporter Hs.llO 1 0 
putative nuclear protein (ORF1-FL49) Hs.323512 0 2 
putative nucleic acid binding protein RY-1 Hs.54649 0 1 
putative nucleotide binding protein，estradiol-induced Hs.279923 0 2 
putative Rab5-interacting protein Hs. 184062 0 3 
putative transmembrane protein; Hs.5809 0 3 
homolog of yeast Golgi membrane protein Yiflp 
Pxl9-like protein Hs.279529 1 0 
quiescin Q6 Hs.77266 0 1 
quinolinate phosphoribosyltransferase Hs.8935 1 0 
(nicotinate-nucleotidepyrophosphorylase 
(carboxylating)) 
genes for 18S, 5.8S, and 28S ribosomal RNAs NIL 1 2 
[Rattus norvegicus] 
Rab9 effector p40 Hs. 19012 0 1 
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RAR-related orphan receptor C Hs. 133314 0 1 
Ras association (RalGDS/AF-6) domain family 1 Hs.26931 0 1 
kidney-specific protein (KS) [Rattus norvegicus] Rn. 14875 1 0 
signal peptidase 21kDa subunit [Rattus norvegicus] Rn. 16883 0 1 
TM6P1 (TM6P1) [Rattus norvegicus] Rn.4055 0 1 
RD RNA-binding protein Hs. 106061 0 1 
receptor (calcitonin) activity modifying protein 1 Hs.32989 0 1 
regeneration associated protein 3 (RAPS) Hs.283923 2 2 
regulator of nonsense transcripts 2 Hs.3862 0 1 
Ret finger protein 2 Hs. 151428 1 0 
reticulon 3 Hs.252831 0 2 
reticulon 4 Hs.65450 0 1 
Ribokinase Hs. 11916 1 0 
ribosomal DNA complete repeating unit NIL 4 10 
RIKEN cDNA 0610011M24 gene [Mus musculus] Mm.28147 1 0 
ring-box 1 Hs.279919 2 2 
RNA binding motif protein 14 Hs.l l l70 1 0 
RNA binding motif protein 3 Hs.301404 3 1 
RNA cyclase homolog Hs. 113052 0 1 
RNA-binding protein SI, serine-rich domain Hs.75104 0 1 
RuvB (E coli homolog)-like 1 Hs.272822 0 1 
RuvB (E coli homolog)-like 2 Hs.6455 0 1 
Sam68-like phosphotyrosine protein, T-STAR Hs. 13565 0 1 
SEC63, endoplasmic reticulum translocon component Hs.31575 0 1 
(S. cerevisiae) like 
secretory granule, neuroendocrine protein 1 (7B2 Hs.2265 0 1 
protein) 
sel-1 (suppressor oflin-12, C.elegans)-like Hs. 181300 0 1 
seladin-1 Hs.75616 1 5 
SET translocation (myeloid leukemia-associated) Hs. 145279 2 0 
SFRS protein kinase 1 Hs.75761 0 1 
SH3 protein interacting with Nek, 90 kDa Hs. 102929 0 1 
Similar to hypothetical protein, clone MGC:880 Hs.24220 0 1 
similar to mouse neuronal protein 15.6 Hs. 111497 0 2 
similar to rat nuclear ubiquitous casein kinase 2 Hs. 118064 1 0 
sin3-associated polypeptide, 18kD Hs.23964 0 4 
single-stranded DNA-binding protein Hs.923 0 2 
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sirtuin (silent mating type information regulation 2, Hs.44017 0 2 
S.cerevisiae, homolog) 2 
small acidic protein (IMAGE145052) NIL 0 1 
small EDRK-rich factor 2 Hs.323806 7 23 
small fragment nuclease Hs.7527 0 3 
small glutamine-rich tetratricopeptide repeat NIL 0 1 
(TPR)-containing (SGT) 
small proline-rich protein 3 Hs. 139322 0 2 
SMT3 (suppressor of mif two 3，yeast) homolog 1 Hs.85119 0 1 
SMT3 (suppressor of mif two 3，yeast) homolog 2 Hs. 180139 0 2 
soc-2 (suppressor of clear, C.elegans) homolog Hs. 104315 1 0 
SON DNA binding protein (SON) Hs.339814 0 1 
sorting nexin 2 Hs. 11183 0 1 
sorting nexin 3 Hs. 12102 0 3 
sperm associated antigen 7 Hs.90436 0 1 
sphingomyelin phosphodiesterase 2, neutral membrane Hs.55235 0 1 
(neutral sphingomyelinase) 
SRY (sex determining region Y)-box 4 Hs.83484 0 1 
staufen (Drosophila, RNA-binding protein) Hs.6113 0 1 
sterol-C4-methyl oxidase-like Hs.239926 1 0 
sudD (suppressor of bimD6, Aspergillus nidulans) Hs.209061 0 1 
homolog 
suppression of tumorigenicity 13 (colon carcinoma) Hs. 119222 1 0 
(Hsp70-interacting protein) (ST13) 
suppression of tumorigenicity 7 Hs.5814 0 1 
SURF-4 Hs.284296 1 1 
surfeit 2 Hs.l59448 0 1 
survival of motor neuron 1，telomeric Hs.288986 0 1 
survival of motor neuron 2，centromeric Hs.77306 0 1 
Janus kinase 1 [Sus scrofa] NIL 0 1 
symplekin; Huntingtin interacting protein I Hs. 107019 0 1 
synaptobrevin-like 1 Hs.24167 0 1 
synaptogyrin 2 Hs.5097 0 4 
synaptophysin-like protein Hs.80919 0 1 
synovial sarcoma translocation gene on chromosome Hs.9774 0 1 
18-like2 
syntaxin 18 Hs. 13406 0 1 
7 6 
Results 
syntrophin, alpha l(dystrophin-associated protein Al, Hs.31121 0 1 
59kD, acidic component) 
T54 protein Hs. 100391 0 1 
Taxi (human T-cell leukemia virus type I) binding Hs.5437 0 1 
protein 1 
T-cell activation protein (PGRl) Hs.285902 1 1 
t-complex 1 Hs.4112 0 5 
t-complex 10 (a murine tcp homolog) (TCPIO) NIL 1 0 
telomerase binding protein, p23 [Mus musculus] Mm.22421 0 2 
tenascin XA (TNXA) NIL 1 0 
testis enhanced gene transcript (BAX inhibitor 1) Hs.74637 2 3 
tetratricopeptide repeat domain 1 Hs.7733 0 1 
TGF beta inducible nuclear protein TINPl Hs.8170 0 1 
thiosulfate sulfurtransferase (rhodanese) Hs.248267 1 3 
thymopoietin (TMPO) Hs. 11355 0 1 
thyroid autoantigen 70kD (Ku antigen) Hs. 197345 0 2 
thyroid hormone receptor binding protein Hs. 159613 0 1 
thyroid hormone receptor interactor 12 Hs. 138617 1 0 
thyroid hormone receptor interactor 7 Hs.77558 0 1 
thyroid receptor interacting protein 15 Hs.30212 0 1 
Tiggerl transposable element NIL 1 1 
tight junction protein 2 (zona occludens 2) Hs.75608 0 1 
tissue specific transplantation antigen P35B Hs.264428 0 1 
TLH29 protein precursor Hs.94695 0 1 
tomoregulin NIL 1 0 
topoisomerase (DNA) II alpha (170kD) Hs. 156346 0 1 
tousled-like kinase 2 Hs.57553 0 1 
TRAP and TNF receptor-associated protein Hs.46847 0 1 
TRAF4 associated factor 1 Hs. 181466 0 1 
TRAM-like protein Hs. 153954 0 1 
translin Hs.75066 0 2 
transporter protein; system N1 Na+ and H+-coupled Hs.76460 1 0 
glutamine transporter 
transporter-like protein Hs. 179902 0 1 
transposon-like element Hs.84775 0 4 
Treacher Collins-Franceschetti syndrome 1 Hs.301266 0 1 
truncated calcium binding protein Hs.279891 0 3 
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TSC-22-like Hs. 102447 0 1 
TTF-I interacting peptide 20 Hs.79531 0 1 
tubulointerstitial nephritis antigen Hs. 127011 0 1 
tumor antigen SLP-8p Hs.48499 0 1 
tumor differentially expressed 1 Hs.272168 0 2 
tumor metastasis-suppressor Hs.285976 1 3 
tumor protein, translationally-controlled 1 Hs.279860 16 15 
tumor suppressor deleted in oral cancer-related 1 Hs.25664 0 1 
(DOC-IR) 
tumor susceptibility gene 101 Hs.ll8910 1 0 
type 1 tumor necrosis factor receptor shedding Hs.247043 1 0 
aminopeptidase regulator 
tyrosylprotein sulfotransferase 2 Hs.26350 0 1 
ubiquitin A-52 residue ribosomal protein Hs.5308 4 16 
fusion product 1 
ubiquitin-activating enzyme El (A1S9T and BN75 Hs.2055 0 1 
temperature sensitivity complementing) 
ubiquitin-like 1 (sentrin) Hs.81424 0 3 
ubiquitin-like 5 Hs. 109701 0 5 
ubiquitously-expressed transcript Hs. 172791 0 1 
uncharacterized bone marrow protein BM033 Hs. 173259 0 1 
uncharacterized hematopoietic stem/progenitor cells Hs.273369 0 1 
protein MDS027 
uncharacterized hematopoietic stem/progenitor cells Hs.43549 0 1 
protein MDS029 
uncharacterized hematopoietic stem/progenitor cells Hs. 16187 0 1 
protein MDS032 
upregulated by 1,25-dihydroxyvitainin D-3 Hs. 179526 1 1 
valosin-containing protein Hs. 106357 0 2 
very long-chain acyl-CoA synthetase homolog 2 Hs. 111401 2 6 
von Hippel-Lindau binding protein 1 Hs. 198307 0 1 
von Hippel-Lindau syndrome Hs. 174007 0 1 
VPS28 protein Hs.293441 2 0 
WD repeat domain 13 Hs. 12142 0 1 
Williams-Beuren syndrome chromosome region 1 NIL 1 1 
WW Domain-Containing Gene Hs.288906 1 0 
yeast Sec3 Ip homolog Hs.70266 0 2 
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zinc finger protein 226 Hs. 145956 0 1 
zinc finger protein 24 Hs. 183593 1 0 
Zinedin Hs. 108665 0 1 
highly similar to NADH:ubiquinone oxidoreductase NIL 1 0 
B22subunit 
highly similar to spondin 2 Hs.306919 1 0 
MGC4399 Hypothetical protein MGC4399 Hs.l83047 0 1 
similar to parathymosin (H. sapiens) (LOC63353) NIL 1 1 
MGC2408 Hypothetical protein MGC2408 Hs. 146161 0 1 
Human DNA sequence from clone RP11-16L21 on Hs.297143 0 9 
chromosome 9. Contains the gene for 
NADP-dependent leukotriene B4 
12-hydroxydehydrogenase, the gene for a novel DnaJ 
domain protein similar to Drosophila, C. elegans and 
Arabidopsis predicted proteins, the GNGIO 
ESTs, Weakly similar to FRHUL ferritin light chain Hs.278937 0 2 
RIKEN cDNA 2010002E04 gene [Mus musculus] Mm.30268 1 0 
DNA sequence from clone RP11-419N10 on NIL 0 1 
chromosome 1 
highly similar to SPECTRIN BETA CHAIN, BRAIN Hs.324648 0 1 
highly similar to HUMRPL18A Homo sapiens NIL 1 11 
ribosomal protein LI8 (RPL18) 
chromosome 8 clone 36G5 map 8p23.1 NIL 0 1 
Similar to U5 snRNP-specific protein (220 kD), Hs.323280 0 1 
ortholog of S. cerevisiae Prp8p, clone MGC:1927, 
similar to eukaryotic translation initiation factor 1A NIL 0 1 
similar to histidine triad nucleotide-binding protein NIL 0 1 
similar to mouse Glt3 or D. malanogaster transcription Hs.279818 1 0 
factor IIB 
similar to non-functional folate binding protein NIL 1 2 
similar to ribosomal protein L22 NIL 0 9 
similar to ribosomal protein L7 NIL 2 5 
similar to ribosomal protein L9 NIL 2 1 
similar to ribosomal protein S28 NIL 0 1 
Other metabolism (n=382) 
1 -acylglycerol-3 -phosphate O-acyltransferase 1 Hs.240534 1 0 
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(lysophosphatidic acid acyltransferase, alpha) 
1-acylglycerol-3-phosphate O-acyltransferase 2 Hs.209119 2 0 
(lysophosphatidic acid acyltransferase, beta) 
2,4-dienoyl CoA reductase 1, mitochondrial (DECRl) Hs.81548 0 1 
2-hydroxyphytanoyl-CoA lyase Hs.63290 0 1 
3-hydroxy-3-methylglutaiyl-Coenzyme A reductase Hs.ll899 0 1 
3-hydroxy-3-methylglutaryl-Coenzyme A synthase 2 Hs.59889 0 5 
(mitochondrial) 
3-hydroxyanthranilate 3,4-dioxygenase Hs. 108441 1 1 
4-hydroxyphenylpyruvate dioxygenase Hs.2899 3 0 
5' nucleotidase (CD73) Hs. 153952 0 1 
5,lO-methenyltetrahydrofolate synthetase Hs.ll8131 2 1 
5 -aminoimidazole-4-carboxainide ribonucleotide Hs.90280 0 1 
formyltransferase/IMPcyclohydrolase 
6-pymvoyl-tetrahydropterin synthase/dimerization Hs.3192 1 2 
cofactor of hepatocyte nuclear factor 1 alpha (TCFl) 
7-dehydrocholesterol reductase Hs.ll806 0 1 
acid phosphatase 1, soluble Hs.75393 0 1 
acid phosphatase 5, tartrate resistant Hs.l211 0 1 
acyl-Coenzyme A oxidase 2, branched chain Hs.9795 1 3 
acylphosphatase 2, muscle type Hs.31791 1 0 
adaptor-related protein complex 1，sigma 1 subunit Hs. 57600 0 1 
adaptor-related protein complex 2, sigma 1 subunit Hs. 119591 1 3 
adenylate kinase 1 Hs.76240 0 1 
adenylate kinase 2 Hs. 171811 0 5 
alanine-glyoxylate aminotransferase (oxalosis I; Hs. 144567 4 4 
hyperoxaluria I; glycolicaciduria; serine-pyruvate 
aminotransferase) 
alanine-glyoxylate aminotransferase 2 Hs. 193228 1 0 
alanine-glyoxylate aminotransferase homolog Hs.271366 2 0 
alanyl (membrane) aminopeptidase (aminopeptidase N,Hs.l239 0 4 
aminopeptidase M, microsomal aminopeptidase, 
CD13,pl50) 
alcohol dehydrogenase 1A (class I), alpha polypeptide Hs.73843 1 0 
alcohol dehydrogenase IB (class I), beta polypeptide Hs.4 6 2 
alcohol dehydrogenase IC (class I), gamma polypeptide Hs.2523 9 3 
alcohol dehydrogenase 4 (class II), pi polypeptide Hs.l219 6 0 
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alcohol dehydrogenase 5 (class III), chi polypeptide Hs.78989 0 2 
aldehyde dehydrogenase 1 family, member Al Hs.76392 3 18 
aldehyde dehydrogenase 1 family, member B1 Hs. 169517 0 2 
aldehyde dehydrogenase 2 family (mitochondrial) Hs. 195432 4 1 
aldehyde dehydrogenase 3 family, member A2 Hs. 159608 0 1 
aldehyde oxidase 1 Hs. 174151 2 2 
aldo-keto reductase family 1, member Al Hs.89529 1 2 
aldo-keto reductase family 1, member BIO Hs. 116724 0 20 
aldo-keto reductase family 1，member C2 Hs.201967 0 31 
aldo-keto reductase family 1, member C3 Hs.78183 0 9 
aldo-keto reductase family 1，member C4 (chlordecone Hs. 177687 2 0 
reductase; 3-alpha hydroxysteroid dehydrogenase, 
type I; dihydrodiol dehydrogenase 4) 
aldo-keto reductase family 1, member D1 (delta Hs.201667 2 0 
4-3 -ketosteroid-5 -beta-reductase) 
aldo-keto reductase family 7, member A2 (aflatoxin Hs.6980 0 1 
aldehyde reductase) (AKR7A2) 
aldo-keto reductase family 7, member A3 (aflatoxin Hs.284236 1 0 
aldehyde reductase) (AKR7A3) 
aldolase A, fructose-bisphosphate Hs.273415 0 5 
aldolase B, fructose-bisphosphate Hs.234234 14 18 
alkaline phosphatase, liver/bone/kidney Hs.250769 0 1 
alkylglycerone phosphate synthase Hs.22580 0 1 
aminoacylase 1 Hs.79 0 1 
Aminolevulinate, delta-, synthase 1 Hs.78712 2 3 
anti-oxidant protein 2 Hs.l20 1 5 
arginase, liver Hs.289057 4 8 
argininosuccinate lyase Hs.61258 1 1 
argininosuccinate synthetase Hs. 160786 1 4 
arginyl aminopeptidase (aminopeptidase B) Hs.283667 1 0 
aiyl hydrocarbon receptor-interacting protein Hs.75305 0 1 
arylacetamide deacetylase (esterase) Hs.587 2 5 
aiylsulfatase E (chondrodysplasia punctata 1) Hs.74131 1 0 
aspartate beta-hydroxylase Hs.283664 0 1 
ATXl (antioxidant protein 1，yeast) homolog 1 Hs.279910 0 3 
baculoviral lAP repeat-containing 6 Hs.250646 0 1 
beta-1,3 -glucuronyltransferase 3 Hs.26492 0 1 
8 1 
Results 
beta-1,4 mannosyltransferase Hs.44592 0 1 
betaine-homocysteine methyltransferase Hs.80756 1 3 
betaine-homocysteine methyltransferase 2 Hs. 172382 0 2 
beta-ureidopropionase Hs. 126926 0 2 
bile acid Coenzyme A: amino acid N-acyltransferase Hs. 159440 0 2 
biliverdin reductase A Hs.81029 0 1 
biliverdin reductase B (flavin reductase (NADPH)) Hs.76289 1 2 
branched chain alpha-ketoacid dehydrogenase kinase Hs. 20644 1 0 
21 kDa signal peptidase subunit [Canine] NIL 0 1 
carbamoyl-phosphate synthetase 1，mitochondrial Hs.50966 1 0 
carbonic anhydrase II Hs. 155097 1 0 
carbonyl reductase Hs.9857 4 2 
carbonyl reductase 1 Hs. 88778 0 5 
carboxylesterase 1 (monocyte/macrophage serine Hs.76688 7 34 
esterase 1) 
carboxylesterase-related protein Hs. 278997 0 1 
carboxypeptidase B2 (plasma) Hs.75572 1 1 
carboxypeptidase B-like protein Hs.274495 2 0 
carnitine acetyltransferase Hs. 12068 0 1 
catalase (CAT) Hs.76359 2 1 
cathepsin B Hs.297939 1 2 
cathepsin C Hs. 10029 1 2 
cathepsin D (lysosomal aspartyl protease) Hs.79572 2 17 
cathepsin F Hs. 11590 1 0 
cathepsin H (CTSH) Hs.288181 1 2 
cathepsin L Hs.78056 2 1 
chromodomain helicase DNA binding protein 4 Hs.74441 0 2 
coproporphyrinogen oxidase (coproporphyria, Hs.89866 1 0 
harderoporphyria) 
crystallin, zeta (quinone reductase) Hs.83114 1 1 
cytochrome P450 21 -hydroxylase (CYP21) gene, partial NIL 1 0 
cds; TNX pseudogene, complete sequence; and 
RP2pseudogene, partial sequence 
cytochrome P450，subfamily IIA Hs.334345 2 0 
(phenobarbital-inducible), polypeptide 6 
cytochrome P450, subfamily IIA Hs.250615 1 0 
(phenobarbital-inducible), polypeptide 7 
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cytochrome P450, subfamily IIB Hs.l360 1 1 
(phenobarbital-inducible), polypeptide 6 
cytochrome P450, subfamily IIC (mephenytoin Hs.702 0 1 
4-hydroxylase), polypeptide 18 
cytochrome P450, subfamily IIC (mephenytoin Hs. 174220 6 1 
4-hydroxylase), polypeptide 8 
cytochrome P450, subfamily IIC (mephenytoin Hs. 167529 5 3 
4-hydroxylase), polypeptide 9 
cytochrome P450, subfamily HE (ethanol-inducible) Hs.75183 21 0 
cytochrome P450，subfamily III A Hs.329704 11 0 
(niphedipine oxidase), polypeptide 3 
cytochrome P450，subfamily III A Hs. 178738 3 0 
(niphedipine oxidase)，polypeptide 4 
cytochrome P450, subfamily IIIA Hs. 104117 2 1 
(niphedipine oxidase), polypeptide 5 
cytochrome P450，subfamily IVF, polypeptide 11 Hs. 187393 0 1 
cytochrome P450, subfamily IVF, polypeptide 2 Hs. 101 1 1 
cytochrome P450, subfamily IVF, polypeptide 3 Hs. 106242 1 1 
(leukotriene B4 omega hydroxylase) 
cytochrome P450, subfamily XVII (steroid Hs.l363 0 6 
17-alpha-hydroxylase), adrenal hyperplasia 
cytochrome P450, subfamily XXVIIA (steroid Hs.82568 2 1 
27-hydroxylase, cerebrotendinous xanthomatosis), 
polypeptide 1 
cytochrome P450, subfamily XXVIIB Hs. 199270 0 1 
(2 5 -hydroxyvitamin D-1 -alpha-hydroxylase), 
polypeptide 1 
cytosolic serine hydroxymethyltransferase NIL 0 1 
D-dopachrome tautomerase Hs. 180015 0 8 
deoxyribonuclease II, lysosomal Hs. 118243 0 1 
diaphorase (NADH) (cytochrome b-5 reductase) Hs.274464 2 0 
diaphorase (NADH/NADPH) (cytochrome b-5 Hs. 80706 0 11 
reductase) 
diazepam binding inhibitor (GABA receptor modulator, Hs.78888 1 4 
acyl-Coenzyme A binding protein) 
dihydrolipoamide branched chain transacylase (E2 Hs. 139410 1 0 
component of branched chain keto acid 
8 3 
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dehydrogenase complex; maple syrup urine disease) 
dihydrolipoamide dehydrogenase (E3 component of Hs.74635 0 1 
pyruvate dehydrogenase complex, 2-oxo-glutarate 
complex, branched chain keto acid dehydrogenase 
complex) 
dolichyl-phosphate (UDP-N-acetylglucosamine) Hs.26433 0 1 
N-acetylglucosaminephosphotransferase 1 
(GlcNAc-l-P transferase) 
dolichyl-phosphate mannosyltransferase polypeptide 3 Hs. 110477 0 8 
electron-transferring-flavoprotein dehydrogenase Hs. 323468 1 0 
endosulfine alpha Hs. 111680 0 8 
endothelin converting enzyme 1 Hs.288203 0 1 
enhancer of rudimentary (Drosophila) homolog Hs. 118757 1 1 
epoxide hydrolase 1，microsomal (xenobiotic) Hs.89649 2 3 
excision repair cross-complementing rodent repair Hs.48576 1 0 
deficiency, complementation group 5 (xeroderma 
pigmentosum, complementation group G (Cockayne 
syndrome)) 
exosome component Rrp46 Hs.283741 0 1 
FabG (beta-ketoacyl-[acyl-carrier-protein] reductase, E Hs.288354 1 1 
coli) like 
famesyl diphosphate synthase (famesyl pyrophosphate Hs.77393 1 4 
synthetase, dimethylallyltranstransferase, 
geranyltranstransferase) 
farnesyl-diphosphate farnesyltransferase 1 Hs.48876 0 1 
fatty acid amide hydrolase Hs. 326190 0 1 
fatty acid binding protein 1, liver Hs.5241 18 1 
fatty acid binding protein 5 (psoriasis-associated) Hs. 153179 0 2 
fatty acid desaturase 2 Hs. 184641 0 5 
fatty acid desaturase 3 Hs.21765 0 1 
fatty-acid-Coenzyme A ligase, long-chain 2 Hs. 154890 2 0 
ferritin light polypeptide Hs.52891 42 817 
ferritin heavy polypeptide Hs.62954 7 69 
fibroblast growth factor (acidic) intracellular binding Hs.7768 0 1 
protein 
fibroblast growth factor 21 Hs.283015 0 1 
flavin containing monooxygenase 3 Hs.80876 1 0 
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flavin containing monooxygenase 5 Hs. 14286 1 0 
formiminotransferase cyclodeaminase Hs.36218 3 0 
formyltetrahydrofolate dehydrogenase Hs.9520 1 2 
fragile 16D oxido reductase (FOR) NIL 1 0 
fiimarate hydratase Hs.75653 1 2 
fumarylacetoacetate Hs.73875 1 2 
galactosidase, alpha (GLA), mRNA Hs.69089 0 2 
gamma-glutamyl hydrolase (conjugase, Hs.78619 0 3 
folylpolygammaglutamyl hydrolase) 
GDP-mannose pyrophosphorylase A Hs.27059 0 2 
glucuronidase, beta Hs. 183868 0 1 
glutamate-ammonia ligase (glutamine synthase) Hs. 170171 1 0 
glutamate-cysteine ligase, catalytic subunit Hs. 151393 0 1 
glutamic-oxaloacetic transaminase 2 Hs. 170197 1 0 
Glutaminase Hs.239189 0 2 
glutamine-fructose-6-phosphate transaminase 1 Hs.l674 0 2 
Glutaredoxin (thioltransferase) Hs. 28988 1 7 
glutaryl-Coenzyme A dehydrogenase Hs. 184141 0 1 
glutathione peroxidase 1 Hs.76686 3 6 
glutathione peroxidase 2 (gastrointestinal) Hs.2704 0 9 
glutathione peroxidase 3 (plasma) Hs. 172153 1 10 
glutathione peroxidase 4 (phospholipid Hs.2706 2 7 
hydroperoxidase) 
glutathione S-transferase A2 Hs.89552 11 35 
glutathione S-transferase A4 Hs. 169907 0 2 
glutathione S-transferase Hal subunit NIL 1 0 
glutathione S-transferase M3 (brain) Hs.2006 0 1 
glutathione S-transferase subunit 13 homolog Hs.279952 0 3 
glutathione S-transferase theta 2 Hs.l581 1 0 
glutathione-S-transferase like; glutathione transferase Hs. 11465 2 3 
omega 
glycine cleavage system protein H (aminomethyl Hs.77631 1 0 
carrier) 
glycine-N-acyltransferase Hs. 18508 1 0 
glyoxalase I Hs.75207 0 1 
glyoxylate reductase/hydroxypyruvate reductase Hs. 155742 3 4 
GM2 activator protein Hs.289082 1 1 
8 5 
Results 
golgi autoantigen，golgin subfamily a，3 Hs.4953 1 0 
Gp25L2 protein Hs.279929 1 2 
GTP cyclohydrolase 1 (dopa-responsive dystonia) Hs.86724 0 1 
GTP cyclohydrolase I feedback regulatory protein Hs.83081 1 2 
guanidinoacetateN-methyltransferase Hs.81131 1 0 
guanylate kinase 1 Hs.3764 0 1 
heat shock 70kD protein 5 (glucose-regulated protein, Hs.75410 0 14 
78kD) 
heme oxygenase (decycling) 1 (HMOXl) Hs.202833 1 1 
hepatocyte nuclear factor 1-beta NIL 0 1 
high-mobility group (nonhistone chromosomal) Hs.274472 0 1 
protein 1 
high-mobility group (nonhistone chromosomal) Hs. 181163 3 7 
protein 17 
histone acetyltransferase Hs.21907 1 0 
HMTl (hnRNP methyltransferase, S. cerevisiae)-like 2 Hs.20521 0 1 
homogentisate 1,2-dioxygenase Hs.l5113 0 2 
hydroxyacid oxidase (glycolate oxidase) 1 Hs. 193640 1 0 
hydroxysteroid (11-beta) dehydrogenase 1 Hs.275215 4 1 
hydroxysteroid (17-beta) dehydrogenase 1 Hs.85279 1 0 
hydroxysteroid (17-beta) dehydrogenase 2 Hs. 155109 1 0 
hydroxysteroid (17-beta) dehydrogenase 4 Hs.75441 1 0 
ilvB (bacterial acetolactate synthase)-like Hs.78880 0 1 
IMP (inosine monophosphate) dehydrogenase 1 Hs.850 0 1 
IMP (inosine monophosphate) dehydrogenase 2 Hs.75432 1 0 
KDEL (Lys-Asp-Glu-Leu) endoplasmic reticulum Hs.78040 0 3 
protein retention receptor 1 
KDEL (Lys-Asp-Glu-Leu) endoplasmic reticulum Hs. 118778 0 1 
protein retention receptor 2 
kynureninase (L-kynurenine hydrolase) Hs. 169139 0 1 
L apoferritin exons 3 and 4 NIL 0 1 
lipase, hepatic Hs.9994 1 0 
liver-specific methionine adenosyltransferase gene Hs.323715 1 0 
low density lipoprotein-related protein 1 Hs.89137 0 1 
Lsml protein Hs.l l l783 0 1 
lysophospholipase I Hs. 12540 1 1 




methionine adenosyltransferase alpha subunit NIL 1 0 
methionine adenosyltransferase I, alpha Hs.323715 2 1 
methionine adenosyltransferase II, beta Hs.54642 1 0 
methionine sulfoxide reductase A Hs.26458 1 0 
methylcrotonoyl-Coenzyme A carboxylase 1 (alpha) Hs.47649 1 0 
microsomal glutathione S-transferase 1 Hs.790 4 6 
microsomal glutathione S-transferase 2 Hs.81874 2 2 
microsomal glutathione S-transferase 3 Hs.111811 2 2 
microsomal NAD+-dependent retinol dehydrogenase 4 Hs. 134958 2 1 
microsomal signal peptidase subunit Hs.68644 0 4 
microsomal triglyceride transfer protein (large Hs. 195799 0 1 
polypeptide, 88kD) 
monoamine oxidase A Hs. 183109 0 1 
monoamine oxidase B Hs.82163 0 1 
N-Acetylglucosamine kinase Hs.7036 0 1 
NAD(P)H menadione oxidoreductase 2, Hs.73956 1 0 
dioxin-inducible 
napsin 2 precursor Hs. 104433 0 1 
nicotinamide N-methyltransferase Hs.76669 3 1 
NMN adenylyltransferase; nicotinamide Hs. 156888 0 1 
mononucleotide adenylyl transferase 
nuclear receptor subfamily 1，group H, member 4 Hs. 171683 0 5 
nuclear receptor subfamily 2, group F, member 6 Hs.239752 0 1 
nucleolin Hs.79110 0 2 
nucleosome assembly protein 1-like 1 Hs. 179662 1 1 
nucleosome assembly protein 1-like 4 Hs.78103 0 1 
0-6-methylguanine-DNAmethyltransferase Hs.l384 1 0 
ornithine decarboxylase antizyme 1 Hs. 125078 2 3 
palmitoyl-protein thioesterase 1 (ceroid-lipofuscinosis, Hs.3873 1 0 
neuronal 1，infantile) 
partial GPLDl gene for glycosylphosphatidylinositol Hs.272529 1 0 
phospholipase D, exon 25 
PCTAIRE protein kinase 1 Hs. 171834 0 1 
peptidase D Hs.73947 1 2 
peptidylprolyl isomerase A (cyclophilin A) Hs. 182937 0 27 
peptidylprolyl isomerase B (cyclophilin B) Hs.699 2 11 
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peptidylprolyl isomerase D (cyclophilin D) Hs. 143482 1 0 
peptidylprolyl isomerase E (cyclophilin E) Hs.33251 0 1 
peroxisomal D3,D2-enoyl-CoA isomerase Hs. 15250 1 0 
peroxisomal short-chain alcohol dehydrogenase Hs.6318 2 0 
phenylalanine hydroxylase Hs.l870 1 1 
phosphoglycerate mutase 1 (brain) Hs. 181013 0 2 
phospholipase A2, group IIA (platelets, synovial fluid) Hs.76422 0 1 
phospholipase C, beta 3 (phosphatidylinositol-specific) Hs.37121 0 1 
phosphoribosyl pyrophosphate synthetase 1 Hs.56 1 1 
phosphoribosyl pyrophosphate synthetase 2 Hs.2910 1 1 
phytanoyl-CoA hydroxylase (Refsum disease) Hs. 172887 2 1 
P0P7 (processing of precursor, S. cerevisiae) homolog Hs. 18747 0 3 
procollagen-lysine, 2-oxoglutarate 5-dioxygenase 3 Hs.153357 0 1 
prolylcarboxypeptidase (angiotensinase C) Hs.75693 0 2 
propionyl Coenzyme A carboxylase, beta polypeptide Hs.63788 1 0 
prosaposin (variant Gaucher disease and variant Hs.78575 5 13 
metachromatic leukodystrophy) 
prostate cancer overexpressed gene 1 Hs. 18910 1 0 
prostatic binding protein Hs.80423 11 14 
protease, cysteine, 1 (legumain) Hs. 18069 2 0 
protease, serine, 11 (IGF binding) Hs.75111 1 0 
protease, serine, 15 Hs.278614 1 1 
protease, serine, 4 (trypsin 4，brain) Hs.58247 0 2 
proteasome (prosome, macropain) 26S subunit, Hs.4745 1 0 
ATPase, 1 
proteasome (prosome, macropain) 26S subunit, Hs.61153 0 1 
ATPase, 2 
proteasome (prosome, macropain) 26S subunit, Hs.250758 0 3 
ATPase, 3 
proteasome (prosome, macropain) 26 S subunit, Hs. 2115 94 1 5 
ATPase, 4 
proteasome (prosome, macropain) 26S subunit, Hs.79387 0 1 
ATPase, 5 
proteasome (prosome, macropain) 26S subunit, Hs.3887 0 1 
non-ATPase，1 




proteasome (prosome, macropain) 26S subunit, Hs.9736 0 1 
non-ATPase, 3 
proteasome (prosome, macropain) 26S subunit, Hs. 148495 0 3 
non-ATPase, 4 
proteasome (prosome, macropain) 26S subunit, Hs. 155543 0 1 
non-ATPase, 7 (Mov34 homolog) 
proteasome (prosome，macropain) 26S subunit, Hs.78466 0 14 
non-ATPase, 8 
proteasome (prosome, macropain) 26S subunit, Hs.5648 0 2 
non-ATPase, 9 
proteasome (prosome, macropain) activator subunit 2 Hs. 179774 1 0 
proteasome (prosome, macropain) inhibitor subunit 1 Hs.75925 0 1 
proteasome (prosome, macropain) subunit, alpha type, 1 Hs.82159 0 2 
proteasome (prosome, macropain) subunit, alpha type, 5 Hs.76913 0 1 
proteasome (prosome, macropain) subunit, alpha type, 6 Hs.74077 0 3 
proteasome (prosome, macropain) subunit, alpha type, 7 Hs.233952 2 25 
proteasome (prosome, macropain) subunit, beta type, 1 Hs.75748 1 2 
proteasome (prosome, macropain) subunit, beta type, 10 Hs.9661 1 1 
proteasome (prosome, macropain) subunit, beta type, 2 Hs.l390 1 1 
proteasome (prosome, macropain) subunit, beta type, 3 Hs.82793 0 2 
proteasome (prosome, macropain) subunit, beta type, 4 Hs. 89545 0 8 
proteasome (prosome, macropain) subunit, beta type, 5 Hs.78596 0 2 
proteasome (prosome, macropain) subunit, beta type, 6 Hs.77060 0 1 
proteasome (prosome, macropain) subunit, beta type, 7 Hs. 118065 1 4 
protein disulfide isomerase related protein Hs.93659 1 2 
protein kinase, AMP-activated, Hs.259842 1 0 
gamma 2 non-catalytic subunit 
protein translocation complex beta Hs.77028 2 16 
protein Z-dependent protease inhibitor precursor Hs. 118620 0 1 
protein-L-isoaspartate (D-aspartate) Hs.79137 0 3 
0-methyltransferase 
putative b,b-carotene-9', lO'-dioxygenase Hs. 181795 0 1 
putative peroxisome microbody protein 175.1 Hs. 166197 1 3 
pyrophosphatase (inorganic) Hs. 184011 1 2 
pyruvate dehydrogenase (lipoamide) beta Hs.979 0 1 
Rab acceptor 1 (prenylated) Hs. 11417 0 6 
RAD23 (S. cerevisiae) homolog A (RAD23A) NIL 1 1 
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RAD23 (S. cerevisiae) homolog B Hs. 178658 0 2 
RAD50 (S. cerevisiae) homolog Hs.41587 1 0 
retinal short-chain dehydrogenase/reductase retSDR2 Hs.l2150 1 1 
retinal short-chain dehydrogenase/reductase retSDR3 Hs. 18788 0 1 
ribonuclease 6 precursor Hs.8297 0 2 
ribonuclease HI, large subunit Hs.25292 0 1 
ribonuclease, RNase A family, 4 Hs.283749 5 0 
ribonuclease/angiogenin inhibitor Hs.75108 0 2 
ribophorin I Hs.2280 0 2 
ribophorin II Hs.75722 0 2 
S-adenosylhomocysteine hydrolase Hs. 172673 0 1 
S-adenosylmethionine decarboxylase 1 Hs.262476 1 1 
Sec61 gamma Hs.9950 1 10 
sec61 homolog Hs. 27895 8 0 5 
selenium binding protein 1 Hs.288973 1 0 
selenophosphate synthetase 2 Hs. 118725 2 3 
serine carboxypeptidase 1 precursor protein Hs. 106747 0 1 
serine dehydratase Hs.76751 1 1 
serine hydroxymethyltransferase 1 (soluble) Hs.8889 1 2 
serine hydroxymethyltransferase 2 (mitochondrial) Hs.75069 0 1 
short-chain dehydrogenase/reductase 1 Hs. 17144 0 1 
sialyltransferase 4C (beta-galactosidase Hs.75268 0 1 
alpha-2,3 -sialytransferase) 
signal peptidase complex (18kD) Hs.9534 0 4 
similar to peroxiredoxin 2 Hs.287517 0 1 
similar to proteasome (prosome, macropain) subunit, NIL 1 1 
alpha type, 2 
similar to S. cerevisiae RERl Hs.40500 0 3 
similar to UDP-glucose pyrophosphoiylase 2; Uridyl NIL 0 1 
diphosphate glucose 
SOD-2 gene for manganese superoxide dismutase NIL 1 2 
sorbitol dehydrogenase Hs.878 1 3 
spermidine/spermine N1 -acetyltransferase Hs.28491 0 1 
spermine synthase Hs.89718 1 0 
stearoyl-CoA desaturase (delta-9-desatiirase) Hs. 119597 4 2 
steroid-5-alpha-reductase, alpha polypeptide 1 (3-oxo-5 Hs.552 0 1 
alpha-steroid delta 4-dehydrogenase alpha 1) 
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sterol carrier protein 2 Hs.75760 1 0 
stress-associated endoplasmic reticulum protein 1; Hs.76698 1 2 
ribosome associated membrane protein 4 
sulfotransferase family, cytosolic, 2A, Hs.81884 2 5 
dehydroepiandrosterone (DHEA) -preferring, member 
1 
SUMO-1 activating enzyme subunit 1 Hs.279868 0 1 
SUMO-1 activating enzyme subunit 2 Hs.4311 0 2 
superoxide dismutase 1，soluble (amyotrophic lateral Hs.75428 6 20 
sclerosis 1 (adult)) 
superoxide dismutase 1, mitochondrial Hs. 318885 0 2 
suppressor of Ty (S.cerevisiae) 4 homolog 1 Hs.79058 0 2 
suppressor of Ty (S.cerevisiae) 5 homolog Hs.70186 0 1 
THl drosophila homolog Hs.5184 0 2 
thiopurine S-methyltransferase Hs.296922 1 0 
thioredoxin peroxidase (antioxidant enzyme) Hs.83383 3 3 
thioredoxin reductase 1 Hs. 13046 0 2 
thymidylate synthetase Hs. 82962 0 2 
tissue factor pathway inhibitor (lipoprotein-associated Hs. 170279 0 1 
coagulation inhibitor) 
transglutaminase 2 (C polypeptide, Hs.8265 0 2 
protein-glutamine-gamma-glutamyltransferase) 
transglutaminase 3 (E polypeptide, Hs.2022 0 2 
protein-glutamine-gamma-glutamyltransferase) 
transketolase (Wernicke-Korsakoff syndrome) Hs.89643 0 2 
transporter 1, ATP-binding cassette, sub-family B Hs. 158164 0 2 
tryptophan 2,3-dioxygenase Hs. 183671 3 1 
tyrosine 3-monooxygenase/tryptophan Hs.279920 1 0 
5-monooxygenase activation protein, beta 
f 
polypeptide 
tyrosine 3-monooxygenase/tryptophan Hs.79474 0 1 
5-monooxygenase activation protein, epsilon 
polypeptide 
tyrosine 3 -monooxygenase/tryptophan Hs.74405 0 3 
5-monooxygenase activation protein, theta 
polypeptide 
tyrosine 3-monooxygenase/tryptophan Hs.75103 1 2 
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5-monooxygenase activation protein, zeta polypeptide 
tyrosine aminotransferase Hs. 161640 1 0 
ubiquitin B Hs. 183842 2 15 
ubiquitin C Hs. 183704 0 20 
ubiquitin carrier protein Hs. 174070 0 1 
ubiquitin specific protease 1 Hs.35086 0 1 
ubiquitin specific protease 5 (isopeptidase T) (USPS) Hs.3759 1 0 
ubiquitin specific protease 9, X chromosome Hs.77578 0 1 
ubiquitination factor E4A (homologous to yeast UFD2) Hs.75275 1 0 
ubiquitination factor E4B (homologous to yeast UFD2) Hs.24594 0 1 
ubiquitin-conjugating enzyme E2A (RAD6 homolog) Hs.80612 0 1 
ubiquitin-conjugating enzyme E2D 2 Hs. 108332 0 2 
(homologous to yeast UBC4/5) 
ubiquitin-conjugating enzyme E2L 3 Hs. 108104 0 1 
ubiquitin-conjugating enzyme E2L 6 Hs. 169895 0 1 
ubiquitin-conjugating enzyme E2M (homologous to Hs. 200478 0 1 
yeast UBC12) 
UDP glycosyltransferase 1 family, polypeptide Al Hs.278896 1 3 
UDP glycosyltransferase 1 family, polypeptide A6 Hs.284239 0 2 
UDP glycosyltransferase 1 family, polypeptide A9 Hs.2056 0 2 
UDP glycosyltransferase 2 family, polypeptide B Hs.278892 0 1 
UDP glycosyltransferase 2 family, polypeptide BIO Hs.294039 1 0 
UDP glycosyltransferase 2 family, polypeptide B l l Hs. 137585 0 1 
UDP glycosyltransferase 2 family, polypeptide B4 Hs.89691 1 11 
UDP glycosyltransferase 2 family, polypeptide B7 Hs.l0319 2 0 
UDP-Gal:betaGlcNAc beta 1,4- galactosyltransferase, Hs. 198248 1 0 
polypeptide 1 
UDP-glucose dehydrogenase Hs.28309 0 1 
UDP-glucose pyrophosphoiylase 2 Hs.77837 2 1 
UDP-glucose:glycoprotein glucosyltransferase 1 Hs. 105794 0 2 
UDP-N-acteylglucosamine pyrophosphorylase 1 Hs.21293 0 4 
UGTl gene locus NIL 1 1 
upstream transcription factor 1 Hs.247842 0 5 
uracil-DNA glycosylase Hs.78853 0 1 
Xq28,2000bp sequence contg. ORF Hs.6487 0 1 
X-ray repair complementing defective repair in Chinese Hs. 84981 1 0 




YMEl (S.cerevisiae)-like 1 Hs.206521 0 1 
Secretory protein (n=132) 
afamin Hs.531 1 0 
albumin Hs. 184411 252 39 
alpha-1 -microglobulin/bikunin precursor Hs.76177 43 36 
alpha-2-glycoprotein 1，zinc Hs.71 7 1 
alpha-2-HS-glycoprotein Hs.324746 13 3 
alpha-2-macroglobulin Hs.74561 4 0 
amyloid P component, serum Hs.l957 3 26 
annexin A5 Hs.300711 0 1 
apolipoprotein A-I Hs.93194 120 0 
apolipoprotein A-II Hs.237658 101 548 
apolipoprotein A-IV Hs.l247 0 7 
apolipoprotein B (including Ag(x) antigen) Hs.585 9 7 
apolipoprotein C-I Hs.268571 81 26 
apolipoprotein C-II Hs.75615 46 49 
apolipoprotein C-III Hs.73849 77 112 
apolipoprotein C-IV Hs. 110675 2 1 
apolipoprotein E Hs. 169401 5 7 
apolipoprotein F Hs.2388 1 0 
apolipoprotein H (beta-2-glycoprotein I) Hs.l252 16 18 
apolipoprotein L Hs. 114309 1 1 
apolipoprotein L, 3 Hs.241535 0 1 
apolipoprotein M (G3A) Hs.247129 5 0 
beta-2-microglobulin Hs.75415 7 20 
B-factor, properdin Hs.69771 8 5 
ceruloplasmin (ferroxidase) Hs.296634 1 1 
chitinase 3-like 1 (cartilage glycoprotein-39) Hs.75184 1 0 
clusterin (complement lysis inhibitor, SP-40,40, sulfated Hs.75106 9 5 
glycoprotein 2, testosterone-repressed prostate 
message 2, apolipoprotein J) 
coagulation factor II (thrombin) Hs.76530 12 5 
coagulation factor IX (plasma thromboplastic Hs.l330 1 1 
component, Christmas disease, hemophilia B) 
coagulation factor X Hs.47913 0 1 
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coagulation factor XII (Hageman factor) Hs. 1321 2 0 
coagulation factor XIII, B polypeptide Hs.68601 0 2 
complement component 1, q subcomponent binding Hs.78614 0 1 
protein 
complement component 1, q subcomponent, alpha Hs.9641 2 0 
polypeptide 
complement component 1，q subcomponent, beta Hs.8986 1 0 
polypeptide 
complement component 1, r subcomponent Hs.l279 8 8 
complement component 1, s subcomponent Hs. 169756 9 3 
complement component 2 Hs.2253 3 1 
complement component 3 Hs.2843 94 19 11 
complement component 4A Hs. 170250 6 7 
complement component 4B Hs.278625 3 1 
complement component 4-binding protein, alpha Hs. 1012 2 0 
complement component 4-binding protein, beta Hs.99886 0 3 
complement component 5 Hs.l281 1 1 
complement component 8, alpha polypeptide Hs.93210 1 1 
complement component 8, beta polypeptide Hs.38069 1 0 
complement component 8, gamma polypeptide Hs.l285 1 2 
complement component 9 Hs.l290 3 0 
complement component Clq receptor Hs.97199 0 1 
complement factor H related 3 Hs.2637 1 0 
C-reactive protein, pentraxin-related Hs.76452 0 11 
cystatin B (stefin B) Hs.695 0 7 
cystatin C (amyloid angiopathy and cerebral Hs. 135084 0 1 
hemorrhage) 
cystatin F (leukocystatin) Hs. 143212 2 0 
defensin, beta 1 Hs.32949 1 1 
deoxyribonuclease I-like 3 Hs.88646 2 0 
ephrin-Al Hs.l624 0 4 
fibrinogen, A alpha polypeptide Hs. 90765 31 12 
fibrinogen, B beta polypeptide Hs.7645 20 15 
fibrinogen, gamma polypeptide Hs.75431 20 14 
fibrinogen-like 1 Hs.l07 5 1 
fibrinogen-like protein 2 (FGL2) Hs.2659 1 0 




glycoprotein, synaptic 2 Hs.306122 0 1 
group-specific component (vitamin D binding protein) Hs. 198246 11 19 
H factor (complement)-like 1 Hs.278568 4 7 
H factor (complement)-like 2 Hs.296941 1 1 
H factor (complement)-like 3 Hs. 154224 3 1 
H factor 1 (complement) Hs. 250651 2 4 
haptoglobin Hs.75990 53 21 
hemopexin Hs.l504 12 4 
hexosaminidase A (alpha polypeptide) Hs. 119403 0 3 
high density lipoprotein binding protein (vigilin) Hs. 177516 0 2 
histidine-rich glycoprotein Hs.l498 5 0 
hyaluronan-binding protein 2 Hs.241363 1 1 
hyaluronoglucosaminidase 1 Hs.75619 0 1 
I factor (complement) Hs.36602 1 1 
inter-alpha (globulin) inhibitor H4 (plasma Hs.76415 4 1 
Kallikrein-sensitive glycoprotein) 
lecithin-cholesterol acyltransferase Hs.325507 1 0 
lipase A, lysosomal acid, cholesterol esterase Hs.85226 1 0 
(Wolman disease) 
lipophilin B (uteroglobin family member), Hs.204096 0 1 
prostatein-like 
LR8 protein Hs. 190161 4 3 
lysozyme (renal amyloidosis) (LYZ) Hs.277431 0 2 
mannan-binding lectin serine protease 1 (C4/C2 Hs.227152 1 2 
activating component of Ra-reactive factor) 
mannan-binding lectin serine protease 2 Hs. 119983 1 0 
mannose-binding lectin (protein C) 2, soluble (opsonic Hs.2314 1 0 
defect) 
monokine induced by gamma interferon Hs.77367 1 0 
Niemann-Pick disease, type C2 gene Hs. 119529 0 3 
orosomucoid 1 Hs.572 23 63 
orosomucoid 2 Hs.278388 2 27 
pancreatic secretory trypsin inhibitor (PSTI) NIL 0 11 
paraoxonase 1 Hs.l898 1 1 
paraoxonase 2 Hs. 169857 3 1 
plasminogen Hs.75576 2 1 
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plasminogen-like Hs. 262869 1 0 
protein C (inactivator of coagulation factors Va and Hs.2351 1 0 
Villa) 
putative 14kD protein containing SHMT homology, Hs.268495 2 0 
clone p u s 1215 
retinol-binding protein 1, cellular Hs. 101850 1 0 
retinol-binding protein 4, interstitial Hs.76461 34 16 
secreted phosphoprotein 1 (osteopontin, bone Hs.313 0 2 
sialoprotein I，early T-lymphocyte activation 1) 
secreted phosphoprotein 2,24kD Hs. 12230 3 0 
secreted protein, acidic, cysteine-rich (osteonectin) Hs. 111779 0 1 
secretory leukocyte protease inhibitor Hs.251754 0 3 
(antileukoproteinase) (SLPI) 
selenoprotein N Hs.8518 0 1 
selenoprotein P, plasma, 1 Hs.3314 7 6 
selenoprotein T Hs.8148 0 1 
selenoprotein W, 1 Hs. 14231 0 1 
selenoprotein X，1 Hs. 279623 1 0 
serine (or cysteine) proteinase inhibitor, clade A Hs.297681 94 33 
(alpha-1 antiproteinase, antitrypsin), member 1 
serine (or cysteine) proteinase inhibitor, clade A Hs.234726 11 4 
(alpha-1 antiproteinase, antitrypsin), member 3 
serine (or cysteine) proteinase inhibitor, clade A Hs. 1305 4 0 
(alpha-1 antiproteinase, antitrypsin), member 6 
serine (or cysteine) proteinase inhibitor，clade A Hs.3697 6 14 
(alpha-1 antiproteinase, antitrypsin), member 8 
serine (or cysteine) proteinase inhibitor, clade B Hs. 183583 0 2 
clade B (ovalbumin), member 1 
serine (or cysteine) proteinase inhibitor, clade C Hs.75599 6 6 
(antithrombin), member 1 
serine (or cysteine) proteinase inhibitor, clade D Hs. 1478 1 2 
(heparin cofactor), member 1 
serine (or cysteine) proteinase inhibitor, clade E (nexin, Hs.82085 0 1 
plasminogen activator inhibitor type 1)，member 1 
serine (or cysteine) proteinase inhibitor, clade F Hs. 173594 4 12 
(alpha-2 antiplasmin, pigment epithelium derived 
factor), member 1 
9 6 
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serine (or cysteine) proteinase inhibitor, clade F Hs. 159509 4 0 
(alpha-2 antiplasmin, pigment epithelium derived 
factor), member 2 
serine (or cysteine) proteinase inhibitor, clade G Hs. 151242 9 4 
(CI inhibitor), member 1 
serum amyloid Al Hs. 181062 0 2 
serum amyloid A2 Hs.332053 0 2 
serum amyloid A4 Hs.l955 9 0 
serum constituent protein (MSE55) NIL 0 1 
serum/glucocorticoid regulated kinase-like Hs.279696 0 1 
similar to yeast BET3 (S. cerevisiae) Hs.288013 1 3 
small inducible cytokine A2 (monocyte chemotactic Hs.303649 2 0 
protein 1，homologous to mouse Sig-je) 
small inducible cytokine subfamily A (Cys-Cys), Hs. 10458 1 0 
member 16 
solute carrier family 22 (extraneuronal monoamine Hs.81086 1 0 
transporter), member 3 
transferrin Hs.284176 16 19 
transthyretin (prealbumin, amyloidosis type I) Hs. 194366 35 20 
trefoil factor 3 (intestinal) Hs.82961 0 2 
vitronectin (serum spreading factor, somatomedin B， Hs.2257 26 40 
complement S-protein) 
Signal transduction/cell cycle regulation (n=267) 
13kDa differentiation-associated protein Hs.44163 0 3 
8-oxoguanine DNA glycosylase Hs.96398 0 1 
A kinase (PRKA) anchor protein (yotiao) 9 Hs.58103 2 0 
A kinase (PRKA) anchor protein 1 Hs.78921 1 0 
A kinase (PRKA) anchor protein 7 Hs. 12835 0 1 
A kinase (PRKA) anchor protein 8 Hs.25059 1 3 
abl-interactor 12 (SH3-containing protein) Hs.256315 0 1 
activated in tumor suppression, clone TSAP19 NIL 0 1 
adenylyl cyclase-associated protein Hs. 104125 1 2 
ADP-ribosylation factor 1 Hs.74571 0 4 
ADP-ribosylation factor 4 Hs.75290 1 4 
ADP-ribosylation factor 4-like Hs. 183153 0 1 
ADP-ribosylation factor 5 Hs.77541 0 1 
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ADP-ribosylation factor GTPase activating protein 1 Hs. 13014 0 1 
ADP-ribosylation factor-like 1 (ARLl) Hs.242894 0 2 
ADP-ribosylation factor-like 2 Hs. 154162 0 1 
angio-associated, migratory cell protein Hs.83347 0 2 
angiogenin, ribonuclease, RNase A family, 5 Hs. 154730 6 0 
angiopoietin-like 3 Hs.209153 2 0 
annexin A2 Hs.217493 0 6 
annexin A4 Hs.77840 0 4 
annexin A6 Hs. 118796 1 0 
annexin A7 Hs.78637 1 0 
associated molecule with the SH3 domain of STAM Hs. 12479 0 1 
AXL receptor tyrosine kinase Hs.83341 1 0 
B-cell CLL/lymphoma 7B Hs. 16269 0 1 
B-cell translocation gene 1, anti-proliferative Hs.77054 0 1 
BCL2/adenovirus E lB 19kD-interacting protein 1 Hs.77572 0 1 
BCL2/adenovirus E l B 19kD-interacting protein 3 Hs.79428 2 0 
BCL2-antagonist/killer 1 Hs.93213 1 0 
BCL2-associated athanogene 4 Hs. 194726 1 0 
BCL2-like 10 (apoptosis facilitator) Hs.283672 1 0 
butyrate response factor 1 (EGF-response factor 1) Hs.85155 0 1 
calcium and integrin binding protein Hs. 10803 0 2 
(DNA-dependent protein kinase interacting protein) 
calcium/calmodulin-dependent protein kinase I Hs. 184402 0 2 
calmodulin 2 (phosphoiylase kinase, delta) Hs. 182278 1 3 
calmodulin 3 (phosphoiylase kinase, delta) Hs.334330 0 2 
calpain 1，(mu/I) large subunit Hs.2575 0 1 
calpain 12 [Mus musculus] Mm. 81144 0 1 
calpain 4, small subunit (30K) Hs.74451 1 6 
Calreticulin Hs. 16488 1 9 
Calumenin Hs.7753 0 1 
caspase 4, apoptosis-related cysteine protease (CASP4) Hs.321247 0 1 
catenin (cadherin-associated protein), alpha 1 (102kD) Hs. 178452 1 2 
CDC28 protein kinase 1 Hs.77550 0 1 
CDC28 protein kinase 2 Hs.83758 0 2 
CDC2-related protein kinase 7 Hs. 123073 0 1 
CDC37 (cell division cycle 37，S. cerevisiae, homolog) Hs. 160958 0 2 
CDC-like kinase 2 Hs.73986 1 0 
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CDC-like kinase 3 Hs.73987 0 1 
CDK4-binding protein p34SEIl Hs.44281 1 0 
cell cycle progression 2 protein Hs.333534 0 1 
cell death-inducing DFFA-like efifector b Hs.288835 3 0 
cell division cycle 2, G1 to S and G2 to M Hs. 184572 0 1 
cell division cycle 25B Hs. 153752 0 1 
cell division cycle 2-like 1 (PITSLRE proteins) Hs. 183418 0 1 
cell division cycle 34 Hs.76932 0 1 
cell division cycle 42 (GTP-binding protein, 25kD) Hs. 146409 0 2 
ceroid-lipofuscinosis, neuronal 3, juvenile (Batten, Hs. 194660 0 2 
Spielmeyer-Vogt disease) 
CGI-39 protein; cell death-regulatoiy protein GRIM 19 Hs.279574 2 9 
chloride intracellular channel 1 Hs.74276 0 4 
choline kinase Hs.77221 0 1 
chromosome segregation 1 (yeast homolog)-like Hs.90073 0 3 
cornichon-like Hs.201673 0 4 
cyclin G2 Hs.79069 0 1 
cyclin L ania-6a Hs.4859 0 1 
cyclin-dependent kinase 4 Hs.95577 0 1 
cytokine inducible SH2-containing protein Hs.8257 1 0 
Decorin Hs.76152 0 1 
dedicator of cyto-kinesis 1 Hs. 82295 0 1 
defender against cell death 1 Hs.82890 0 3 
development and differentiation enhancing factor 2 Hs. 12802 0 1 
developmentally regulated GTP-binding protein 1 Hs. 115242 0 1 
diacylglycerol kinase, zeta (104kD) Hs.89981 0 1 
disabled (Drosophila) homolog 2 Hs.81988 1 1 
Diubiquitin Hs.44532 1 3 
DNAJ domain-containing Hs.279884 0 1 
dual specificity phosphatase 1 Hs. 171695 0 3 
F-box only protein 8 Hs.76917 1 0 
frizzled (Drosophila) homolog 1 Hs.94234 0 1 
frizzled (Drosophila) homolog 3 Hs.40735 0 1 
FYN oncogene related to SRC, FGR, YES Hs. 169370 0 1 
G protein-coupled receptor 30 Hs. 113207 1 0 
G protein-coupled receptor 37 Hs.27747 0 1 
G protein-coupled receptor 48 Hs. 160271 0 1 
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G protein-coupled receptor kinase 7 (GPRK7) Hs.261828 0 1 
G protein-coupled receptor, family C, group 5, member Hs.58014 0 2 
C (GPRC5C) 
gap junction protein, beta 1,32kD Hs.333303 1 2 
GDP dissociation inhibitor 1 Hs.74576 0 1 
GDP dissociation inhibitor 2 Hs. 56845 1 1 
glioma tumor suppressor candidate region gene 2 Hs.326588 1 2 
growth factor receptor-bound protein 2 Hs.296381 1 0 
guanine nucleotide binding protein (G protein), Hs.288642 0 1 
alpha activating activity polypeptide 
guanine nucleotide binding protein (G protein), Hs.215595 3 2 
beta polypeptide 1 (GNBl) 
guanine nucleotide binding protein (G protein), Hs.91299 0 1 
beta polypeptide 2 (GNB2) 
guanine nucleotide binding protein (G protein), Hs.5662 6 7 
beta polypeptide 2-like 1 
guanine nucleotide binding protein (G protein), Hs.5322 0 6 
gamma 5 
guanine nucleotide binding protein 10 Hs.79126 0 3 
heat shock protein 75 Hs. 182366 0 1 
histidine triad nucleotide-binding protein Hs.256697 4 16 
hormonally upregulated neu tumor-associated kinase Hs. 109437 0 1 
HSl binding protein Hs.l5318 0 3 
Ibdl NIL 0 1 
I-kappa-B-interacting Ras-like protein 2 Hs.22937 0 1 
inhibitor of growth family, member 1 -like Hs • 107153 1 1 
inositol 1,3,4-triphosphate 5/6 kinase Hs.6453 0 1 
inositol polyphosphate-1 -phosphatase Hs.32309 1 0 
inositol(myo)-l(or 4)-monophosphatase 2 Hs.5753 0 1 
insulin induced gene 1 Hs.56205 0 2 
insulin receptor Hs.89695 0 1 
interferon, alpha-inducible protein 27 Hs. 278613 1 4 
interferon, gamma-inducible protein 30 Hs. 14623 1 6 
inteiferon-stimulated protein, 15 kDa Hs.833 0 2 
interleukin 1 receptor accessory protein Hs. 173880 0 1 
interleukin 6 receptor Hs. 193400 0 1 
interleukin enhancer binding factor 2,45kD Hs.75117 0 5 
1 0 0 
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interleukin-l receptor-associated kinase 1 Hs. 182018 1 2 
intersectin 1 (SH3 domain protein) Hs.66392 0 1 
jun B proto-oncogene Hs. 198951 1 0 
leukemia-associated phosphoprotein p i 8 Hs.81915 0 1 
LPS-induced TNF-alpha factor Hs.76507 1 1 
macrophage migration inhibitory factor Hs.73798 3 7 
MAD2 (mitotic arrest deficient, yeast, homolog)-like 2 Hs. 19400 0 1 
MAGEFl protein (MAGEFl) Hs.306123 0 1 
mitogen-activated protein kinase 12 Hs.55039 0 1 
mitogen-activated protein kinase 14 Hs.79107 0 1 
mitogen-activated protein kinase kinase kinase 11 Hs. 89449 0 1 
mitogen-activated protein kinase kinase kinase 7 Hs.7510 0 1 
myeloid cell leukemia sequence 1 (BCL2-related) Hs.86386 0 5 
myristoylated alanine-rich protein kinase C substrate Hs.75607 0 1 
Neuroendocrine secretory protein 55 Hs. 113368 0 8 
neuropathy target esterase Hs.5038 1 0 
N-myc downstream regulated Hs.75789 0 12 
non-metastatic cells 1, protein (NM23A) Hs. 11863 8 1 5 
non-metastatic cells 2, protein (NM23B) Hs.275163 1 8 
non-metastatic cells 3, protein Hs.81687 0 1 
non-metastatic cells 4，protein Hs.9235 1 0 
nuclear receptor binding protein Hs.272736 0 2 
nuclear receptor interacting protein 1 Hs.155017 1 0 
ornithine decarboxylase 1 Hs.75212 0 1 
P53-induced protein PIGPCl Hs.303125 1 3 
PAK2 Hs.284275 0 1 
peroxiredoxin 1 Hs. 180909 1 7 
peroxiredoxin 2 Hs. 146354 0 2 
peroxiredoxin 3 Hs.75454 0 1 
peroxiredoxin 5 Hs.31731 0 1 
phosphatidic acid phosphatase type 2A Hs.41569 0 3 
phosphatidic acid phosphatase type 2C Hs.24879 0 3 
phosphatidylinositol 4-kinase, catalytic, alpha Hs. 171625 0 1 
polypeptide 
phosphatidylinositol 4-kinase, catalytic, beta Hs. 154846 0 1 
polypeptide 
phosphoinositide-3 -kinase, regulatory subunit, Hs.6241 0 1 
1 0 1 
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polypeptide 1 (p85 alpha) 
phosphoprotein regulated by mitogenic pathways Hs.7837 1 0 
PPAR(gamma) angiopoietin related protein Hs.9613 0 1 
programmed cell death 5 Hs. 166468 1 1 
programmed cell death 9 Hs.28555 0 1 
Prohibitin Hs.75323 0 3 
proliferating cell nuclear antigen Hs.78996 0 2 
proliferation-associated 2G4,38kD Hs.5181 0 2 
protein kinase C, delta Hs. 155342 1 0 
protein kinase Chk2 Hs. 146329 1 0 
protein kinase, cAMP-dependent, Hs.l519 1 0 
regulatory, type I，beta 
protein kinase, interferon-inducible double stranded Hs. 18571 0 1 
RNA dependent activator 
protein phosphatase 1，catalytic subunit, beta isoform Hs.21537 0 1 
protein phosphatase 1, regulatory (inhibitor) Hs. 82887 0 1 
subunit 11 
protein phosphatase 1, regulatory (inhibitor) Hs.267819 0 1 
subunit 2 
protein phosphatase 1, regulatory subunit 10 Hs. 106019 0 2 
protein phosphatase 1, regulatory subunit 7 Hs.36587 0 1 
protein phosphatase 2 (formerly 2A)，catalytic subunit, Hs.91773 1 0 
alpha isoform 
protein phosphatase 2 (formerly 2A)，catalytic subunit, Hs.80350 1 0 
beta isoform 
protein tyrosine phosphatase, non-receptor type 3 Hs. 153932 0 2 
protein tyrosine phosphatase, non-receptor type 6 Hs.63489 1 0 
protein tyrosine phosphatase, receptor type, A Hs.26045 0 1 
protein tyrosine phosphatase, receptor type, B Hs. 123641 0 1 
protein tyrosine phosphatase, receptor type, F Hs.75216 0 1 
prothymosin, alpha (gene sequence 28) Hs.250655 2 9 
putative cyclin G1 interacting protein (CGII) Hs. 10028 2 2 
putative lymphocyte GO/Gl switch gene Hs.95910 1 0 
Rab geranylgeranyltransferase, beta subunit Hs.78948 0 2 
RABl, member RAS oncogene family Hs.3642 0 2 
RAB 10, member RAS oncogene family Hs.236494 0 2 
RAB 11 A, member RAS oncogene family Hs.75618 1 0 
1 0 2 
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RAB1 IB, member RAS oncogene family Hs.239018 0 1 
RAB18, member RAS oncogene family Hs.21094 0 1 
RAB4, member RAS oncogene family Hs. 119007 0 1 
RAB5B, member RAS oncogene family Hs.77690 0 1 
RAB7, member RAS oncogene family-like 1 Hs. 115325 0 1 
RAD9 (S. pombe) homolog Hs.240457 0 1 
RAN, member RAS oncogene family Hs. 10842 0 3 
RAP IB, member of RAS oncogene family Hs. 156764 0 1 
Ras homolog enriched in brain 2 (RHEB2) NIL 1 0 
ras homolog gene family, member A Hs.77273 0 6 
ras homolog gene family, member B Hs.204354 0 1 
ras homolog gene family, member C Hs. 179735 0 1 
ras related protein rab-24 Hs. 16258 0 1 
Ras suppressor protein 1 (RSUl) Hs.75551 1 0 
ras-related C3 botulinum toxin substrate 1 Hs. 173737 0 1 
(rho family, small GTP binding protein Racl) 
ras-related protein Hs.25829 0 1 
regulator of G-protein signalling 14 Hs.9347 0 1 
requiem, apoptosis response zinc finger gene Hs. 13495 0 1 
retinoblastoma-binding protein 2 Hs.76272 1 0 
retinoblastoma-binding protein 7 Hs.31314 0 1 
retinoic acid receptor responder 2 Hs.37682 4 7 
retinoic acid receptor responder 3 Hs. 17466 0 1 
retinoid X receptor, alpha Hs.20084 1 0 
retinoid X receptor, beta (RXRB) Hs.79372 0 1 
Rho GTPase activating protein 1 Hs. 138860 1 1 
Rho-associated, coiled-coil containing Hs. 17820 0 1 
protein kinase 1 
Ric (Drosophila)-like, expressed in many tissues Hs.96038 0 1 
RYK receptor-like tyrosine kinase Hs.79350 0 1 
SlOO calcium-binding protein AlO Hs. 119301 1 10 
SI00 calcium-binding protein A l l (calgizzarin) Hs.256290 0 3 
SlOO calcium-binding protein A2 Hs.38991 0 2 
SlOO calcium-binding protein A4 Hs.81256 0 1 
S100 calcium-binding protein A9 (calgranulin B) Hs. 112405 1 1 
SlOO calcium-binding protein P Hs.2962 0 11 
SARI protein Hs. 110796 0 1 
1 0 3 
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sequestosome 1 Hs. 182248 2 13 
serine/threonine kinase 24 (Ste20，yeast homolog) Hs. 168913 1 0 
serine/threonine protein kinase Kp78 splice variant 
CTAK75a NIL 0 3 
serine/threonine protein phosphatase catalytic subunit Hs.80324 0 I 
signal recognition particle 14kD Hs. 180394 0 4 
signal recognition particle receptor, B subunit [Mus Mm.7588 0 1 
musculus] 
signal sequence receptor, alpha Hs.250773 0 2 
signal sequence receptor, beta Hs.74564 0 20 
signal sequence receptor, delta Hs. 102135 3 5 
signal sequence receptor, gamma Hs.28707 1 2 
signal transducer and activator of transcription 3 Hs.321677 1 0 
(acute-phase response factor) 
GNB5 Guanine nucleotide binding protein Hs. 155090 0 1 
small inducible cytokine subfamily A member 15 Hs.272493 1 2 
small inducible cytokine subfamily A member 20 Hs.75498 0 1 
small inducible cytokine subfamily B member 11 Hs. 103982 1 0 
small inducible cytokine subfamily B member 14 Hs.24395 3 0 
small inducible cytokine subfamily E, member 1 Hs. 146401 1 0 
SRp25 nuclear protein Hs. 103561 1 2 
STE20-like kinase Hs. 12040 1 0 
syndecan 1 Hs.82109 1 3 
syndecan binding protein (syntenin) Hs.8180 0 1 
target of mybl (chicken) homolog Hs.9482 0 1 
Thioredoxin Hs.76136 4 31 
thymosin, beta 10 Hs.76293 3 20 
thymosin, beta 4，X chromosome Hs.75968 10 34 
TNF receptor-associated factor 4 Hs.8375 0 1 
transfonner-2 alpha (htra-2 alpha) Hs.24937 0 1 
transforming growth factor, beta-induced, 68kD Hs. 118787 1 3 
transforming, acidic coiled-coil containing protein 1 Hs. 173159 0 1 
trans-golgi network glycoprotein (TGN) NIL 1 o 
transportin-SR Hs.69235 1 0 
tumor necrosis factor (ligand) superfamily, member 10 Hs.83429 3 1 
tumor necrosis factor alpha-inducible cellular protein NIL 0 2 
containing leucine zipper domains; Huntingtin 
1 0 4 
Results 
interactingprotein L; transcrption factor 
IIIA-interacting protein(FIP2) 
tumor necrosis factor, alpha-induced protein 1 Hs.76090 1 1 
tumor protein D52-like 2 Hs. 154718 0 1 
TYRO protein tyrosine kinase binding protein Hs.9963 1 0 
tyrosine kinase 2 Hs.75516 0 1 
ubiquitin-conjugating enzyme E2 variant 1 Hs.75875 0 1 
uridine-cytidine kinase 1 Hs.9597 0 1 
v-akt murine thymoma viral oncogene homolog 1 Hs.71816 0 2 
vascular endothelial growth factor Hs.73793 0 1 
vasodilator-stimulated phosphoprotein Hs.93183 0 1 
v-ets avian erythroblastosis virus E26 Hs.85146 2 1 
oncogene homolog 2 
v-fos FBJ murine osteosarcoma Hs.25647 1 0 
viral oncogene homolog 
v-maf musculoaponeurotic fibrosarcoma (avian) Hs.51305 0 1 
oncogene family, protein F (MAFF) 
v-maf musculoaponeurotic fibrosarcoma (avian) Hs.30250 0 1 
oncogene homolog 
v-inyb avian myeloblastosis viral oncogene Hs. 179718 0 1 
homolog-like 2 (MYBL2) 
v-raf-1 murine leukemia viral oncogene homolog 1 Hs.85181 1 1 
v-rel avian reticuloendotheliosis Hs.75569 0 1 
viral oncogene homolog A 
VRK3 for vaccinia related kinase 3 Hs.98289 1 0 
Zyxin Hs.75873 0 2 
Transcription and translation (n=287) 
15 kDa selenoprotein Hs. 90606 0 2 
40S ribosomal protein S27 isoform Hs. 108957 0 3 
activated RNA polymerase II transcription cofactor 4 Hs.74861 0 1 
activating transcription factor 4 (tax-responsive Hs. 181243 0 1 
enhancer element B67) 
activating transcription factor 5 Hs.9754 4 63 
AND-1 protein Hs.72160 0 1 
asparaginyl-tRNA synthetase Hs. 181311 0 3 
basic transcription factor 3 Hs. 101025 1 3 
1 0 5 
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cAMP responsive element binding protein 1 Hs.79194 0 1 
cAMP responsive element binding protein 3 (luman) Hs.287921 0 1 
CCAAT/enhancer binding protein (C/EBP), alpha Hs.76171 5 8 
CCAAT/enhancer binding protein (C/EBP), gamma Hs.2227 0 1 
CCAAT-box-binding transcription factor Hs. 184760 0 1 
chaperonin containing TCP 1，subunit 3 (gamma) Hs.l708 0 3 
chaperonin containing TCPl, subunit 4 (delta) Hs.79150 1 1 
chaperonin containing TCPl, subunit 7 (eta) Hs. 108809 2 1 
chaperonin containing TCP 1，subunit 8 (theta) Hs. 15071 0 1 
chromobox homolog 4 [Mus musculus] Mm.8556 1 1 
chromosome 11 open reading frame 13 Hs.72925 1 0 
Cipl-interacting zinc finger protein Hs.23476 0 1 
cleavage stimulation factor, 3' pre-RNA, subunit 1, Hs. 172865 0 1 
50kD 
C0P9 (constitutive photomorphogenic, Arabidopsis, Hs. 198767 0 2 
homolog) subunit 5 
CUG triplet repeat, RNA-binding protein 1 Hs. 81248 0 1 
cysteine-rich protein 1 (intestinal) Hs. 17409 0 2 
DEAD-box protein abstract Hs.274317 0 2 
down-regulator of transcription 1, TBP-binding Hs. 16697 0 1 
DRl-associated protein 1 Hs.295362 0 1 
E4F transcription factor 1 Hs. 154196 1 0 
E74-like factor 3 (ets domain transcription factor, Hs. 166096 0 3 
epithelial-specific) 
ets variant gene 2 Hs. 194061 0 1 
ets variant gene 4 (El A enhancer-binding protein, Hs.77711 0 1 
ElAF) 
eukaryotic translation elongation factor 1 alpha 1 Hs. 181165 19 43 
eukaryotic translation elongation factor 1 alpha l-like Hs.274466 1 1 
14 
eukaryotic translation elongation factor 1 beta 1 Hs.261802 0 6 
eukaryotic translation elongation factor 1 delta (guanine Hs.223241 4 13 
nucleotide exchange protein) 
eukaryotic translation elongation factor 1 gamma Hs.2186 2 12 
eukaryotic translation elongation factor 2 Hs.75309 4 0 
eukaryotic translation initiation factor 1A Hs.4310 0 1 
eukaryotic translation initiation factor 2, Hs.211539 1 0 
1 0 6 
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subunit 3 (gamma, 52kD) 
eukaryotic translation initiation factor 2B, Hs.283627 0 1 
subunit 3 (gamma, 58kD) 
eukaryotic translation initiation factor 2B, Hs.2437 0 1 
subunit 5 (epsilon, 82kD) 
eukaryotic translation initiation factor 3, Hs. 192023 0 1 
subunit 2 (beta, 36kD) 
eukaryotic translation initiation factor 3, Hs.58189 0 1 
subunit 3 (gamma, 40kD) 
eukaryotic translation initiation factor 3, Hs.28081 0 1 
subunit 4 (delta, 44kD) 
eukaryotic translation initiation factor 3, Hs.7811 0 1 
subunit 5 (epsilon, 47kD) 
eukaryotic translation initiation factor 3, Hs. 106673 0 5 
subunit 6 (48kD) 
eukaryotic translation initiation factor 3, Hs.55682 0 2 
subunit 7 (zeta，66/67kD) (EIF3S7) 
eukaryotic translation initiation factor 3, Hs.4835 0 1 
subunit 8 (llOkD) (EIF3S8) 
eukaryotic translation initiation factor 3, Hs.57783 0 3 
subunit 9 (eta, 116kD) 
eukaryotic translation initiation factor 4 gamma, 1 Hs.211568 1 3 
eukaryotic translation initiation factor 4 gamma, 2 Hs. 183684 1 2 
eukaryotic translation initiation factor 4A, isoform 1 Hs. 129673 1 1 
eukaryotic translation initiation factor 4A, isoform 2 Hs. 173912 0 2 
eukaryotic translation initiation factor 4E-like 3 Hs. 19122 0 1 
eukaryotic translation initiation factor 5 Hs.286236 1 1 
eukaryotic translation termination factor 1 Hs.77324 2 0 
fibrillarin Hs. 99853 0 1 
GAP-associated tyrosine phosphoprotein p62 (Sam68) Hs. 119537 1 2 
GCNl (general control of amino-acid synthesis 1， Hs.75354 0 1 
yeast)-like 1 
GCN5 (general control of amino-acid synthesis, yeast, Hs.94672 2 2 
homolog)-like 1 
glutaminyl-tRNA synthetase Hs.79322 0 2 
glutamyl-prolyl-tRNA synthetase Hs.55921 0 1 
guanine monphosphate synthetase Hs.5398 0 1 
1 0 7 
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HI histone family, member 2 Hs.7644 0 2 
H2A histone family, member O Hs.795 0 7 
H2A histone family, member Y Hs.75258 0 1 
H2A histone family, member Z Hs. 119192 1 1 
H3 histone，family 3A Hs. 181307 4 15 
H4 histone family, member I Hs. 143080 0 1 
heat shock lOkD protein 1 (chaperonin 10) Hs.ll97 2 9 
heat shock 27kD protein 1 Hs.76067 9 8 
heat shock 60kD protein 1 (chaperonin) Hs.79037 0 2 
hematological and neurological expressed 1 Hs. 109706 0 1 
heterochromatin-like protein 1 Hs.278554 0 1 
heterogeneous nuclear protein similar to rat helix Hs.249247 0 3 
destabilizing protein 
heterogeneous nuclear ribonucleoprotein Al Hs.249495 1 3 
heterogeneous nuclear ribonucleoprotein A2/B1 Hs.232400 0 1 
heterogeneous nuclear ribonucleoprotein C (C1/C2) Hs. 182447 3 1 
heterogeneous nuclear ribonucleoprotein D-like Hs. 170311 0 1 
heterogeneous nuclear ribonucleoprotein F Hs.808 1 0 
heterogeneous nuclear ribonucleoprotein HI (H) Hs.245710 1 0 
heterogeneous nuclear ribonucleoprotein H2 (H') Hs.278857 0 1 
heterogeneous nuclear ribonucleoprotein K Hs. 129548 1 6 
heterogeneous nuclear ribonucleoprotein L Hs.2730 1 0 
heterogeneous nuclear ribonucleoprotein U (scaffold Hs. 103804 0 3 
attachment factor A) 
histone deacetylase 1 Hs.88556 0 1 
histone deacetylase 2 Hs.3 3 52 0 2 
HIV-1 rev binding protein 2 Hs. 154762 0 2 
HUSl (S. pombe) checkpoint homolog Hs. 152983 0 1 
inhibitor of DNA binding 1, dominant negative Hs.75424 1 0 
helix-loop-helix protein 
inhibitor of DNA binding 2, dominant negative Hs. 180919 1 2 
helix-loop-helix protein 
interferon regulatory factor 3 Hs.75254 0 2 
isoleucine-tRNA synthetase Hs. 172801 1 0 
Kruppel-like factor 4 (gut) Hs.7934 0 1 
kmppel-related zinc finger protein hcKrox Hs. 159265 0 1 
LI3 protein Hs.43946 0 2 
1 0 8 
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leucine rich repeat (in FLU) interacting protein 1 Hs.326159 1 0 
leucine zipper transcription factor-like 1 Hs.30824 1 0 
lysyl-tRNA synthetase Hs.3100 0 1 
MAD (mothers against decapentaplegic, Drosophila) Hs.37501 0 1 
homolog 5 
ribosomal protein LI2, mitochondrial Hs. 109059 2 0 
ribosomal protein LI9, mitochondrial Hs.75574 1 0 
ribosomal protein L23, mitochondrial Hs.3254 1 0 
ribosomal protein L3, mitochondrial Hs.79086 0 3 
ribosomal protein S12, mitochondrial Hs.9964 0 1 
chaperonin containing TCP-1 zeta-2 subunit NIL 2 0 
[Mus musculus] 
nascent-polypeptide-associated complex alpha Hs.32916 4 13 
polypeptide 
non-histone chromosome protein 2 (S. cerevisiae)-like 1 Hs. 182255 0 2 
nuclear factor of kappa light polypeptide gene enhancer Hs.81328 1 0 
in B-cells inhibitor, alpha 
nuclear factor of kappa light polypeptide gene enhancer Hs.323834 0 3 
in B-cells inhibitor-like 2 
nuclear RNA helicase, DECD variant of DEAD box Hs. 179606 1 0 
family 
nuclease sensitive element binding protein 1 Hs.74497 3 2 
poly(A)-binding protein, cytoplasmic 1 Hs. 172182 0 5 
poly(A)-binding protein, cytoplasmic 4 Hs. 169900 0 1 
poly(A)-binding protein, nuclear 1 Hs. 117176 0 1 
poly(rC) binding protein 2 Mm.I l l 0 1 
poly(rC)-binding protein 1 Hs.2853 1 0 
poly(rC)-binding protein 2 Hs.63525 2 1 
poly(rC)-binding protein 3 Hs. 121241 0 1 
polyamine-modulated factor 1 Hs. 94446 0 6 
polyglutamine binding protein 1 Hs.30570 0 1 
polymerase (DNA directed), delta 2 Hs.74598 0 2 
polymerase (DNA-directed), delta 4 Hs.82520 0 1 
polymerase (RNA) II (DNA directed) polypeptide D Hs. 194638 0 1 
polymerase (RNA) II (DNA directed) polypeptide E Hs.24301 1 2 
polymerase (RNA) II (DNA directed) polypeptide F Hs.46405 2 2 
polymerase (RNA) II (DNA directed) polypeptide G Hs. 14839 0 2 
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polymerase (RNA) II (DNA directed) polypeptide J Hs. 80475 0 3 
polymerase (RNA) II (DNA directed) polypeptide K Hs. 150675 0 3 
polymerase (RNA) II (DNA directed) polypeptide L Hs.71618 2 5 
polymerase (RNA) III (DNA directed) (62kD) Hs. 250745 0 1 
polypyrimidine tract binding protein Hs. 172550 0 1 
protein arginine N-methyltransferase 3(hnRNP Hs. 152337 0 1 
methyltransferase S. cerevisiae)-like 3 
protein disulfide isomerase-related protein Hs. 182429 0 2 
protein inhibitor of activated STAT protein PIASy Hs. 105779 0 1 
protein phosphatase 1，regulatory (inhibitor) subunit 8 Hs.78961 1 2 
purine-rich element binding protein B Hs.301005 0 1 
putative translation initiation factor Hs. 150580 2 16 
ribosomal protein LIO Hs.29797 9 32 
ribosomal protein LlOa Hs.252574 0 4 
ribosomal protein L l l Hs. 179943 4 14 
ribosomal protein L12 Hs. 182979 1 11 
ribosomal protein L13 Hs. 180842 5 3 
ribosomal protein LI3a Hs.ll9122 11 80 
ribosomal protein L14 Hs.738 4 14 
ribosomal protein LI5 Hs.74267 4 17 
ribosomal protein L17 Hs.82202 2 20 
ribosomal protein L17 isolog Hs. 10026 0 3 
ribosomal protein L18 Hs.75458 2 32 
ribosomal protein LI8a Hs. 163593 2 28 
ribosomal protein LI9 Hs.252723 5 19 
ribosomal protein L21 Hs. 184108 4 12 
ribosomal protein L22 Hs.99914 0 4 
ribosomal protein L23 Hs.234518 2 13 
ribosomal protein L23a Hs. 184776 4 28 
ribosomal protein L24 Hs. 184582 3 17 
ribosomal protein L26 Hs.91379 4 16 
ribosomal protein L27 Hs. 111611 3 22 
ribosomal protein L27a Hs.76064 4 36 
ribosomal protein L28 Hs.4437 3 57 
ribosomal protein L29 Hs. 183698 10 16 
ribosomal protein L3 Hs. 119598 5 12 
ribosomal protein L30 Hs. 111222 7 56 
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ribosomal protein L31 Hs. 184014 5 20 
ribosomal protein L32 Hs. 169793 7 28 
ribosomal protein L34 Hs.250895 6 12 
ribosomal protein L35 Hs. 182825 3 34 
ribosomal protein L36 Hs.300759 0 1 
ribosomal protein L36a Hs. 118857 0 2 
ribosomal protein L37 Hs. 179779 20 33 
ribosomal protein L37a Hs.5566 11 48 
ribosomal protein L38 Hs.2017 3 17 
ribosomal protein L39 Hs.300141 6 21 
ribosomal protein L4 Hs.286 4 10 
ribosomal protein L41 Hs.324406 0 1 
ribosomal protein L44 Hs. 178391 2 7 
ribosomal protein L5 Hs. 180946 3 3 
ribosomal protein L6 Hs. 174131 3 6 
ribosomal protein L7 Hs.l53 1 6 
ribosomal protein L7a Hs.99858 3 16 
ribosomal protein L8 Hs. 178551 1 25 
ribosomal protein L9 Hs. 157850 16 19 
ribosomal protein P0(L0C51154) Hs.274201 1 0 
ribosomal protein S10 Hs.76230 3 31 
ribosomal protein S l l Hs. 182740 7 48 
ribosomal protein S12 (RPS12) Hs.288224 5 25 
ribosomal protein S13 Hs. 165590 2 14 
ribosomal protein S14 NIL 13 21 
ribosomal protein S15 Hs. 133230 7 32 
ribosomal protein SI5a Hs.2953 5 16 
ribosomal protein S16 Hs.80617 3 41 
ribosomal prortein S17 Hs.5174 5 39 
ribosomal protein S18 Hs.275865 12 49 
ribosomal protein S19 Hs.298262 9 96 
ribosomal protein S2 Hs. 182426 3 11 
ribosomal protein S20 Hs.8102 10 43 
ribosomal protein S21 Hs.l948 6 94 
ribosomal protein S23 Hs.3463 5 19 
ribosomal protein S24 Hs. 180450 3 17 
ribosomal protein S25 Hs. 113029 5 11 
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ribosomal protein S26 Hs.299465 1 12 
ribosomal protein S27 (metallopanstimulin 1) Hs. 195453 12 79 
ribosomal protein S27a Hs.3297 0 3 
ribosomal protein S28 Hs. 153177 3 10 
ribosomal protein S29 Hs.539 15 14 
ribosomal protein S3 Hs.252259 5 23 
ribosomal protein S3 A Hs.77039 1 6 
ribosomal protein S4, X-linked Hs. 108124 22 42 
ribosomal protein S5 Hs.76194 2 40 
ribosomal protein S6 Hs.241507 6 14 
ribosomal protein S6 kinase, 70kD，polypeptide 2 Hs. 103081 1 0 
ribosomal protein S7 Hs.301547 3 20 
ribosomal protein S8 Hs. 151604 7 23 
ribosomal protein S9 Hs. 180920 6 21 
ribosomal protein, large P2 Hs. 119500 3 22 
ribosomal protein, large, PO Hs.73742 5 39 
ribosomal protein, large, PI Hs. 177592 9 74 
ring finger protein (C3HC4 type) 8 Hs.24439 0 1 
ring finger protein 10 Hs.5094 1 0 
ring finger protein 15 Hs.59545 0 1 
ring finger protein 2 (RNF2) Hs. 124186 0 1 
ring finger protein 24 (RNF24) Hs.30524 0 1 
ring finger protein 5 Hs.216354 1 0 
ring finger protein 7 Hs. 14084 0 3 
RNA-binding protein regulatory subunit Hs. 10958 0 1 
serine arginine-rich pre-mRNA splicing factor SR-Al Hs. 103521 1 0 
SIAHBPl Fuse-binding protein-interacting Hs.74562 1 3 
repressor 
LSM6 Sm protein F Hs.42438 1 0 
SMA3 Hs.289061 0 1 
small EDRK-rich factor lA (telomeric) (SERF 1 A) NIL 1 4 
small nuclear ribonucleoprotein 70kD polypeptide Hs. 174051 1 1 
small nuclear ribonucleoprotein D2 polypeptide Hs.53125 0 8 
small nuclear ribonucleoprotein D3 polypeptide Hs.l575 0 1 
small nuclear ribonucleoprotein polypeptide B Hs.82575 0 3 
small nuclear ribonucleoprotein polypeptide C Hs.l063 0 1 
small nuclear ribonucleoprotein polypeptide E Hs.l066 0 1 
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small nuclear ribonucleoprotein polypeptide G Hs.77496 0 5 
small nuclear ribonucleoprotein polypeptides B and B1 Hs.83753 0 8 
splicing factor (CC1.3) (CC1.3) NIL 2 2 
splicing factor 30，survival of motor neuron-related Hs.79968 1 0 
splicing factor, arginine/serine-rich (transformer 2 Hs.30035 1 0 
Drosophila homolog) 10 
splicing factor, arginine/serine-rich 11 Hs. 11482 0 1 
splicing factor，arginine/serine-rich 2 Hs.73965 0 1 
splicing factor, arginine/serine-rich 3 Hs. 167460 2 1 
splicing factor, arginine/serine-rich 7 (35kD) Hs. 184167 0 2 
Src-like-adapter Hs.75367 0 1 
stem-loop (histone) binding protein Hs.75257 0 2 
structure specific recognition protein 1 Hs.79162 0 1 
TATA box binding protein (TBP)-associated factor, Hs.60679 0 1 
RNA polymerase II，Q 32kD 
Tat-interacting protein (30kD) Hs. 90753 0 1 
tensin Hs. 3 51432 1 1 
transcription elongation factor A (SII), 1 Hs.78869 0 2 
transcription elongation factor B (SIII), Hs. 184693 1 2 
polypeptide 1 (15kD, elongin C) 
transcription elongation factor B (SIII), Hs. 171626 2 6 
polypeptide 1-like 
transcription elongation factor B (SIII), Hs. 172772 3 8 
polypeptide 2 (18kD, elongin B) 
transcription factor 1，hepatic; LF-Bl，hepatic nuclear Hs.73888 0 1 
factor (HNFl), albumin proximal factor 
transcription factor-like 5 (basic helix-loop-helix) Hs.30696 0 1 
transcriptional regulator protein Hs.27299 0 1 
transformation/transcription domain-associated protein Hs.203952 0 1 
translation factor suil homolog Hs.21756 0 1 
translational inhibitor protein pi4.5 Hs. 18426 2 0 
Ts translation elongation factor, mitochondrial Hs.3273 1 0 
U2(RNU2) small nuclear RNA auxiliary factor 1 Hs.59271 0 1 
(non-standard symbol) 
U3 small nuclear RNA (U3b2) NIL 3 4 
U4/U6-associated RNA splicing factor Hs. 11776 0 1 
U6 snRNA-associated Sm-like protein Hs.76719 0 3 
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U6 snRNA-associated Sm-like protein LSm7 Hs.70830 0 2 
U6 snRNA-associated Sm-like protein LSm8 Hs.241578 0 1 
ubiquitin carboxyl-terminal esterase LI (ubiquitin Hs.76118 0 1 
thiolesterase) 
ubiquitin fusion degradation 1-like Hs.181369 0 1 
uncharacterized hypothalamus protein HSMNPl Hs. 179666 2 13 
uncharacterized hypothalamus protein HTOlO Hs.6375 0 1 
vacuolar protein sorting 26 (yeast homolog) Hs.67052 0 1 
vacuolar protein sorting 41 (yeast homolog) Hs. 180941 0 1 
vascular Rab-GAP/TBC-containing Hs. 164170 1 0 
X-box binding protein 1 Hs. 149923 2 1 
zinc finger protein 143 (clone pHZ-1) Hs. 154095 0 1 
zinc finger protein 216 Hs.3776 0 1 
zinc finger protein 217 Hs. 155040 2 1 
zinc finger protein 331; zinc finger protein 463 Hs. 147644 1 0 
zinc finger protein 36 (KOX18) Hs. 132390 0 2 
zinc finger protein 44 (KOX 7) Hs.278480 0 1 
zinc finger protein 9 (a cellular retroviral nucleic acid Hs.2110 0 2 
binding protein) 
zinc finger protein homologous to Zfp-36 in mouse Hs. 1665 0 5 
zinc finger protein ZNF140-like protein Hs. 125287 0 1 
zinc finger protein-like 1 Hs.155165 0 1 
zinc-fingers and homeoboxes 1 Hs. 12940 0 2 
1 1 4 
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3.2 Identification of genes differentially expressed in HCC using in 
silico method 
All the ESTs in HCC and normal counterpart tissues that were matched to known 
genes in GenBank and EMBL database have been categorized according to their 
putative structural and cellular functions (Table 8). Detailed comparison of 
individual gene expression was studied by Poisson probability. Analysis of 
approximately 2,000 unique known genes found from two cDNA libraries was 
undertaken to identify gene differentially expressed in HCC. A total of 85 unique 
genes were thus identified. Of these, 55 were identified as strong candidates 
(P<0.00002) for differentially expression in HCC (17 genes were found up-regulated 
and 38 genes were found down-regulated) (Table 9a & b)，while 30 were identified 
as weak candidates (0.00002<P<0.0002) for differential expression. The majority of 
the strong candidates were either secretory proteins (eg. acute phase protein and 
plasma protein) or genes related to transcriptional and translational machinery (eg. 
ribosomal proteins). 
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Table 9a. Genes potentially overexpressed in HCC. Poisson probabilities were 
calculated as described in text. Functional categories are as per Table 8. Strong 
candidates for differential expression:尸<0.00002. Weak candidates for differential 
expression: 0.00002<P<0.0002. 
Unigene ID Gene Description *Function value 
A. Strong candidates for differential expression 
Hs.52891 ferritin L-chain OM 4.332e-92 
Hs.237658 apolipoprotein A-II OS 4.189e-21 
Hs.1948 ribosomal protein S21 TT 6.802e-ll 
Hs.298262 ribosomal protein S19 TT 4.168e-09 
Hs.9754 activating transcription factor 5 TT 9.808e-08 
Hs.4437 ribosomal protein L28 TT 1.329e-07 
Hs.62954 ferritin H-chain OM 1.304e-06 
Hs.201967 aldo-keto reductase family 1，member C2 OM 2.792e-06 
(dihydrodiol dehydrogenase 2; bile 
acid binding protein; 3-alpha 
hydroxysteroid dehydrogenase, type 
III) 
Hs. 177592 ribosomal protein, large, PI TT 3.502e-06 
Hs.119122 ribosomal protein LI3a TT 5.885e-06 
Hs.76194 ribosomal protein S5 TT 9.277e-06 
Hs. 182937 peptidylprolyl isomerase A (cyclophilin TT 1.454e-05 
A) 
Hs. 195453 ribosomal protein S27 TT 2.102e-05 
Hs.80617 ribosomal protein S16 TT 3.638e-05 
Hs. 111222 ribosomal protein L30 TT 6.455e-05 
Hs.75458 ribosomal protein LI8 TT 1.610e-04 
Hs. 177530 ATP synthase, H+ transporting, EN 1.619e-04 
mitochondrial F1 complex, epsilon 
subunit 
B. Weak candidates for differential expression 
Hs. 116724 aldo-keto reductase family 1, member OM 2.61 Oe-04 
BIO (aldose reductase) 
Hs.74564 signal sequence receptor, beta CS 2.610e-04 
(translocon-associated protein beta) 
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Hs. 183704 ubiquitin C OM 2.610e-04 
Hs. 178551 ribosomal protein L8 TT 3.422e-04 
Hs. 182825 ribosomal protein L35 TT 3.724e-04 
Hs. 182740 ribosomal protein S l l TT 5.951e-04 
Hs. 163593 ribosomal protein LI8a TT 6.421e-04 
Hs.76064 ribosomal protein L27a TT 7.193e-04 
Hs. 74047 electron-transfer-flavoprotein, beta EN 9.019e-04 
polypeptide 
Hs.278388 orosomucoid 2 OS 9.019e-04 
Hs.5174 ribosomal protein S17 TT 9.247e-04 
Hs.73742 ribosomal protein, large, PO TT 9.247e-04 
Hs.76230 ribosomal protein SIO TT 9.732e-04 
Hs. 174031 cytochrome c oxidase subunit VIb EN 1.263e-03 
Hs.233952 proteasome (prosome, macropain) OM 1.765e-03 
subunit, alpha type, 7 
*CS: Signal transduction/cell cycle regulation; EN: energy metabolism; H: hormone and hormonal 
control; M: membrane associated; MI: miscellaneous; OM: other metabolism; OS: secretory protein; 
TT: Transcription and translation. 
**Poisson Probability (F) 
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Table 9b. Genes potentially down-regulated in HCC. Poisson probabilities were 
calculated as described in text. Functional categories are as per Table 8. Strong 
candidates for differential expression:户<0.00002. Weak candidates for differential 
expression: 0 . 0 0 0 0 2〈户 < 0 . 0 0 0 2 . 
Unigene ID Gene Description *Function value 
A. Strong candidates for differential expression 
Hs.93194 apolipoprotein A-I OS < 7.113e-246 
Hs.297681 serine (or cysteine) proteinase inhibitor, clade OS 4.424e-46 
A (alpha-1 antiproteinase, antitrypsin), 
member 1 
Hs.268571 apolipoprotein C-I OS 1.108e-42 
Hs.75183 cytochrome P450, subfamily HE OM < 1.090e-28 
Hs.75990 haptoglobin OS 2.015e-24 
Hs.5241 fatty acid binding protein 1，liver OM 1.239e-23 
Hs.90765 fibrinogen, A alpha polypeptide OS 2.946e-15 
Hs.76461 retinol-binding protein 4, interstitial OS 3.383e-14 
Hs. 118786 metallothionein 2A MI 2.469e-13 
Hs.329704 cytochrome P450, subfamily IIIA OM < 9.769e-13 
(niphedipine oxidase), polypeptide 3 
Hs. 194366 transthyretin (prealbumin, amyloidosis type OS 3.020e-12 
I) 
Hs.1955 serum amyloid A4, constitutive OS < 6.314e-10 
Hs.324746 alpha-2-HS-glycoprotein OS 7.446e-10 
Hs.76177 alpha-1 -microglobuliiVbikunin precursor OS 1.429e-09 
Hs.84298 CD74 antigen (invariant polypeptide of M < 1.377e-08 
major histocompatibility complex, class II 
antigen-associated) 
Hs.1504 hemopexin OS 1.634e-07 
Hs.284394 complement component 3 OS 2.658e-07 
Hs.71 alpha-2-glycoprotein 1, zinc OS 2.671e-07 
Hs.75615 apolipoprotein C-II OS 3.475e-07 
Hs.234726 serine (or cysteine) proteinase inhibitor, clade OS 1.189e-06 
A (alpha-1 antiproteinase, antitrypsin), 
member 3 
Hs.76530 coagulation factor II (thrombin) OS 1.574e-06 
Hs.75431 fibrinogen, gamma polypeptide OS 2.175e-06 
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Hs.277477 major histocompatibility complex, class I, C M 2.334e-06 
Hs. 154730 angiogenin, ribonuclease, RNase A family, 5 CS < 4.532e-06 
Hs.1219 alcohol dehydrogenase 4 (class II), pi OM < 4.532e-06 
polypeptide 
Hs. 174220 cytochrome P450，subfamily l i e OM 4.532e-06 
(mephenytoin 4-hydroxylase), polypeptide 
8 
Hs.2523 alcohol dehydrogenase IC (class I), gamma OM 5.446e-06 
polypeptide 
Hs. 169756 complement component 1, s subcomponent OS 5.446e-06 
Hs.7645 fibrinogen, B beta polypeptide OS 5.723e-06 
Hs.73849 apolipoprotein C-III OS 8.966e-06 
Hs. 151242 serine (or cysteine) proteinase inhibitor, clade OS 4.801 e-05 
G (CI inhibitor), member 1 
NIL apolipoprotein M (G3 A) OS < 6.592e-05 
Hs.1498 histidine-rich glycoprotein OS < 6.592e-05 
Hs. 162 insulin-like growth factor binding protein 2 H < 6.592e-05 
(36kD) 
Hs.283749 ribonuclease, RNase A family, 4 OM < 6.592e-05 
Hs.107 fibrinogen-like 1 OS 6.592e-05 
Hs.4 alcohol dehydrogenase IB (class I)，beta OM 1.920e-04 
polypeptide 
Hs. 184411 albumin OS <0.01 (By 
Chi Square) 
B. Weak candidates for differential expression 
Hs.75106 clusterin (complement lysis inhibitor, OS 2.368e-04 
SP-40,40, sulfated glycoprotein 2, 
testosterone-repressed prostate message 2, 
apolipoprotein J) 
Hs.279860 tumor protein, translationally-controlled 1 MI 4.538e-04 
Hs.539 ribosomal protein S29 TT 6.298e-04 
Hs. 195432 aldehyde dehydrogenase 2 family OM 7.989e-04 
(mitochondrial) 
Hs.275215 hydroxysteroid (11-beta) dehydrogenase 1 OM 7.989e-04 
HS.76415 inter-alpha (globulin) inhibitor H4 (plasma OS 7.989e-04 
Kallikrein-sensitive glycoprotein) 
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Hs.239625 integral membrane protein 2B M 7.989e-04 
Hs.75812 phosphoenolpyruvate carboxykinase 2 EN 7.989e-04 
Hs.75309 eukaryotic translation elongation factor 2 TT < 7.989e-04 
Hs. 156110 immunoglobulin kappa constant MI < 7.989e-04 
Hs. 1305 serine (or cysteine) proteinase inhibitor, clade OS < 7.989e-04 
A (alpha-1 antiproteinase，antitrypsin), 
member 6 
Hs. 159509 serine (or cysteine) proteinase inhibitor, clade OS < 7.989e-04 
F (alpha-2 antiplasmin, pigment 
epithelium derived factor), member 2 
Hs.74561 alpha-2-macroglobulin OS < 7.989e-04 
Hs.69771 B-factor, properdin OS 1.033e-03 
Hs. 12056 asialoglycoprotein receptor 1 M 1.448e-03 
*CS: Signal transduction/cell cycle regulation; EN: energy metabolism; H: hormone and hormonal control; 
M: membrane associated; MI: miscellaneous; OM: other metabolism; OS: secretory protein; 
TT: Transcription and translation. 
**Poisson Probability (P) 
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3.3 Sequence analysis of KIAA0022 
In the large-scale liver partial cDNA sequencing project, numerous novel sequences 
were found from the human HCC library and its normal counterpart library. Three of 
them were found to be matched to the KIAA0022 sequence using the BLAST 
algorithm. The expression of KIAA0022 at transcriptional level was elevated in 
HCC. 
3.3.1 Structural analysis of KIAA0022 
The full-length cDNA of the KIAA0022 was cloned into the TA cloning vector 
(pcDNA4/HisMax®-T0P0®) and the DNA sequencing was performed. According to 
the sequencing result, the total length of KIAA0022 cDNA is 3698 bases (Figure 3)， 
the coding region is 513 bases in length which started from nucleotide number 185 
and ended at 697 from the mRNA sequence, encodes a 171 amino acid residue 
protein (Figure 4) (The coding region is predicted by ORF finder in NCBI， 
http://www.ncbi.nlm.nih.gov/gorf/gorf.htmn. The polyadenylation signal (AATAAA) 
were found at nucleotide number 978 to 983 and 3675 to 3680 respectively. 
The molecular weight of this protein was predicted as 19.49 kDa. The protein 
sequence has an excess of acidic residues (18 aspartyl, 11 glutamyl, 6 tyrosyl, 
4cysteyl) over basic ones (13 lysyl, 4 histidyl and 2 arginyl) (Figure 5). Therefore, it 
appears to be acidic with isoelectric point (pi) 4.34 which was determined by a 
computer software DNASIS. The hydrophobicity and the protein secondary structure 
(predicted by Chou and Fasman method) were determined by a computer program 
DNASIS and shown in Figure 6 and Figure 7 respectively. These information are 
useful in designing immunogenic peptide for raising antibodies. 
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Searching the protein motif within the coding region of KIAA0022 was performed 
by using the Conserved Domain Database using RPS-BLAST in NCBI. Database 
searches identified a domain that is closely conserved to C-type lectin KIAA0022. 
This is located in amino acid number 20 to 100 and amino acid number 37 to 124 
respectively from two results (Figure 8). 
3.3.2 Homology alignment 
From the BLASTN results of the KIAA0022, a mouse cDNA clones were shown to 
be highly similar to the KIAA0022 sequence. It is one of the RIKEN cDNA 
sequences. Its accession numbers is BC005501. The homology matching analyzed 
was performed by a computer program SeqPup. The results of alignment showed 
that BC005501 is closely related to KIAA0022 (Figure 9). KIAA0022 shares overall 
protein sequence identities of 71% with BC005501. 
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Figure 3. The cDNA sequences ofKIAA0022. 
10 20 30 40 50 60 
GCTCCGGGCC GCGCTGCCCG CGCTCCTGCT GCCGTTGCTG GGCCTCGCCG CTGCTGCCGT 
70 80 90 100 110 120 
CGCGGACTGT CCTTCATCTA CTTGGATTCA GTTCCAAGAC AGTTGTTACA TTTTTCTCCA 
130 140 150 160 170 180 
AGAAGCCATC AAAGTAGAAA GCATAGAGGA TGTCAGAAAT CAGTGTACTG ACCATGGAGC 
190 200 210 220 220 230 
GGACATGATA AGCATACATA ATGAAGAAGA AAATGCTTTT ATACTGGATA CTTTGAAAAA 
240 250 260 270 280 290 
GCAATGGAAA GGCCCAGATG ATATCCTACT AGGCATGTTT TATGACACAG ATGATGCGAG 
300 310 320 330 340 350 
TTTCAAGTGG TTTGATAATT CAAATATGAC ATTTGATAAG TGGACAGACC AAGATGATGA 
360 370 380 390 400 410 
TGAGGATTTA GTTGACACCT GTGCTTTTCT GCACATCAAG ACAGGTGAAT GGAAAAAAGG 
420 430 440 450 460 470 
AAATTGTGAA GTTTCTTCTG TGGAA.GGAAC ACTATGCAAA ACAGCTATCC CATACAAAAG 
480 490 500 510 520 530 
GAAATATTTA TCAGATAACC ACATTTTAAT ATCAGCATTG GTGATTGCTA GCACGGTAAT 
540 550 560 570 580 590 
TTTGACAGTT TTGGGAGCAA TCATTTGGTT CCTGTACAAA AAACATTCTG ATTCTCGTTT 
600 610 620 630 640 650 
CACCACAGTT TTTTCAACCG CACCCCAATC ACCTTATAAT GAAGACTGTG TTTTGGTAGT 
660 670 680 690 700 710 
TGGAGAAGAA AATGAATATC TGTTCAATTT GACTAAGTTT TTGGTAATCT TGCACTAAGA 
720 730 740 750 760 770 
CATCAACAAA ATGCCCTGGC AGAGATAACD TTGGGAAAGA TTTTAATATA AAACTTGACA 
780 790 800 810 820 830 
TTGGATATTA GAGCTTTAAT GGTATTCCTT ATTCCAGTAA CATTTTTATG TACTCATCTG 
840 850 860 870 880 890 
CTGTGAAAAG TCTTTAGGTT CATTAAAAAA ACAGGTTTTA GAAATGATCT TAGATCTAAT 
900 910 920 930 940 950 
ATAGTGATTT TAAGCATCCC GTCAAAGGCA GAATCTGTCA CTTGAATGAA GGAAAGCTTA 
960 970 980 990 1000 1010 
AAGCCCAAGC AGATAAAAAT AAAAGCCCAG CCTATTTGTC TTGCCTGCTG TATCTTCCCT 
1020 1030 1040 1050 1060 1070 
ATTTAGTTGA CCCACTTTAG TTTATATGTT TATTAGTAAA CATGAAATGG GGAATAAGTG 
1 2 3 
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1080 1090 1100 1120 1130 1140 
ATTTTAAGTA CAT CC CAT AC ATTTAAATAT CTTTGATAAT TGTTATTTTT TTGGCAGATA 
1150 1160 1170 1180 1190 1200 
ATTCCTCTAG AATGTGTATC TTTTTATGAT TTAGATGAAG AAAATTTTAC AACTTTTAAC 
1 2 1 0 1220 1230 1240 1250 1260 
ACCCCACACC AATTTTAGTT TCATTACTTT TACACACACC ATTTTATCAC AAATGACTCA 
1270 1280 1290 1300 1310 1320 
AGTTTTAATG AATGTTTATA AATTATTTGA AACAAAATAT GATCGCTGTG TCCAGGATGG 
1330 1340 1350 1360 1370 1380 
CATAGAGAAA GCTGGCAATT AGGTTAACAC TTACATATTA TAGTGCCCCT TTAAGGATTT 
1390 1400 1410 1420 1 4 3 0 1440 
CTCTCTTGCC ACCATACCTT TTGTACTTTC CCCTATACAA GATGTATCTC ATTCTCCTCA 
1450 1460 1470 1480 1490 1500 
AGCATTTATA AATTTTTCCT TCAATGACAT GAAAACTGTG CAAGCAAAAA CCGAAGAAAA 
1 5 1 0 1520 1530 1540 1550 1560 
ACACTTAAGT ACAACTGTAG TGACAGTGAT CAAAGTTTTC AGTGCATTTA TTGTACATTT 
1570 1580 1590 1600 1 6 1 0 1 6 2 0 
TAAGAAAAAG GTGAAAATCA TTTGGGGAGT AAAAAAATGA AAAAGCTGAA ACGAGTAATT 
1630 1640 1650 1660 1 6 7 0 1680 
TTCCTCACCA TCAATAAGCC AAAAACAGGA AAGATAAAGA ATGTATAAAT TTCACGTAAA 
1 6 9 0 1700 1 7 1 0 1720 1 7 3 0 1 7 4 0 
TTAGTCACGT ATCACTTATC AATGGGGATA CGTTCTAAGA AATGCATAGT TAGGGAATCT 
1 7 5 0 1760 1770 1780 1 7 9 0 1 8 0 0 
TGTGTGAAAA TCAGCTTGTA TTTACACAAA CCCAGATGGT AGAGCCTATT TTGTCCCAAA 
1 8 1 0 1 8 2 0 1830 1840 1 8 5 0 1 8 6 0 
CCTACACAGC ATGTTACTGT GCTGAATACT GCAGACAATT GTAACACAAT ATTTGTGTAT 
1 8 7 0 1880 1890 1900 1910 1 9 2 0 
CTAAATATAG AAAAGGTACA GTAAAAATAT GGTCTACTAA GGAAACACTG TTCTATATGT 
1 9 3 0 1940 1 9 5 0 1960 1 9 7 0 1980 
GGTCCACTAC TGACTGAAGT ATACTGTCTA GAAGTCTGAG GCTCAAAGAA AAGTAATCCC 
1 9 9 0 2 0 0 0 2 0 1 0 2 0 2 0 2 0 3 0 2 0 4 0 
TCTTCTGAAT CCACACCCCA TCAATTATCT TACTTTCTTC TGGGGAGATA GATAGATATA 
2 0 5 0 2 0 6 0 2 0 7 0 2 0 8 0 2 0 9 0 2 1 0 0 
CTATCTCACT AGCTTGACTA ATGGCAACAA AGTTCCAGCT TGTGTAGTCT CTTTTTATTG 
2 1 1 0 2 1 2 0 2 1 3 0 2 1 4 0 2 1 5 0 2 1 6 0 
AC CAC AT GAA TCGAAAACAC T CAT CAC AAT TAATGGCACT AT CAT T AAT G AGACATGAGT 
2 1 7 0 2 1 8 0 2 1 9 0 2 2 0 0 2 2 1 0 2 2 2 0 
AACTAAAAAG TGAATAGAAA ACTATTAACA GTGCGGCTAC ATGGTACTGA AAATGCAGGC 
1 2 4 
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2 2 3 0 2 2 4 0 2 2 5 0 2 2 6 0 2 2 7 0 2 2 8 0 
ATTACACCAG CTGTTACACA AGCACAAGCA TGCTCTGTAA GAGCTTTACA TTTCTGAGAT 
2 2 9 0 2 3 0 0 2 3 1 0 2 3 2 0 2 3 3 0 2 3 4 0 
TTTGTATAGT GATTGAGATG TCTATTTTAT TATTGATAGA CTATTACTAA TGTCAATATT 
2 3 5 0 2 3 6 0 2 3 7 0 2 3 8 0 2 3 9 0 2 4 0 0 
GAACACTACC CTGGAATTCC TGCCTGGTTT TCCTACCCAA ATTGTACCAC TCCCTGAAGA 
2 4 1 0 2 4 2 0 2 4 3 0 2 4 4 0 2 4 5 0 2 4 6 0 
ACTACAGGCA CAGTAAAAAA AATATGGCGT ATTATGTGAA CTAAAAGAGT TCTAAAGGAG 
2 4 7 0 2 4 8 0 2 4 9 0 2 5 0 0 2 5 1 0 2 5 2 0 
TTCTTAAAGG AGTGGTAGAA TTTGGGTAGG AAAGTGATTA AGTCCAACTT AAAACCAACA 
2 5 3 0 2 5 4 0 2 5 5 0 2 5 6 0 2 5 7 0 2 5 8 0 
GTCTCAAACG TCTACAACTA CAATGTCCAA TGAGCCACTA GCCACATGAG GCTATTTAAG 
2 5 9 0 2 6 0 0 2 6 1 0 2 6 2 0 2 6 3 0 2 6 4 0 
TAAATTTAGT TTAAAATCCA GTTTTCGAAT TACATTAGCC ACATTGTCAA GTGTTCAAAT 
2 6 5 0 2 6 6 0 2 6 7 0 2 6 8 0 2 6 9 0 2 7 0 0 
CACAGGTGGT TAGTGGCTAC TGTACTGGGC AACATACATT ATAGAACATT TTCATTATAG 
2 7 1 0 2 7 2 0 2 7 3 0 2 7 4 0 2 7 5 0 2 7 6 0 
GAAGTTTTAT TGGGCAGTGC TGCTCTTAAA TCCTACCTTC CACTCAACTC CCATACAACT 
2 7 7 0 2 7 8 0 2 7 9 0 2 8 0 0 2 8 1 0 2 8 2 0 
TTCTTTTGTA CATTTTGATA CTTTCTACCT AATGGCAGCT CTTCCAAAAT AGCTGCTTTA 
2 8 3 0 2 8 4 0 2 8 5 0 2 8 6 0 2 8 7 0 2 8 8 0 
AACTCTGATT TAATTTTCAA TATTTGGTTT CATTTTTCAA CAGGCCAAGA GGCCTCTGGT 
2 8 9 0 2 9 0 0 2 9 1 0 2 9 2 0 2 9 3 0 2 9 4 0 
AATGAAGTGC TATATATATA TATATATGAC GGAGTCTCAC TGTGCTGCCC AGGCTACAGT 
2 9 5 0 2 9 6 0 2 9 7 0 2 9 8 0 2 9 9 0 3 0 0 0 
GCAGTTGGCT CGATCTGGCT CTCTCCAATC TCCGCCTTGC AGGTTTTCAA GCAATTCTCC 
3 0 1 0 3 0 2 0 3 0 3 0 3 0 4 0 3 0 5 0 3 0 6 0 
TGCCTCAGCC TCCTTAGTAG CTGGGACCAC AGACATCTGT CACCACACCC AGCTAACTTT 
3 0 7 0 3 0 8 0 3 0 9 0 3 1 0 0 3 1 1 0 3 1 2 0 
TTGTATTTTT GGTAGAGACG GGGTTTCGCC ATATTGACTG GGCTGGTCTC AAACTCCTGA 
3 1 3 0 3 1 4 0 3 1 5 0 3 1 6 0 3 1 7 0 3 1 8 0 
CCTCAAGTGA TCCACCCACC TTGGTCTCCC AAAGTGCTGG GATTACATGC GTGAGCCACC 
3 1 9 0 3 2 0 0 3 2 1 0 3 2 2 0 3 2 3 0 3 2 4 0 
ACACTTGGCC TACATTTTTT CTTTATATAC CAGAACATCT ATAACAGGCA CCTTATCTAC 
3 2 5 0 3 2 6 0 3 2 7 0 3 2 8 0 3 2 9 0 3 3 0 0 
TCATTAGTGA AGAGATAATT GGATTACACA GGCAGGCTTG TTTACTACAT CCAGAATGTA 
3 3 1 0 3 3 2 0 3 3 3 0 3 3 4 0 3 3 5 0 3 3 6 0 
GAAACTGCTT TCTTCAACAT CTTGGTTCTA GCTAGTAATA ACAATATAAT TCTTTGGCAG 
1 2 5 
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3 3 7 0 3 3 8 0 3 3 9 0 3 4 0 0 3 4 1 0 3 4 2 0 
ATATTCAGAA TAACATTTTA AACTACATTT TCTTAGAAAA TTGCATTCTT GTAGTGAGCA 
3 4 3 0 3 4 4 0 3 4 5 0 3 4 6 0 3 4 7 0 3 4 8 0 
GTGTATGGTC TCTTTTGTTC AGAATTTAAA ACTGATAACC AATGAAAGCC TTTTCTCTTA 
3 4 9 0 3 5 0 0 3 5 1 0 3 5 2 0 3 5 3 0 3 5 4 0 
TTCCTCTACC GTCATTTACA TGATAATCTG AAGCTAATAT GACAATATTT AAATACTATG 
3 5 5 0 3 5 6 0 3 5 7 0 3 5 8 0 3 5 9 0 3 6 0 0 
TGGTACTAGG GAACTACAAG AATACTGTAA AGCTTAAGCC ATTGTTATCA CTGTCATTTA 
3 6 1 0 3 6 2 0 3 6 3 0 3 6 4 0 3 6 5 0 3 6 6 0 
GCATTTAATA ACAAAACTAT ACAGAATTAT GTGCATACCA ATGAATGTTT TGTACCATCT 
3 6 7 0 3 6 8 0 3 6 9 0 3 6 9 8 
AGTTAAATTT TTTAAATAAA GTTTTATGGG TTAAGCAG 
1 2 6 
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Figure 4. The open reading frame o f K I A A 0 0 2 2 as predicted by O R F finder in N C B I . 
The full length o f K I A A 0 0 2 2 c D N A sequence w a s used for the open reading frame 
prediction. The longest reading frame w a s chosen, wh ich w a s from nucleotide 185 to 
697 . 
• ~ • • 1 1 
n ~ 1 = ] 
m ~ • I 
I — • • 
I • • • I 
Length: 170 aa 
^ Z T J 185 a t g a t a a g c a t a c a t a a t g a a g a a g a a a a t g c t t t t a t a c t g g a t 
i rame irom to Lengm M I S I H N E E E N A F I L D 
+2 • 185 .. 697 513 230 ac t t tgaaaaagcaa tggaaaggcccaga tga ta t cc t ac taggc 
T L K K Q W K G P D D I L L G 
-2 • 280 .. 564 285 275 a t g t t t t a t g a c a c a g a t g a t g c g a g t t t c a a g t g g t t t g a t a a t 
+1 • 2878 .. 3093 216 M F Y D T D D A S F K W F D N 
320 t caaa t a tgaca t t t ga t aag tggacagaccaaga tga tga tgag 
-2 • 1912 .. 2106 195 S N M T F D K W T D Q D D D E 
‘1 睡 , 365 g a t t t a g t t g a c a c c t g t g c t t t t c t g c a c a t c a a g a c a g g t g a a 
+1 • i •• D L V D T C A F L H I K T G E 
+1 • 1174 .. 1341 168 410 t g g a a a a a a g g a a a t t g t g a a g t t t c t t c t g t g g a a g g a a c a c t a 
W K K G N C E V S S V E G T L 
-1 • 2930 .. 3088 159 455 t g c a a a a c a g c t a t c c c a t a c a a a a g g a a a t a t t t a t c a g a t a a c 
.3 • 1437 .. 1580 144 C K T A I P Y K R K Y L S D N 
500 c a c a t t t t a a t a t c a g c a t t g g t g a t t g c t a g c a c g g t a a t t t t g 
+3 • 3 . . 1 3 7 135 H I L I S A L V I A S T V I L 
1 • i^Ao i^Qo 1 ” 545 a c a g t t t t g g g a g c a a t c a t t t g g t t c c t g t a c a a a a a a c a t t c t 
+1 • 刚 • • 而 i i ^ T V L G A I I W F L Y K K H S 
-3 • 2094 2219 126 590 gat t c t c g t t tcaccacagt 1111 tcaaccgcaccccaa tcacc t 
D S R F T T V F S T A P Q S P 
-1 • 74 .. 199 126 635 t a t a a t g a a g a c t g t g t t t t g g t a g t t g g a g a a g a a a a t g a a t a t 
.3 • 2913 .. 3032 120 • Y N E D C V L V V G E E N E Y 
680 c c t g t t c a a t t t g a c t a a 697 
-2 • 160 .. 276 117 P V Q F D * 
1 2 7 
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Figure 5. The amino acid composition of KIAA0022 as determined by the computer 
software DNASIS. 
Amino A c i d C o u n t Mol^c 0 10 20 30 40 
A l a A 8 4 . 6 7 ^ 
A r g R 2 1 . 1 6 • 
Asn N G 4 . 6 7 
Asp D 18 1 0 . 5 2 — 
Cys C 4 2 . 3 3 • 
G i n Q 4 2 . 3 3 • 
G l u E 11 6 . 4 3 
G l y G 7 4 . 0 9 • 
H i s H 4 2 . 3 3 “ 
l i e I 12 7 . 0 1 — 
Leu L 1 4 8 . 1 8 — 
Lys K 13 7 . 6 0 — 
Met H 3 1 . 7 5 • 
Phe F 10 5 . 8 4 
P r o P 5 2 . 9 2 • 
S e r S 12 7 . 0 1 
T h r T 13 7 . 6 0 
T r p U 5 2 . 9 2 • 
T y r Y 6 3 . 5 0 圓 
V a l V 11 6 . 4 3 
Asx B 0 0 .00 
Glx Z 0 0 . 0 0 
*** * 1 0 . 5 8 
Xxx X 0 0 . 0 0 
T o t a l 1 7 1 9 9 . 8 7 
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1 2 8 
Results 
Figure 7. The secondary structure of KIAA0022 as predicted by a computer software 
called DNASIS. C: coil; H(h): helix-tum-helix; S(s): sheet; T: turn. 
10 20 30 40 50 60 70 
MISIHNEEENAFILDTLKKQWKGPDDILLGMFYDTDDASFKWFDNSNmTOKTOQDDDEDLVDTCAFLH 
HELIX HHHHHHHHHHHHHHHHHhh hHHHHHHh hHHHHh Hhh hhhhhhhhhh 
SHEET SSSs ssssssssss ssssssss ssssss sSsss SSssssSSS 
TURN TITITIT TYm TTTnT T I T m T m T TYH 
COIL 
80 90 100 110 120 130 140 
IKTGEWKKGNCEVSSVEGTLCKTAIPYKRKYLSDNHILISALVIASTVILTVLGAIIWFLYKKHSDSRFT 
HELIX hhhhh HHhhhhhhhhhH hhhhhhhhhhhhhhhhhhhhhhhhhHHHh 
SHEET SSs SSSSSSSSSsSSSs SSSSSSSSSSSSSSSSSSSSSSSSs sS 
TURN T m r m T t t t t r v m n r n T 
COIL C 
150 160 170 
TVFSTAPQSPYNEDCVLWGEENEYPVQFD* 
HELIX hhhhhHHHHHHhhhhH 
SHEET SSSSS sSSSs SSSSs 
TURN n r n r n T 
COIL C C 
1 2 9 
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Figure 8. The protein motif of KIAA0022 as predicted by Conserved Domain 
Database using RPS-BLAST in NCBI. 
Click on boxes for multiple alignments 
1 2 0 4 0 6 0 OO 1 0 0 1 2 0 1 4 0 1 6 0 1 7 0 
gnl|CDDI4055, pfam00059, lectin—c，Lectin C-type domain. This family 
includes both long and short form C-type. 
CD-Length = 107 residues, only 75.7% aligned 
Score = 45.0 bits (106), Expect = le-06 
Query: 2 ISIHNEEENAFILDTUaCQWKGPDDILLGMFYDTDDASFKWFDNSIWFDKW-TDQDDDE 60 
Sbjct: 20 VSIQSAEEQDFLTSLTKA- - -SNSYAWICLTDINTEGTWWITXJSPWIWAPGEPN^ 76 
Query: 61 DLVDTCAFLHIKTGEWKKGNCEVS 84 
Sbjct: 77 GNKEDCVEIYTDNGKWNDEPCGSK 100 
gnllCDDI27, smart00034, CLECT, C-type lectin (CTL) or carbohydrate-recognition 
domain (CRD); Many of these domains function as calcium-dependent 
carbohydrate binding modules. 
CD-Length = 124 residues, only 71.0% aligned 
Score = 41.4 bits (96), Expect = 2e-05 
Query: 1 MISIHNEEENAFILDTLKKQWKGPDDILLGMFYDTDDASFKWFDNSNMr-FDK_DDD 59 
Sbjct: 37 USIHSEEENDFLLSLLKNS--NSDYYWIGLSRPDSNGSWQWSDGSGPVDYSNW--APGE 92 
Query: 60 EDLVDTCAFLHIKT-GEWKKGNCEVSSVEGTLCK 92 
Sbjct: 93 PGGSGNCmSTSGGGKWNDVSCr- -SKLPFICE 124 
1 3 0 
Results 
Figure 9. Homology alignment of the protein sequences. A bar ‘-，represents a space 
inserted for maximizing the homology. The consensus amino acid residues are in 
bold face. 
KIAA0022(Hu) MISIHNEEEN AFILDTLKKQ WKGPDDILLG MFYDTDDASF KWFDNSNMTF 
BC005501(Mm) MVSIHNEEEN AFILDTLQKR WKGPDDLLLG MFYDTDDATF KWYDHSNMTF 
KIAA0022(Hu) DKWTDQDDDE DLVDTCAFLH IKTGEWKKGN CEVSSVEGTL CKTAIPYKRK 
BC005501(Mm) DKWADQDG-E DLVDTCGFLY TKTGEWRKGD CEISSVEGTL CKAAIPYDKK 
KIAA0022(Hu) YLSDNHILIS ALVIASTVIL TVLGAIIWFL YKKHSDSRFT TVFSTAPQSP 
BC005501(Mm) YLSDNHILIS TLVIASTVTL AVLGAIIWFL YRRNARSGFT S-FSPAPLSP 
KIAA0022 (Hu) YNEDCVLWG EENEYPVQFD 
BC005501 (Mm) YSDGCALWA EEDEYAVQLD 
1 3 1 
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3.4 Tissue distribution and expression profile of KIAA0022 using 
Northern blot analysis 
The normal tissues distribution of KIAA0022 in human was revealed using Northern 
Hybridization. KIAA0022 cDNA probe was used to hybridize a Northern blot 
containing normalized poly-(A) RNA from a variety of human tissues. According to 
the autoradiography film (Figure 10), a very strong signal could be seen in lane 8 
(liver). Moderately high signals could be found in lane 3, 9, 11，12 (skeletal muscle, 
small intestine, lung, peripheral blood leukocyte respectively). Moderately low 
signals could be detected in lane 2, 6，7, 10 (heart, spleen, kidney, placenta 
respectively). The expression was barely detectable in lane 1, 4, 5 respectively (brain, 
colon, thymus respectively). The size of the KIAA0022 mRNA was about 3.7kb. 
1 3 2 
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Figure 10. Northern hybridization showing the tissue distribution and expression 
level of gene KIAA0022 in human. A: The Northern blot (Clontech Cat. No. 
PT1200-1) contains approximately l | i l of poly A+ RNA per lane from twelve 
different human tissues. Lane 1: Brain; Lane 2: Heart; Lane 3: Skeletal muscle; 
Lane 4: Colon; Lane 5: Thymus; Lane 6: Spleen; Lane 7: Kidney; Lane 8: Liver; 
Lane 9: Small intestine; Lane 10: Placenta; Lane 11: Lung; Lane 12: Peripheral 
blood leukocyte. B: The band intensities were quantified and plotted in a bar chat as 
showed below. 
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3.5 Subcellular localization of the KIAA0022 tagging by green 
fluorescence protein 
The subcellular localization of KIAA0022 was analyzed by a GFP-KIAA0022 
hybrid which was constructed by cloning KIAA0022 into pEGFP-Cl vector 
(Clontech). The GFP-KIAA0022 hybrid construct and pEGFP-Cl vector were used 
to transiently transfect cancerous liver cells, HepG2. The subcellular localization of 
the GFP-only protein and GFP-KIAA0022 fusion protein were examined by 
fluorescent microcopy. The GFP-only protein was found in both nucleus and 
cytoplasm. The GFP-KIAA0022 fusion protein was also found in both cytoplasm 
and nucleus but with discrete accumulation in granular subcellular structures 
throughout the cytoplasm (Figure 11). 
1 3 4 
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Figure 11. Subcellular localization of KIAA0022-GFP fusion proteins in HepG2 cell 
line. A: Subcellular localization of KIAA0022 at nucleus and cytoplasm with 
discrete accumulation in granular (arrows) subcellular structures throughout the 
cytoplasm. B: Subcellular localization of GFP only protein. 
• 
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3.6 Yeast two-hybrid screening assay 
The protein interacting partner of the KIAA0022 in liver was investigated by 
screening a normal liver pretransformed library using yeast mating. The mating 
mixtures were spread onto the SD/-Ade/-His/-Leu/-Trp (QDO) plates. Yeast colonies 
which grew on the QDO plates (>2mm) were examined by P-galactosidase assay. A 
total of 43 colonies grew on the QDO plates and positive result (blue colony 
occurred within 8 hours) from 3-galactosidase assay was found in 36 colonies. 
Those colonies that showed positive result were further characterized by PCR and 
DNA sequencing. 
Thirty colonies succeed in both PCR and sequencing reaction. The sequence 
homologies were analyzed via the BLAST program for matches in the GenBank 
database. The reading frame of each sequence was checked and the results were 
summarized in Table 10. The protein interacting partners with correct reading frame 
were further confirmed using yeast co-transformation experiment (MATCHMAKER 
Two-Hybrid System 3, Clontech). A clone containing an insert that matched to a 
putative tumor suppressor gene, the ras homolog gene family, member I (ARHI) was 
identified in this experiment. The result was shown in Figure 12. 
1 3 6 
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Table 10. Clones that were identified to be putative protein interacting partners of 
KIAA0022 from the normal liver library screening using yeast mating. *The 
protein-protein interaction has been further confirmed using yeast co-transformation 
experiment. 
Putative Identity GenBank Number of 
accession Clones 
Golgi complex associated NM_022735 6 
protein 1 (GOCAPl)  
Integrin, beta 5 (ITGB5) — NM—002213 3 
*Ras homolog gene family, N M 一 0 0 4 6 7 5 1 
member I (ARHI)  
Haplotype U7 mitochondrion AF_3 82011 1 
Figure 12. p-galactosidase assay of KIAA0022 and ARHI yeast co-transformants. A: 
pGBKT7-KIAA0022 + pACT2-ARHI; B: pGBKT7 + pACT2-ARHI; C: positive 
control; D: negative control 
m 1 _ J 




4.1 Large-scale partial cDNA sequencing 
The progress of human genome project was enhanced by the large-scale EST 
sequencing from different human cDNA libraries of different organs (Adams et al, 
1993; Collet & Joseph 1994; Hwang et al., 1997). To date, many human cDNA 
libraries in different organs have been sequenced, included brain, eye, heart, liver, 
lung, kidney, spleen, thymus, pancreas, testis, ovary etc (Hwang et al., 2000). 
Furthermore, more than 11,000,000 ESTs from 403 organisms have been deposited 
in GenBank as of May 2002 and more than 4,000,000 ESTs were of human origin 
(http://www. ncbi.nlm. nih. gov/dbEST/dbESTsummary. html). All these data 
represent an important resource for studying the human genome and also the genes 
differentially expressed in different organs. Recently, the large-scale sequencing 
technology has been employed in studying diseases and also the genetic changes in 
various cancers. Genes differentially expressed in brain cancer, colon cancer, 
prostate cancer and liver cancer have been successfully studied using expressed 
sequence tag and serial analysis of gene expression (SAGE). These results provided 
much insight into the initiation and progression of cancer (Luo et al., 2002; 
Vasmatzis et al, 1998; Yamashita et al., 2001). Although there are some minor 
drawbacks on the strategy of expressed sequence tag sequencing, including relatively 
high redundancy of abundantly expressed or overexpressed genes and difficultly in 
tagging rare transcripts, expressed sequence tag sequencing approach have proven to 
be an effective and powerful tool for differential gene expression study and 
contributes significantly towards the Human Genome Project. 
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4.2 Characterization of the ESTs 
The Expressed Sequences Tag approach has been proven to be a rapid and efficient 
means of discovering genes on a large scale (Hwang et al, 1997). There is an 
assumption that the number of EST clones will be a direct reflection of the 
abundance of messenger RNA (mRNA) in the population used to prepare the library 
(Miernyk, 2001). By comparing the expression profiles of normal and diseased 
tissues (in our case, HBV-infected liver and HCC liver), up- or down-regulated genes 
can be easily identified. This can provide insights into the genes involved in the 
pathogenesis of HCC. 
Comparison of functional categories of EST between HCC and its normal 
counterpart 
A total of 1,973 distinctive genes out of 16,394 clones sequenced from both HCC 
and its normal counterpart libraries were revealed in this EST sequencing project. 
The first ten known genes expressed highly in HCC and corresponding noncancerous 
liver were listed in Table 11. It can be found that lots of ribosomal proteins are 
highly expressed in liver cancer while a number of liver synthesized functional 
proteins such as albumin, apolipoprotein family and coagulation factors are abundant 
in the corresponding noncancerous liver. This observation is in agreement with the 
major normal liver function such as homeostatic and detoxification. 
Functional categorization of ESTs with known gene matches indicated several 
differences in gene expression between the cancerous tissue and its normal 
counterpart. The distribution of ESTs of the HCC and normal counterpart tissue 
libraries each of the categories was compared (Table 12). Expression frequency of 
transcripts related to cell structure/motility including cytoskeleton related protein 
1 3 9 
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Tablell. First 10 known genes highly expressed in HCC and the normal counterpart 
tissue. 
HCC library Freq (%) Normal counterpart library Freq (%) 
ferrtin light chain 817 (7.04) albumin 252 (5.26) 
apolipoprotein A-II 548 (4.72) apolipoprotein A-I 120 (2.51) 
aoplipoprotein C-III 112(0.97) apolipoprotein A-II 101 (2.11) 
ribosomal protein S19 96 (0.83) serine (or cysteine) 94 (1.96) 
ribosomal protein S21 94 (0.81) proteinase inhibitor, clade A 
ribosomal protein L13a 80 (0.69) apolipoprotein C-I 81 (1.69) 
ribosomal protein S27 79 (0.68) apolipoprotein C-III 77 (1.61) 
(metallopanstimulin 1) haptoglobin 53(1.11) 
ribosomal protein, large, PI 74 (0.64) apolipoprotein C-II 46 (0.96) 
ferritin heavy polypeptide 69 (0.59) alpha-1 -microglobulin/bikunin 43 (0.90) 
activating transcription 63 (0.54) precursor 
factor 5 ferritin light chain 42 (0.88) 
Freq (%): Frequency (percentage) 
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Discussion 
Table 12. Comparison of the genes expression between HCC and normal counterpart 
library based on their functional categorization. 
Category Normal HCC 
counterpart library Library 
Contractile element 0.2% 0.4% 
Cytoskeleton related 1.2% 1.6% 
Extracellular matrix 0.8% 1.1% 
Energy metabolism 4.4% 7.2% 
Hormone and hormonal control 1.1% 0.7% 
Membrane associated 3.6% 3.2% 
Other metabolism 14.4% 22.6% 
Signal transduction/cell cycle 4.6% 7.0% 
regulation 
Secretory protein 44.3% 17.2% 
Transcription and translation 17.6% 30.4% 
Miscellaneous 7.8% 8.6% 
100% 100% 
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contractile elements, extracellular matrix proteins and also proteins involved in 
hormonal control were relatively higher in HCC. The transcript levels of membrane 
associated proteins are more or less the same amongst two libraries. In the categories 
of energy metabolism, signal transduction/cell cycle regulation, other metabolism 
and transcription/translation machinery, HCC exhibited a significant increase 
(P<0.001) as compared to its adjacent noncancerous part. In the category of 
secretory proteins, HCC showed a significant decrease in number of EST types 
(P<0.001) as compared to that of its normal counterpart tissue. These results are 
consistent with the rapidly growing phenotype of the cancerous tissue. 
Secretory Protein 
It is reasonable that the proteins in the category of secretory proteins are less 
abundant in HCC than in normal liver. As expected, liver cancer cells lose a number 
of cellular ftinctions that are present in normal hepatocytes. As compared with other 
organs, liver, which is richer in the expression of secretory proteins, produces less 
and less secretory proteins when it progresses into tumor. One of the most abundant 
groups of proteins in this category is apolipoproteins. 
Proteins involved in other metabolism 
Transcripts in the category of "other metabolism" were more abundant in HCC than 
in the normal counterpart library (P<0.001). Liver is the main organ for biosynthesis 
of proteins that are useful for homeostasis of the human body, therefore it is 
reasonable that normal liver comprises of a large number of genes in this category 
(14.4%). This group of proteins becomes even more abundant when a normal liver 
• cell transforms itself into cancer cell (22.6%). It seems that many kinds of 
metabolism other than those found in a normal liver are urgently required in HCC, as 
the metabolic rate of actively-dividing cancer cells is relatively higher than that of 
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normal cells. 
Protein involved in transcription and translation 
The expression level of transcripts related to transcription and translation increases 
from 17.6% to 30.4% when the hepatocyte was transformed. The enhanced 
expression of transcription and translation related proteins in HCC reflects the great 
demand on protein synthesis in the active cell division and complex metabolic 
pathways under the progress of HCC development. 
4.3 Identification of genes differentially expressed in liver cancer 
using Poisson probability 
Detailed comparison of individual gene expression has been studied using Poisson 
probability. It allows for convenient assessment of the relative abundance of large 
numbers of transcripts in different pathological stages, in our study, HCC liver and 
normal counterpart liver. A list of potentially differentially expressed genes in HCC 
was generated based on the calculation of the frequencies of gene expression with 
Poisson probabilities (Table 9). A total of 55 genes were thus identified as strong 
candidates (尸<0.00002) for differentially expression in HCC. Seventeen genes were 
found to be up-regulated and 38 genes were found to be down-regulated in HCC 
respectively. 
When comparing the potentially differentially expressed genes identified from our 
study (EST sequencing approach) with recent reports on the genes up-regulated or 
down-regulated as identified by cDNA microarray technology, several genes in our 
list matched other research findings. Gene expression microarray is one of the 
current important technologies that can identify the changes in expression of a large 
number of genes simultaneously and quickly. However, studies on differentially 
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Table 13 a. Comparison the up-regulated candidate genes in HCC with literature 
Unigene 
clusterlD Gene Name Cytoband Function Literature Cited 
Lipid metabolism and immune defence 
Hs.237658 apolipoprotein A-II 1q21-q23 Apolipoprotein A-2; component of high density lipoprotein 7 
Energy metabolism 
Hs. 177530 ATP synthase, H+ transporting, 20q13.3 this is the smallest of the 5 chains of the enzymatic component 7 
mitochondrial F1 complex, epsilon subunit (coupling factor cf(1)) of the mitochondrial atpase complex (by 
similarity). 
Immune defence 
Hs. 182937 peptidylprolyl isomerase A (cyclophilin A) 7 p 1 3 - p 1 l 2 Cyclophilin A; peptidylprolyl isomerase, major intracellular receptor for 7 
the immunosuppressant cyclosporin A 
Iron storage 
Hs. 111334 ferritin, light polypeptide 19q13.3-q13.4 Ferritin light polypeptide; iron storage protein 2,7 
Hs.62954 ferritin, heavy polypeptide 1 11q13 Ferritin heavy polypeptide 1; iron-storage protein 4,6,7 
Translation 
Hs. 177592 ribosomal protein, large, P1 15q11.2 Ribosomal protein P1; acidic phosphoprotein component of the large 7 
60S ribosomal subunit 
Hs.76194 ribosomal protein S5 19q13.4 Ribosomal protein S5; component of the 4 0 S ribosomal subunit 7 
Hs.80617 ribosomal protein S16 19q Ribosomal protein S16; component of the small 40S ribosomal 1,7 
subunit 
Hs.298262 ribosomal protein S19 19q13.2 Ribosomal protein S19; component of the small 4 0 S ribosomal 7 
subunit 
Hs. 1948 ribosomal protein S21 20q13.3 Ribosomal protein S21 ； component of the small 4 0 S ribosomal 7 
subunit 
Hs. 195453 ribosomal protein S 2 7 (metallopanstimulin 1q21 Ribosomal protein S27 (metallopanstimulin 1); component of the 7 
1) small 40S ribosomal subunit; contains a C4 zinc finger motif 
Hs.119122 ribosomal protein L I 3 a 19q13.3 Ribosomal protein L13A; component of the large 6 0 S ribosomal 7 
subunit 
Hs.343354 ribosomal protein L I 8 19q13 Ribosomal protein L18; component of the large 6 0 S ribosomal subunit 7 
Hs.4437 ribosomal protein L28 19q13.4 Ribosomal protein L28; component of the large 6 0 S ribosomal subunit 7 
Hs.111222 ribosomal protein L30 8 Ribosomal protein L30; component of the large 6 0 S ribosomal subunit 7,8 
Detoxif ication and drug metabolism 
Hs.201967 Aldo-keto reductase family 1 • member C2 10p15-p14 Aldo-keto reductase 1, C2; converts dihydrotestosterone to 5 7 
a-androstane-3 a, 17 b-diol; binds bile, possibly functions in 
intracellular bile transport and xenobiotic metabolism 
Transcription 
Hs.9754 activating transcription factor 5 19q13.3 DMA-binding protein; repressor of cAMP-induced transcription 7 
1; Lau et a/, 2000 2: Kim et al, 2001 3: Shirota et al, 2001 
4: Xu XR et al, 2001 5: Okabe et al, 2001 6: Xu L ei al, 2001 
7: Ours finding 8: Kondoh et al, 1999 
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Table 13b. Comparison the down-regulated candidate genes in HCC with literature 
Unigene 
clusterlD Gene Name Cytoband Function Literature cited 
Lipid metabolism and immune defence 
Hs.93194 apolipoprotein A-1 11q23-q24 Apolipoprotein A-l; component of high density lipoprotein and a cofactor 2,7 
for plasma lecithin-cholesterol acyltransferase 
Hs.268571 apolipoprotein C-l 19q13.2 Apolipoprotein CI 7 
Hs.75615 apolipoprotein C-ll 19q13.2 Apolipoprotein Cll; cofactor for lipoprotein lipase that hydrolyzes 4 
triglyceride-rich lipoproteins 
Hs.73849 apolipoprotein C-lll 11q23.1-q23.2 Apolipoprotein C-3; major component of triglyceride-rich lipoproteins 6,7 
Nil apolipoprotein M (G3A), mRNA 7 
Hs.1955 serum amyloid A4, constitutive 11p15.1-p14 Serum amyloid A4; apolipoprotein component of non-acute phase high 2,7 
density lipoprotein 
Hs.5241 fatty acid binding protein 1, liver 2p11 Liver fatty acid binding protein 1; binds hydrophobic ligands; member of a 6,7 
family of small intracellular proteins 
Blood coagulation and Immune defence 
Hs.90765 fibrinogen, A alpha polypeptide 4q28 Alpha subunit of fibrinogen; has a role in blood clotting and other 7 
responses to injury 
Hs.7645 fibrinogen, B beta polypeptide 4q28 Beta subunit of fibrinogen; has a role in blood clotting and other responses 1,4,6,7 
to injury 
Hs.75431 fibrinogen, gamma polypeptide 4q28 Gamma subunit of fibrinogen; has a role in blood dotting and other 1.4,6.7 
responses to injury 
Hs.107 fibrinogen-like 1 8p22-p21.3 Similar to the beta and gamma subunits of fibrinogen; lacks fibrinogen 7 
platelet-binding, x-linking, and thrombin-sensitive regions 
Hs.1498 histidine-rich glycoprotein 3q27 Histidine-rich plasma glycoprotein; plays a role in modulating coagulation 7 
and fibrinolysis 
Hs.76530 coagulation factor II (thrombin) 11p11-q12 Prothrombin; precursor of the serine protease thrombin 7 
Immune defence 
Hs.84298 CD74 antigen (invariant polypeptide of major 5q32 Gamma chain antigen associated with M H C class II antigen 5,7 
histocompatibility complex, class II 
antigen-associated) 
Hs. 169756 complement component 1, s subcomponent 12p13 Complement component C I s , a serine protease; contains a cysteine-rich 7 
segment 
Hs.284394 complement component 3 19p13.3-p13.2 Complement component 3 7 
Hs.75990 haptoglobin 16q22.1 Haptoglobin; glycoprotein that binds free hemoglobin： similar to serine 6.7 
proteases 
HS.1504 hemopexin 11p15.5-p15.4 Hemopexin; b-glycoprotein that transports heme to hepatocytes for iron 2,7 
salvage 
Hs.76177 alpha-1-microglobulin/bikunin precursor 9q32-q33 Precursor for serum glycoproteins alpha-1-microglobulin and bikunin; 7 
alpha-1-microglobulin is a tipcalin transport protein for small hydrophilic 
proteins, bikunin is a serine protease inhibitor 
Hs.71 alpha-2-glycoprotein 1’ zinc 7q22.1 Zn-alpha 2-glycoprotein 7 
Hs.324746 alpha-2-HS-glycoprotein 3q27 Alpha 2-HS-glycoprotein; plasma protein that may have a role in bone 7 
mineralization and the immune response; similar to collagen 
Hs.297681 serine (or cysteine) proteinase inhibitor, clade 14q32.1 Anti-elastase (alpha-1-antitrypsin); serpin serine protease inhibitor 7 
A {alpha-1 antiproteinase, antitrypsin), 
member 1 
Hs.234726 serine (or cysteine) proteinase inhibitor, clade 14q32.1 Alpha-1-antichymotrypsin; member of the serpin family of serine protease 7 
A (aIpha-1 antiproteinase, antitrypsin), inhibitors 
member 3 
HS.151242 serine (or cysteine) proteinase inhibitor, clade 11q12-q13.1 C I inhibitor; regulates the first component of complement and vascular 7 
G (C1 inhibitor), member 1 permeability; member of the serine protease inhibitor (serpin) superfamily 
Hs. 194366 transthyretin (prealbumin, amyloidosis type I) 18q12.1 Transthyretin (prealbumin); carrier protein, transports thyroid hormones 2,6,7 
and retinol in the plasma 
Hs.184411 serum albumin 4q11-q13 serum albumin, the main protein of plasma, has a good binding capacity 2,7 
for water. ca++, na+. k+, fatty acids, hormones, bilirubin and drugs, its 
main function is the regulation of the colloidal osmotic pressure of blood. 
Detoxification and drug metabolism 
Hs. 174220 cytochrome P450. subfamily IIC (mephenytoin 10cen-q26.11 Member of cytochrome P450 IIC subfamily; metabolizes steroids, fatty 1.3,4.5,7 
4-hydroxylase). polypeptide 8 acids, and xenobiotics; member of heme-binding monooxygenase 
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superfamily 
Hs.75183 cytochrome P450, subfamily HE 10q24.3-qter Cytochrome P450 HE. N-nitrosodimethylamine demethylase; 1,4,6,7 
(ethanol-inducible) ethanol-inducible monooxygenase that metabolizes carcinogens 
Hs.329704 cytochrome P450, subfamily IIIA (niphedipine 7q22.1-7q31.3 Member of the glucocorticoid-inducible cytochrome P450 IIIA subfamily 7 
oxidase), polypeptide 3 3 
Hs.118786 metallothionein 2A 16q13 Member 2A of metallothionein family of heavy metal-binding proteins; 2,5,6,7 
active in metal homeostasis and protects against heavy-metal toxicity 
Alcohol metabolism 
Hs.4 alcohol dehydrogenase 1B (class 丨)_ beta 4q21-q23 Alcohol dehydrogenase 2 (alcohol:NAD+ oxidoreductase) class I beta 1.6,7 
polypeptide subunit; oxidizes ethanol 
Hs.2523 alcohol dehydrogenase 1C (class I), gamma 4q21-q23 Alcohol dehydrogenase 3 (alcohol;NAD+ oxidoreductase) class I. gamma 2,7 
polypeptide subunit; oxidizes ethanol 
Hs.1219 alcohol dehydrogenase 4 (class II)丨 pi 4q21-q24 Alcohol dehydrogenase 4 (alcohol:NAD+ oxidoreductase) class 11, pi 6,7 
polypeptide subunit; oxidizes ethanol, may degrade circulating epinephrine and 
norepinephrine 
Retinot metabolism 
Hs.76461 retinol-binding protein 4, interstitial 10q23-q24 Retinol-binding protein 4; may function in circulatory vitamin A transport 2.7 
Hs.283749 ribonuclease, RNase A family, 4 14 7 
Apoptosis 
Hs.162 insulin-like growth factor binding protein 2 2q33-q34 Insulin-tike growth factor binding protein 2; binds to and modulates 7 
(36kD) insulin-like growth factor activity 
Angiogenesis 
Hs. 154730 angiogenin, ribonuclease, RNase A family, 5 14q11.1-q11.2 Angiogenin; induces blood vessel formation; strongly similar to pancreatic 7 
ribonuclease 
1: Lau et a/, 2000 2: Kim et al. 2001 3: Shirota et al. 2001 
4: Xu XR et al, 2001 5: Okabe et al, 2001 6: Xu L et al, 2001 
7: Ours finding 8: Kondoh et al, 1999 
1 4 6 
Discussion 
expressed genes using microarray might be restricted by the number of pre-spotted 
gene candidates on the slides or membranes. 
Recently, our group and other research groups have reported the use of cDNA 
microarray hybridization, differential display and large-scale cDNA sequencing 
method to identify differentially expressed genes in HCC. In order to have a 
complete interpretation of the global pattern of gene expression in HCC, we 
compared our results with other research groups (Table 13a and 13b). In the 
comparison, different research groups identified some identical gene candidates and 
some gene candidates with similar cellular functions. Moreover, different research 
groups have identified unique differentially expressed gene candidates for HCC 
(Kim et al., 2001; Lau et al., 2000; Kondoh et al.’ 1999; Okabe et al., 2001; Shirota 
et al., 2001; Xu L et al； 2001; Xu XR et al., 2001). 
Of 38 strong candidate genes whose expression in HCC was reduced, 25 belonged to 
the secretory proteins included apolipoprotein family. Apolipoproteins are 
multifunctional proteins involved not only in cholesterol transport and metabolism 
but also immune modulation. Amongst different apolipoproteins found, the 
expression of genes encoding apolipoprotein A-I, C-I, C-II, C-III, and M as well as, 
serum amyloid A4 are down-regulated in HCC. Surprisingly, the expression of genes 
encoding apolipoprotein A-II are up-regulated in HCC in our study. In the HCC 
cDNA library, the most abundant secretory protein is apolipoprotein A-II (548 out of 
11,606). The level of its expression in HCC was found to have a 2.2-fold increase as 
compared to its expression in normal liver (4.7% in HCC vs 2.1% in normal 
counterpart, P<0.001). Apolipoproteins are commonly expressed in normal liver. It 
was reported that hepatitis C virus (HCV) core protein can directly bind 
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apolipoprotein A-II. This observation implies that HCV core protein may modulate 
cellular transduction signals and alter lipid metabolism (Sabile et al” 1999). 
However, previous report did not show a correlation between the increased 
expression of A-II and carcinogenesis or tumor progression, thus the significance of 
this increase remains to be elucidated. 
In our study, beside apolipoproteins, a large number of genes participating in acute 
phase response were potentially down-regulated in HCC. During infections and 
injuries, liver will produce a number of serum proteins called acute phase proteins 
for countering the inflammation challenge and for restoration of homeostasis. The 
restoration of homeostasis in acute phase response involved activation of genes 
encoding phagocytic functions (classical complement components including Clq, 
Clr, Cls, C3, C5R1, C9 and FHR-3 and major histocompatibility complex, MHC), 
coagulation and fibrinolysis (fibrinogen, fibrinogen-like 1 protein, histidine-rich 
glycoprotein, coagulation factor II), transportation (hepatoglobin, hemopexin, 
alpha-1 -microglobulin/bikunin precursor, alpha-2-macroglobulin, transthyretin) and 
antiproteolytic actions (various serine/cysteine proteinase inhibitor). The acute phase 
response involved quite a complicated network of acute phase proteins that are 
coordinated in a highly complex fashion (Baumann & Gauldie, 1994; Milland et al., 
1990; Moshage, 1997). The roles of the change in the acute response genes to the 
growth and differentiation of HCC is uncertain but previous report suggested that the 
serum level of acute phase proteins are closely associated with the degree of hepatic 
dysfunction (Shiota et al., 1995). The down-regulation of a significant portion of 
genes involved in acute phase response and immune defence as shown in our study 
suggest that the cancer cell may escape from the attack of our immune system. 
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The group of acute phase response genes is mostly regulated by a group of liver 
enriched transcription factors such as hepatic nuclear factor 1 (HNF-1), HNF-3, 
HNP-4, HNF-6 and CCAAT/enhancer binding protein (C/EBP). According to the 
previous reports, HNF-1, HNF-3 beta, HNF-4 alpha and HNF-6 gamma were 
up-regulated while C/EBP was down-regulated in HCC (Flodby et al., 1995; Kalkuhl 
et al, 1996; Wang et al., 1998; Xu L et al., 2001; Zannis et al” 2001a; Zannis et al., 
2001b). Liver-specific transcriptional control is involved in the cascade of liver cell 
proliferation, differentiation, acute phase response and regeneration. Activating 
transcription factors (ATF)/cAMP responsive element binding protein (CREB) 
represents a large group of basic region leucine zipper (bZip) protein which can bind 
to the consensus ATF/CRE site ‘TGACGTCA’ (Hai & Hartman, 2001). One of the 
ATF members, ATF5 has been found to be up-regulated in HCC in our study. Further 
understanding of the roles of the group of liver enriched transcriptional factors in 
hepatocarcinogenesis will be helpful in the development of diagnosis and treatment 
of HCC. 
The cytochromes P450 are a large group of constitutive and inducible 
heme-containing enzymes, which have a central role in the oxidative metabolism of 
a diverse range of drug and toxic chemicals. Several members of cytochromes P450 
were found to be suppressed in HCC. However, the exact roles of decreased 
expression of cytochromes P450 in HCC remain unclear. Recent research showed 
that some subfamily members of cytochromes P450 affect both cellular proliferation 
and apoptosis. HepG2 cells that overexpress CYP2E1 show a slower growth rate and 
CYP2E1 can induce cellular apoptosis through the generation of reactive oxygen 
species (Chen & Cederbaum, 1998) Cytochromes P450 were implicated for 
pharmacogenetic therapy of tumor cells (Huang et al., 2000; StefFens et al., 2000). 
CYP4B1 efficiently and rapidly induces cell death in HCC cells independent of 
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functional p53 (Mohr et al., 2000). The different subfamily members of cytochromes 
P450, which were shown to be down-regulated in HCC in our study should serve as 
potential therapeutic targets of HCC. 
Our study also confirms the findings that the family of metallothionein (MT) 
including MTIE, MTIF, MTIQ MTIH and MT2A are down-regulated in HCC. 
Metallothioneins are a group of cystine-rich, low-molecular weight proteins with 
important roles in hepatic metabolism, regulation, storage of trace-metals and 
detoxification of toxic metals. Recently, nuclear metallothionein has been found to 
protect the cell from DNA damage and apoptosis, and also to regulate gene 
expression during certain stages of cell cycle (Cherian & Apostolova, 2000). 
Furthermore, the relationship between MT and trace-metals in HCC have been 
studied. It was found that the accumulation of copper and the presence of MT in liver 
may be related to carcinogenesis of HCC (Ebara et al., 2000). Immunostaining of 
metallothionein in 20 HCC cases showed that most of the HCC have no or a low 
grade of MT staining as compared with control or adjacent cirrhotic livers (Cai et al., 
1998). HCC is different from other cancer cells as it always undergoes active 
apoptosis. The relationship between the absence of MT and the appearance of 
apoptotic cells in human liver tumor suggest that metallothionein may play a role in 
the regulation of apoptosis in liver cancer cells (Deng et al., 1998). 
Insulin-like growth factors (IGFs) are important regulators of cell division and 
differentiation. In their free forms, IGFs form a complex with specific binding 
proteins. IGFBPs have been considered to be major regulators of IGF action and IGF 
transport proteins between compartments. Liver plays an important role in 
maintaining the serum levels of several of the insulin-like growth factor binding 
proteins (IGFBPs), with a key role in the regulation of serum concentrations of free 
IGFs and the production of IGFBPs. For the relationship between cancer and 
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IGFBPs, previous reports have shown that IGFBP-1 and -2 levels reflect changes 
related to malignant states (Ranke & Elmlinger, 1997). In our study, IGFBP-2 was 
found to be down-regulated in HCC cDNA library. Shirota Y and his co-workers 
reported that the expression of IGFBP-2 was enhanced in well-differentiated and 
moderately differentiated HCCs, but reduced in poorly differentiated HCCs (Shirota 
et al., 2001). IGFBP-1, 3 and 4 have been found to be significantly down-regulated 
in hepatocellular carcinoma tissues (Gong et al., 2000). Recent report showed 
IGFBP-3 has functions similar to that of a tumor suppressor gene that have reduced 
expression in HCC. This may be used as a therapeutic target for HCC (Hanafusa et 
al., 2002). Since growth factors are known to affect cell growth, it is reasonable that 
IGFBPs play an important inhibitory role in the development and/or growth of 
hepatocellular carcinoma in humans. However, the relationship between IGFBPs and 
carcinogenesis or tumor progression are still not very clear and its role in tumor 
development remains to be investigated. 
Many antioxidant proteins such as antioxidant protein 1, antioxidant protein 2， 
glutathione peroxidase and Cu/Zn superoxide dismutase were found in HCC, 
whereas they are rather uncommon transcripts in the normal counterpart library. 
Actually, antioxidant proteins may play a very important role in the survival of 
cancer cells. As described in previous reports, many cancer cells are resistant to a 
number of anti-neoplastic drugs that can generate free-radicals damage (Bouzyk et 
al., 1997; Lazo et al., 1998). This can explain why the cancer cells can protect 
themselves from anti-neoplastic drugs. The most abundant transcript in this group is 
ferritin L-chain (817 out of 11,606 ESTs). The level of its expression in HCC was 
found to have an 8-fold increase as compared to that of adjacent normal tissue (7.0% 
in HCC vs 0.9% in normal liver, P<0.001). Ferritin L-chain is a 24.5 kDa protein, 
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whose role was first characterized by its cooperation with ferritin H-chain in iron 
uptake (Levi et al., 1992). It was claimed to fiinction as an RNA-binding protein, and 
it can participate in transcriptional and post-transcriptional regulation in a previous 
study (Heise et al., 1997). The cis-acting regulatory iron responsive element of human 
ferritin L-chain mRNA allows repression of translation under iron deprivation while 
enhancing mobilization of the transcripts into polysomes following iron repletion 
(Mikulits et al, 1997). It was further shown that ferritin L-chain, together with Hsp70, 
can have cytoprotection from oxidative injury (Elia et al., 1999). In our study, ferritin 
L-chain expression was found to be up-regulated in HCC. We speculate that the 
function of ferritin L-chain may be related to its antioxidant activity, which is 
consistent with the appearance of many antioxidant proteins in HCC. 
Regulation of translation plays an important role in controlling gene expression 
eukaryotic cells. De-regulation of translation factor activity leads to drastic changes in 
cell growth, including transformation and tumorigenesis has been illustrated in 
previous reports (Sonenberg, 1993). In our study, numerous translation factors were 
found to be up-regulated significantly in HCC compared with non-cancerous tissues 
including ribosomal protein S21, S19, L28, PI, L13a, S5, S27, S16，L30 and L18. 
De-regulation of ribosomal protein S16 and L30 in HCC have been shown in previous 
reports (Kondoh et al., 1999; Kondoh et al., 2001; Lau et al., 2000; Shuda et al., 
2000). This is conceivable that active proliferating HCC needs a more active 
translation machinery. We have found a number of de-regulated translation factors in 
HCCs. Functional analysis of these transcripts may provide valuable information for 
the liver malignancy. 
The present EST project has enriched the database genes that are found up-regulated 
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or down-regulated in HCC. These candidate genes can be further clarified in other 
tissue samples of HCC using cDNA microarray technology whether they can reflect 
stages of carcinogenesis, and become markers for clinical diagnosis of HCC. As 
discussed in chapter 1.4, blood examinations are more convenient for the diagnosis or 
screening of HCC. Therefore, all the strong gene candidates (differentially expressed 
in HCC) in category of secretory protein may become useful markers for HCC. 
Apolipoprotein A-II and ferritin may be the better choice since they showed 
significant up-regulation in HCC. Such a database will also be useful for future 
studies in the identification of SNP or SNP haplotypes that correlate with HCC 
suspectibility and for the discovery of new drugs targets for HCC. 
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4.4 Characterization of KIAA0022 
KIAA0022 was firstly isolated from a cDNA library of human immature myeloid cell 
line KG-1 by Nomura and his co-workers (Nomura et al., 1994). To date, the 
information obtained from dbEST showed that KIAA0022 was highly represented in 
a prostate tumor. In our large-scale liver partial cDNA sequencing project, it showed 
overexpression in HCC tissue. The result of the Northern blot analysis showed that 
KIAA0022 is expressed in a wide variety human normal tissues, with moderately high 
expression in skeletal muscle, small intestine, lung and also peripheral blood 
leukocyte respectively but predominantly expressed in liver. This suggested that 
KIAA0022 may be more important for the normal liver function than the other 
tissues. 
Regarding to the protein domain encoded in KIAA0022, the pEGFP-KIAA0022 
fusion protein was expected to be found in the cell surface or extracellular matrix 
because of its roles in cell adhesion or carbohydrate recognition that we have 
mentioned in chapter one. However, it was found to be distributed throughout the 
cytoplasm and nucleus but also with discrete accumulation in granular structures in 
the cell during the subcellular localization study. Recently, Lucas and his coworkers 
found that a mammalian calcium-dependent lectin, p58/ERGIC-53 serves as a 
glycoprotein-sorting receptor between the endoplasmic reticulum (ER) and the Golgi 
complex (Velloso et al., 2002). We speculated that the granular structure throughout 
the cytoplasm may be related to the cell organelles such as Golgi complex or 
endoplasmic reticulum. Therefore, further investigation of its cell organelle 
localization should be done. 
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A list of putative protein interacting partners of KIAA0022 have been screened out by 
yeast two-hybrid library screening assay (Table 10) and one of them has been 
confirmed by yeast co-transformation experiment. Further confirmation of their 
interaction can be performed using Co-immunoprecipitation assay and fluorescence 
resonance energy transfer (FRET) experiment The confirmed protein interacting 
partner is a putative tumor suppressor gene called ARHI: ras homolog gene family, 
member I which is a member of the ras superfamily, and is expressed in normal 
ovarian and breast epithelial cells but not in ovarian and breast cancers. Thus, this 
gene appears to be a putative tumor suppressor gene whose function is abrogated in 
ovarian and breast cancers and previous report suggested that decreased expression of 
ARHI may play an important role in the pathogenesis of breast cancer (Hisatomi et al, 
2002; Yu et al., 1999). Does the expression pattern of ARHI in liver same as in ovary 
and breast? Up to now, no studies have investigated the expression levels of ARHI in 
HCC tissue and the normal counterpart tissue. However, we speculated that ARHI 
may play a role in de-regulation of KIAA0022. The other putative partners identified 
from the screening assay such as integrin, beta 5 (ITGB5) and golgi complex 
associated protein 1 (GOPCAPl) are both membrane related proteins. ITGB5 acts as 
a vitronectin receptor that is a member of cell-surface proteins family 
Oittp://www.ncbi.nlm.nih.gov/LocusLinkV GOPCAPl was found to be a peripheral 
protein associated with the golgi membrane, where a COOH-terminal domain of it 
interacts with the COOH-terminal cytoplasmic domain of giantin in previous report 
(Sohda et al., 2001). These findings agree with that of the role of C-type lectin in 
cellular adhesion and its intracellular functions such as the proteins receptor in ER or 
golgi. However, the interactions between these two proteins and KIAA0022 have not 
been proven by the yeast co-transfomation experiment. Therefore, the significance of 
their interaction remains to be elucidated. 
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In the present study, the normal tissues distribution in human, the subcellular 
localization and the putative protein interacting partners of KIAA0022 have been 
investigated. Further study of its biological function will be helpful in understanding 
the involvement of it in pathogenesis of HCC or other cancers. 
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Appendix 1 
TOPO® Cloning Site of pcDNA4/HisMax®-TOPO® 
T7 pfomotef/primino site 
821 CTGGCTAACT kGhGhhCCCk CTGCTTACfG GCTTATCGAA ATTAATACGA CTCACTATAG 
_ _ _ I I 
881 GG?iGACCCAA GCTGGCTAGC GTTTAAACTT AAGCTTAGCG CAGAGGCTTG GGGCAGCCGA 
QBISP163 tfartttational  
941 GCGGCAGCCA GGCCCCGGCC CGGGCCTCGG TTCCAGAAGG GAGA6GAGCC CGCCAAGGCG 
1001 CGCAAGAGAG CGGGCTGCCT CGCAGTCCGA GCCGGAGAGG GAGCGCGAGC CGCGCCGGCC 
PdyNstidine Raflbn  
1061 CCGGACGGCC fCCGAAACC ATG GGG GGT TCT CAT CAT CAT CAT CAT CAT 
M翁t Gly Gly Se r H i s His His His His H i s 
Xpress 彻 forward priwit^  i^ te 供 Epik^ 
1 X 1 0 GGT hfQ GCT AGC ATG ACT GGT GGA CAG Chh ATG GGT CGG GAT CTG TAC 
Gly Met Ala S«jr Met Thr Gly Gly Gin Gin Met Gly Arg Asp Leu Tyr 
BarnHI 
1158 GAC GAT GAC GAT AAG GTA CAG GCC C f l J g g S g B ^ G GGC CTG TACCTAG' 
CTG CTh CTG Cth TTC CAT GTC CGG G A O H S i S K T C CCG GAC ATGGATC 
(Asp Asp Asp hsp Gin Aia Leu 
Enterokiruise recognition site [K cleavage site 
BstX\' Rsn EwRV fMt Xh^l Xtol 
1201 GJifCCAGTGT GGTGGAAfTC TGCAGATATC CAGCACAGTG GCGGCCGCTC GAGTCTAGAG 
I BGH levefsc primInQ ste 
1261 GGCCC6TTTA AACCCGCTGJi TC?\GCCTCGA CTGTGCCTTC TAGTTGCCAG CCATCTGTTG 
•Mole lliai there arc Iwo Ev/X I sites f»lltming ihc TOFO* Cloning site, 
**Restriction sites are labeled to indicate the actual cleavage site. The vector is � 
supplied linearized between base pair 1184 and 1185. This is the TOPO Cloning 
site. 
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Appendix 1 
pEGFP-C1 Vector Information PT3028-5 
GenBank Accession #: U55763 Catalog #6084-1 
ApaU f S/iaBI 
偏 。 训 严 丨 _ 
X ^ ^ ^ ^ ^ j U f c o 4 7 Ml (5971 
/ CMV Age I (601) 
fcooio9i / 7 egfA \ 
4.7 kb SV40 
\ \ KanV M v A y ^ ^ MCS 
\ X^eo'' sv40ori f1 J J ^ (1330 1417) 
M/tf IC1G42) 
^ t P D f d III (1872) 
Stul 
(2577) 
[.GFP 丨诚 1 棚 侧 1376 1 欲 丨 3St |4«< ST^ 
TAG AAG fee GGA CTC AGA TCT CGA GCf CAA GCT TCG AATTCT GCA GTC GAC GGTACC GCG GGCCCG GGA TCCACC GGA TCT AGA TAA HTf； ATH A 
S s p E I Bgl II 彻 I \ I Hind III f c o R I Pstl Sail Kpal / i i p a I \ SmjH I 勘 a I * ~BdF 
fcnllu >lccl 柳7UI‘I|S明 1201 
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Appendix 1 
pGBKT? Victor (nformation PT3248-5 
GenBank Accession #: Submission in Progress. catalog # K1612-1 
— HinilW 
( pGBKT? ^ 飄丨 
\ 7.3 kb j 
A c-Mvc epitope tag 
MATCHfMKEfl DNiUD V^ tar 
"， I 咖 < 1 8 «一 _— • C>UDHA._ImO«_  
TCA TCG GAA GAG AGTAGTAAC M A 66T CAA A6A CAG TT6 ACT GTA K Q GCG 6 M TTT 
1.1. 
1212 TTStBUMcingPrinwf . � 
« T7 Pfwiwtct ^ t-Myt E|iit»p«Ta9 
GTA ATA CGA CTC ACT ATA 686 CGA GCC GCC ATC M S GAG GAG CAG AA6 CTG ATC TCA GAG GAG GAC 
STMT 
GCC 6AATTCC£G6g6 ATC CGT CGA CCT GCAGCG GCC GCA IMliTAWATMttCC 
Nm /vcoi sm scm smau San Ps!i iw 
� 2 . ^ S i 树“ _ 
• T J i t t m u M t o r 




, y OHA-BO Se^ ttencing Prirwr 
MAICHMAKEIf3- DNA-BD Vmiot Insert Strawiog Anpliirer 
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Appendix 1 
Poisson Probability gives the probability distribution of number of rare events that 
occur in an interval of time or in a region. In this project, it was used to test the 
significance of the difference of a particular gene in HCC library compared with that 
of the normal counterpart library. Genes that existed in the libraries were sorted by 
Poisson probability into two categories: strong candidates for differentially 
expressed genes: P<0.00002，weak candidates for differentially expressed genes: 
0.00002<P<0.0002. The calculation was done by Microsoft Excel. The formula for 
the calculation are the following: 
e - '入X 
P ( X ) = 
Where e = a mathematical constant equal approximately to 2.7183 
X = the expected frequency of the candidate gene in normal counterpart 
library 
X = the real frequency of the candidate gene in normal counterpart library 
For example, 
Number of EST of ribosomal protein LI 3a in HCC library and normal counterpart 
library were 80 and 11 respectively. Therfore, 
\ = (T/total no. of EST in HCC)*total no. of EST in normal counterpart library 
where T = no. of ESTs coding for ribosomal protein L13a in the library 
=80 
total no. of ESTs in HCC library =11606 
total no. of ESTs in normal counterpart library = 4788 
？i = (80 /11606) /4788 
= 3 3 
-33 3 3 1 1 
p(x) = ^ jj 
“ 1 1 ！ 
= 5 . 8 8 5 e - 0 6 
Conclusion: Since P(X) is <0.00002, the probability that the difference of ribosomal 
protein LI3a in HCC library compared with that of the normal counterpart library 
was significant and thus ribosomal protein LI3a was classified as a strong candidate 
differentially expressed gene. 
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